var title_f39_42_40608="Radionuclide imaging of Chagas cardiomyopathy";
var content_f39_42_40608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Radionuclide imaging of Chagas cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images of a 63-year-old man presenting with&nbsp;syncope due to episodes of sustained ventricular tachycardia with Chagas cardiomyopathy and normal echocardiogram. This figure shows",
"    <sup>",
"     99m",
"    </sup>",
"    Tc sestamibi&nbsp;myocardial perfusion SPECT images for assessment of myocardial viability and",
"    <sup>",
"     123",
"    </sup>",
"    I&nbsp;MIBG myocardial SPECT (lower rows) for assessment of cardiac sympathetic innervation. There is a large defect&nbsp;in",
"    <sup>",
"     123",
"    </sup>",
"    I&nbsp;MIBG uptake involving the inferior and apical walls with corresponding normal&nbsp;",
"    <sup>",
"     99m",
"    </sup>",
"    Tc sestamibi&nbsp;uptake, consistent with viable but denervated myocardium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40608=[""].join("\n");
var outline_f39_42_40608=null;
var title_f39_42_40609="Posterior tibial artery puncture site";
var content_f39_42_40609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior tibial artery puncture site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The site for arterial puncture of the posterior tibial artery is shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40609=[""].join("\n");
var outline_f39_42_40609=null;
var title_f39_42_40610="Patient information: Infertility in men (The Basics)";
var content_f39_42_40610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15425\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"         Male reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"          Female reproductive anatomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/45/36562\">",
"         Patient information: Androgen replacement in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/25/6547\">",
"         Patient information: Infertility in couples (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/16/11523\">",
"         Patient information: Infertility in women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/42/22180\">",
"         Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/62/40932\">",
"         Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/14/10468\">",
"         Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/4/34883\">",
"         Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Infertility in men (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/infertility-in-men-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H459360763\">",
"      <span class=\"h1\">",
"       What is male infertility?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Male infertility is the term doctors use when a man has trouble getting a woman pregnant. In order to get a woman pregnant, a man needs to have a normal number of healthy sperm. Doctors call this a &ldquo;normal sperm count.&rdquo; Men with infertility can have one of the following problems with their sperm:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        They have no sperm at all",
"       </li>",
"       <li>",
"        They do not have enough sperm &ndash; this is called having a &ldquo;low sperm count&rdquo;",
"       </li>",
"       <li>",
"        They have unhealthy sperm &ndash; the sperm might move abnormally or have abnormal shapes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are many reasons that men can have an abnormal sperm count. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems in the testicles, such as a block in the path the sperm takes to reach the penis (",
"        <a class=\"graphic graphic_figure graphicRef68075 \" href=\"mobipreview.htm?21/43/22194\">",
"         figure 1",
"        </a>",
"        ) &ndash; For example, a block can be caused by a past infection or by a vasectomy. A vasectomy is a surgery a man can choose to have so that he can&rsquo;t get a woman pregnant. In a vasectomy, a doctor cuts or blocks the sperm&rsquo;s path.",
"       </li>",
"       <li>",
"        Having low levels of hormones",
"       </li>",
"       <li>",
"        Genetic problems that men might be born with",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      But most of the time, doctors cannot explain why a man has an abnormal sperm count.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H459360770\">",
"      <span class=\"h1\">",
"       When should I see a doctor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most doctors recommend that a man be tested if a couple cannot get pregnant after having unprotected sex for one year. At that time, both the man and the woman are often tested. But if you are worried, talk with your doctor or nurse. He or she might recommend that you have tests done sooner.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H459360777\">",
"      <span class=\"h1\">",
"       What tests will I have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will order a test called a &ldquo;sperm count&rdquo; to check your sperm. This test counts your sperm and checks to see how healthy they are. For this test, a man needs to provide a sample of his sperm.",
"     </p>",
"     <p>",
"      If your sperm count is low, your doctor will repeat the test one or more times. If repeat sperm counts are still abnormal, your doctor might do other tests. For example, he or she might do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        An exam to measure the size of your testicles",
"       </li>",
"       <li>",
"        Tests to see if there is a block in your testicles",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H459360784\">",
"      <span class=\"h1\">",
"       What treatments can help men with infertility?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different treatments can help men with infertility still be able to father children. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        In vitro fertilization, also called &ldquo;IVF&rdquo; &ndash; During IVF, a doctor takes an egg or eggs from a woman and sperm from a man. He or she puts them together in a test tube so that the sperm can fertilize an egg. Then the fertilized egg is put into the woman&rsquo;s uterus to grow (",
"        <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"         figure 2",
"        </a>",
"        ). Many times, a doctor will do a treatment called &ldquo;intracytoplasmic sperm injection,&rdquo; or &ldquo;ICSI,&rdquo; along with IVF. During ICSI, a doctor takes only one sperm and puts it right next to an egg. IVF with ICSI is often used for men who have low sperm counts or abnormal sperm. But this treatment can also be used for men who seem to make no sperm. This is because these men might still have sperm in their testicles that a doctor can take out and use for the procedure.",
"       </li>",
"       <li>",
"        Surgery to open up a block in the testicle &ndash; For example, a man who had a vasectomy in the past can have surgery to reopen the sperm&rsquo;s path.",
"       </li>",
"       <li>",
"        Hormone treatment to increase sperm counts &ndash; Some men have low hormone levels in the brain and can be treated with hormone shots.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H459360791\">",
"      <span class=\"h1\">",
"       Do treatments always work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Treatments do not always help a couple get pregnant. The same treatment can help one couple get pregnant, but not another couple.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H459360798\">",
"      <span class=\"h1\">",
"       How do I decide which treatment to have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Talk with your doctor about the benefits and downsides of the different treatments. To choose the treatment that is right for you and your partner, you might want to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How well your doctor thinks the treatment will work",
"       </li>",
"       <li>",
"        Cost of the treatment &ndash; Health insurance pays for treatment in some states, but not all.",
"       </li>",
"       <li>",
"        How long your doctor thinks the treatment will take",
"       </li>",
"       <li>",
"        Downsides of the treatment",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H459360805\">",
"      <span class=\"h1\">",
"       What choices do I have if I choose to stop or not have treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Couples who choose to stop or not have treatment have other options. They can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Try to have a baby using another man&rsquo;s sperm, such as sperm from a sperm bank",
"       </li>",
"       <li>",
"        Adopt a child",
"       </li>",
"       <li>",
"        Not have children of their own",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Couples can have a tough time making these decisions. You might find it helpful to talk to a counselor or go to a support group for people who are facing the same issues.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H459360812\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/25/6547?source=see_link\">",
"       Patient information: Infertility in couples (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11523?source=see_link\">",
"       Patient information: Infertility in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/45/36562?source=see_link\">",
"       Patient information: Androgen replacement in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"       Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"       Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34883?source=see_link\">",
"       Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"       Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/42/40610?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15425 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40610=[""].join("\n");
var outline_f39_42_40610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360763\">",
"      What is male infertility?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360770\">",
"      When should I see a doctor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360777\">",
"      What tests will I have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360784\">",
"      What treatments can help men with infertility?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360791\">",
"      Do treatments always work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360798\">",
"      How do I decide which treatment to have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360805\">",
"      What choices do I have if I choose to stop or not have treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459360812\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"      Male reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"       Female reproductive anatomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/45/36562?source=related_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=related_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=related_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/25/6547?source=related_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=related_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34883?source=related_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_42_40611="Normal marrow aspirate low";
var content_f39_42_40611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal bone marrow aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate smear from a normal individual, as seen under low power (60x). The majority of cells in this field belong to the granulocyte series. (Wright Giemsa stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40611=[""].join("\n");
var outline_f39_42_40611=null;
var title_f39_42_40612="Topical thrombin: Drug information";
var content_f39_42_40612=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topical thrombin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/50/14115?source=see_link\">",
"    see \"Topical thrombin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/62/2020?source=see_link\">",
"    see \"Topical thrombin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Evithrom&reg;;",
"     </li>",
"     <li>",
"      Recothrom&reg;;",
"     </li>",
"     <li>",
"      Thrombi-Gel&reg;;",
"     </li>",
"     <li>",
"      Thrombi-Pad&reg;;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg;;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Epistaxis Kit;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Pump Spray Kit;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Syringe Spray Kit",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Hemostatic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hemostasis:",
"     </b>",
"     Topical:",
"     <b>",
"      Note:",
"     </b>",
"     For topical use only; do not administer intravenously or intra-arterially:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Evithrom&reg;: Dose depends on area to be treated; up to 10 mL was used with absorbable gelatin sponge in clinical studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recothrom&reg;: Dose depends on area to be treated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Gel&reg; 10, 40, 100: Wet product with up to 3 mL, 10 mL, or 20 mL, respectively, of 0.9% sodium chloride or SWFI; apply directly over source of the bleeding with manual pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Pad&reg;: Apply pad directly over source of bleeding; may apply dry or wetted with up to 10 mL of 0.9% sodium chloride. If desired, product may be left in place for up to 24 hours; do not leave in the body.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombin-JMI&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Solution: Use 1000-2000 units/mL of solution where bleeding is profuse; use 100 units/mL for bleeding from skin or mucosal surfaces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Powder: May apply powder directly to the site of bleeding or on oozing surfaces",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5663803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/62/2020?source=see_link\">",
"      see \"Topical thrombin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Evithrom&reg;: Children and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recothrom&reg;: Infants &ge;1 month, Children, and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pad, topical [preservative free; bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Thrombi-Pad&reg; 3x3: &ge;200 units (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for reconstitution, topical [bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg;: 5000 units, 20,000 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg; Epistaxis kit: 5000 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg; Pump Spray Kit: 20,000 units [supplied with diluents]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg; Syringe Spray Kit: 5000 units; 20,000 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for reconstitution, topical [preservative free; recombinant]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recothrom&reg;: 5000 units; 20,000 units [production involves products derived from hamster and snake sources; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evithrom&reg;: 800-1200 units/mL (2 mL, 5 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, topical [preservative free; bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombi-Gel&reg; 10: &ge;1000 units (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombi-Gel&reg; 40: &ge;1000 units (5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombi-Gel&reg; 100: &ge;2000 units (5s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F227301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only; do not administer intravenously or intra-arterially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Evithrom&reg;: Must be thawed prior to use. May thaw in refrigerator (1 day) or at room temperature (1 hour). The 2 mL and 5 mL vials may also be thawed at 37&deg;C (98.6��F) for up to 10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recothrom&reg;: May apply reconstituted solution directly or in combination with absorbable gelatin sponge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Gel&reg;: May cut or roll to desired shape prior to wetting; once wetted and prior to applying, knead thoroughly to saturate the pad remove trapped air bubbles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Pad&reg;: May apply dry or wet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombin-JMI&reg;: May be applied directly as a powder or as reconstituted solution; sponge surface free of blood prior to application, if possible.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemostasis whenever minor bleeding from capillaries and small venules is accessible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Gel&reg;; Thrombi-Pad&reg;: Temporary control as trauma dressing for moderate-to-severe bleeding wounds; control of surface bleeding from vascular access sites and percutaneous catheter/tubes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5663226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       For topical use only. Do not administer intravenously or intra-arterially.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       To reduce the risk of intravascular administration, the Institute for Safe Medication Practices (ISMP) has the following recommendations:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - Prepare, label, and dispense topical thrombin from the pharmacy department (including doses used in the operating room).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - Do not leave vial or syringe at bedside.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - Add auxiliary label to all labels and syringes stating &ldquo;For topical use only - do not inject&rdquo;.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - When appropriate, use solutions which can be applied with an absorbable gelatin sponge or use a dry form on oozing surfaces.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - When appropriate, use spray kits to help differentiate between parenteral products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding, aPTT increased, INR increased, lymphocyte count decreased, neutrophil count increased, PT prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Incision site complication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antibody development, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thrombin or any component of the formulation; not for direct injection into the circulatory system (for topical use only); additionally,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Evithrom&reg; is also contraindicated in patients with known anaphylactic or severe systemic reactions to blood products; also contraindicated for the treatment of severe or brisk arterial bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recothrom&reg; is also contraindicated in patients with hypersensitivity to hamster proteins; also contraindicated for the treatment of massive or brisk arterial bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Thrombi-Gel&reg;: Should not be used in closure of skin incisions, due to possible interference with healing of skin edges.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Thrombin-JMI&reg; and Thrombi-Pad&reg; are also contraindicated in patients with hypersensitivity to material of bovine origin.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abnormal hemostasis:",
"     <b>",
"      [U.S. Boxed Warning]: Bovine-source topical thrombin may be associated with abnormal hemostasis, ranging from asymptomatic laboratory alterations to severe bleeding and/or thrombosis.",
"     </b>",
"     Abnormalities appear to be immunologically mediated; repeated applications increase risk. Consult expert in coagulation disorders if laboratory evidence and/or signs and symptoms of bleeding are noted. Re-exposure of patients who develop antibodies to bovine thrombin preparations should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Evithrom&reg;: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Recothrom&reg;: Use caution in patients with known hypersensitivity to snake proteins (manufacturing process uses an enzyme isolated from a snake protein); the potential for allergic reaction theoretically exists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombi-Gel&reg;: Do not use in the presence of infection; use caution in areas of contamination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombi-Pad&reg;: Do not use in the presence of infection; use caution in areas of contamination. Product is nonabsorbable; do not leave in the body.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For topical use only. Do not inject intravenously or intra-arterially. Intravascular clotting, possibly leading to death, may occur following injection. Powder and solution formulations may be used in combination with absorbable gelatin sponges.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5663227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate reproduction studies have not been conducted. Reproduction studies conducted with the solvent/detergent used in processing the human-derived product showed adverse events in animals. Only residual levels of the solvent/detergent would be expected to remain in the finished product.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Thrombin-JMI Epistaxis External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000 unit (1): $87.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Thrombin-JMI External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000 unit (1): $87.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 unit (1): $356.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Thrombogen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (1): $34.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pads",
"     </b>",
"     (Thrombi-Pad External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3\"X3\" (10): $648.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Evithrom External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800-1200 units/mL (5 mL): $115.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Recothrom External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000 unit (1): $103.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 unit (1): $412.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Recothrom Spray Kit External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 unit (1): $418.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Thrombin-JMI External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000 unit (1): $86.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 unit (1): $339.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Thrombogen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $3.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (1): $18.02",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Thrombostat (NZ);",
"     </li>",
"     <li>",
"      Trombine (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activates platelets and catalyzes the conversion of fibrinogen to fibrin to promote hemostasis.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10285 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40612=[""].join("\n");
var outline_f39_42_40612=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708964\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227307\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227313\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227309\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663803\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227310\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227299\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227286\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227301\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227300\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663226\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227311\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227303\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227290\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300134\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227294\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227296\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663227\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323961\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038843\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227289\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10285\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10285|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/50/14115?source=related_link\">",
"      Topical thrombin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/62/2020?source=related_link\">",
"      Topical thrombin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_42_40613="Ivermectin (systemic): Drug information";
var content_f39_42_40613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ivermectin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/43/12980?source=see_link\">",
"    see \"Ivermectin (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/49/33557?source=see_link\">",
"    see \"Ivermectin (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13841863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stromectol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13841867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anthelmintic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13841913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Onchocerciasis:",
"     </b>",
"     Oral: 150 mcg/kg as a single dose; retreatment may be required every 3-12 months until asymptomatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strongyloidiasis:",
"     </b>",
"     Oral: Manufacturer recommendations: 200 mcg/kg as a single dose; perform follow-up stool examinations. Alternative dosing: 200 mcg/kg/day for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ascariasis due to",
"     </b>",
"     <b>",
"      <i>",
"       Ascaris lumbricoides",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 150-200 mcg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cutaneous larva migrans (CLM) due to",
"     </b>",
"     <b>",
"      <i>",
"       Ancylostoma braziliense",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 200 mcg/kg daily for 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Filariasis due to",
"     </b>",
"     <b>",
"      <i>",
"       Mansonella ozzardi",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 200 mcg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Filariasis due to",
"     </b>",
"     <b>",
"      <i>",
"       Mansonella streptocerca",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 150 mcg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Filariasis due to",
"     </b>",
"     <b>",
"      <i>",
"       Wucheria bancrofti",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 200 mcg/kg as a single dose given in combination with albendazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gnathostomiasis due to",
"     </b>",
"     <b>",
"      <i>",
"       Gnathostoma spinigerum",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 200 mcg/kg/day for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Lice due to",
"     </b>",
"     <b>",
"      <i>",
"       Pediculus humanus capitis, Pediculus humanus corporis, Phthirus pubis",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 200 mcg/kg/dose; generally requires more than 1 dose; number of doses and dosage intervals have not been established; 200 mcg/kg/dose  for 3 doses every 7 days (Foucault, 2006) and 200 mcg/kg/dose repeated once after 10 days (Jones, 2003) have been shown to be effective; alternatively 400 mcg/kg/dose on days 1 and 8 has been utilized in",
"     <i>",
"      Pediculus humanus capitis",
"     </i>",
"     (Chosidow, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Scabies due to",
"     </b>",
"     <b>",
"      <i>",
"       Sarcoptes scabiei",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 200 mcg/kg as a single dose; repeat in 2 weeks (drug of choice for immunocompromised patients with crusted scabies)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Trichuriasis due to",
"     </b>",
"     <b>",
"      <i>",
"       Trichuris trichiura",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 200 mcg/kg/day for 3 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13841912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/49/33557?source=see_link\">",
"      see \"Ivermectin (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Parasitic infections:",
"     </b>",
"     Oral: Children &ge;15 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13841914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13841927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stromectol&reg;: 3 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13841865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13841916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach with water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13841870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of the following infections: Strongyloidiasis of the intestinal tract due to the nematode parasite",
"     <i>",
"      Strongyloides stercoralis",
"     </i>",
"     . Onchocerciasis due to the immature form of the  nematode parasite",
"     <i>",
"      Onchocerca volvulus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13841871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of other parasitic infections, including",
"     <i>",
"      Ancylostoma braziliense, Ascaris lumbricoides, Sarcoptes scabiei, Gnathostoma spinigerum, Mansonella ozzardi, Mansonella streptocerca, Pediculus humanus capitis, Pediculus humanus corporis, Phthirus pubis, Trichuris trichiura, Wucheria bancrofti",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13841883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Miscellaneous: Mazzotti-type reaction (with onchocerciasis): Pruritus (28%), fever (23%), skin involvement (23%; including edema/urticarial rash), lymph node tenderness (1% to 14%), lymph node enlargement (3% to 13%), arthralgia/synovitis (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (4%), peripheral edema (3%), facial edema (1%), orthostatic hypotension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2%), nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia (3%), leukocytes decreased (3%), hemoglobin increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (2%), AST increased  (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal  distention, abdominal pain, anemia, anorexia, anterior uveitis, asthma exacerbation, back pain, bilirubin increased, chest discomfort, chorioretinitis, choroiditis, coma, confusion, conjunctival hemorrhage (associated with onchocerciasis), conjunctivitis, constipation, dyspnea, encephalopathy (rare; associated with loiasis), eyelid edema, eye sensation abnormal, fatigue, fecal incontinence, headache, hepatitis, hypotension, INR increased (with concomitant warfarin), keratitis, lethargy, leukopenia, mental status changes, myalgia, neck pain, rash, red eye, seizure, somnolence, standing/walking difficulty, Stevens-Johnson syndrome, stupor, toxic epidermal necrolysis, tremor, urinary incontinence, urticaria, vertigo, vision loss (transient), vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13841879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ivermectin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13841880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cutaneous/systemic reactions: Data have shown that antihelmintic drugs like ivermectin may cause cutaneous and/or systemic reactions (Mazzoti reaction) of varying severity including ophthalmological reactions in patients with onchocerciasis. These reactions are probably due to allergic and inflammatory responses to the death of microfilariae. Patients with hyper-reactive onchodermatitis may be more likely than others to experience severe adverse reactions, especially edema and aggravation of the onchodermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Loiasis: Pretreatment assessment for",
"     <i>",
"      Loa loa",
"     </i>",
"     infection is recommended in any patient with significant exposure to endemic areas (West and Central Africa); serious and/or fatal encephalopathy has been reported (rarely) during treatment in patients with loiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised patients: Repeated treatment may be required in immunocompromised patients (eg, HIV); control of extraintestinal strongyloidiasis may necessitate suppressive (once monthly) therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <i>",
"      Onchocerca volvulus:",
"     </i>",
"     Ivermectin has no activity against adult",
"     <i>",
"      O. volvulus",
"     </i>",
"     parasites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13841889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13841887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azithromycin (Systemic): May increase the serum concentration of Ivermectin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ivermectin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13841894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food: Bioavailability is increased 2.5-fold when administered following a high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13841873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13841874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies; therefore, the manufacturer classifies ivermectin as pregnancy category C. Ivermectin is not recommended for use in pregnancy. Although studies during pregnancy are limited, several mass treatment programs have not identified an increased risk of adverse fetal, neonatal, or maternal outcomes following ivermectin use in the first and second trimesters.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13841876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13841877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ivermectin is measurable in low concentrations in breast milk and is less than maternal plasma concentrations. Peak concentrations of ivermectin in breast milk may occur 4-12 hours after the oral dose. In one study, the calculated infant daily dose was 2.75 mcg/kg in a 1-month-old infant and would not be expected to cause adverse effects in the infant. The manufacturer and the CDC do not have safety data in children &lt;15 kg and the CDC does not recommend the use of ivermectin in lactating women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13841915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach with water.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F13841930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stromectol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (20): $111.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13841918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin and eye microfilarial counts, periodic ophthalmologic exams; follow up stool examinations",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13841933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ascapil (IN);",
"     </li>",
"     <li>",
"      Detebencil (AR);",
"     </li>",
"     <li>",
"      Ectin (IN);",
"     </li>",
"     <li>",
"      Ivermectol (IN);",
"     </li>",
"     <li>",
"      Ivermin (EC);",
"     </li>",
"     <li>",
"      Ivertal (AR);",
"     </li>",
"     <li>",
"      Iverx (CN);",
"     </li>",
"     <li>",
"      Ivexterm (CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Ivomec (CH);",
"     </li>",
"     <li>",
"      Kaonol (CN, PE);",
"     </li>",
"     <li>",
"      Kilox (EC, GT, HN, NI, PA);",
"     </li>",
"     <li>",
"      Leverctin (BR);",
"     </li>",
"     <li>",
"      Maikeding (CL);",
"     </li>",
"     <li>",
"      Mectizan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Quamox (PE);",
"     </li>",
"     <li>",
"      Quanox Gotas (CO);",
"     </li>",
"     <li>",
"      Revectina (BR);",
"     </li>",
"     <li>",
"      Sanifer (UY);",
"     </li>",
"     <li>",
"      Securo (AR);",
"     </li>",
"     <li>",
"      Simpiox (CO);",
"     </li>",
"     <li>",
"      Stromectol (AU, FR, GR, NL, NO, NZ, SG);",
"     </li>",
"     <li>",
"      Vermectil (BR);",
"     </li>",
"     <li>",
"      Vermectin (TH);",
"     </li>",
"     <li>",
"      Vermokill (PY);",
"     </li>",
"     <li>",
"      Yvermil (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13841897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ivermectin is a semisynthetic anthelminthic agent; it binds selectively and with strong affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to increased permeability of cell membranes to chloride ions then hyperpolarization of the nerve or muscle cell, and death of the parasite.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13841899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect in treatment of onchocerciasis: 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect in treatment of strongyloides: 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3-3.5 L/kg (healthy males); does not cross blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (major), CYP2D6 (minor), and CYP2E1 (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Increased with high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/42/40613/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chosidow O, Giraudeau B, Cottrell J, et al, &ldquo;Oral Ivermectin Versus Malathion Lotion for Difficult-to-Treat Head Lice,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(10):896-905.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/42/40613/abstract-text/20220184/pubmed\" id=\"20220184\" target=\"_blank\">",
"        20220184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Silva N, Guyatt H, and Bundy D, &ldquo;Anthelmintics. A Comparative Review of Their Clinical Pharmacology,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(5):769-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/42/40613/abstract-text/9129865/pubmed\" id=\"9129865\" target=\"_blank\">",
"        9129865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2007, 5(Suppl):e1-15.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foucault C, Ranque S, Badiaga S, et al, &ldquo;Oral Ivermectin in the Treatment of Body Lice,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 2006, 193(3):474-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/42/40613/abstract-text/16388498/pubmed\" id=\"16388498\" target=\"_blank\">",
"        16388498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frankowski BL and Bocchini JA Jr, &ldquo;Head Lice,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(2):392-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/42/40613/abstract-text/20660553/pubmed\" id=\"20660553\" target=\"_blank\">",
"        20660553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gonz&aacute;lez CA, Sahag&uacute;n Prieto AM, Diez Li&eacute;bana MJ, et al, &ldquo;The Pharmacokinetics and Interactions of Ivermectin in Humans--a Mini-Review,&rdquo;",
"      <i>",
"       AAPS J",
"      </i>",
"      , 2008, 10(1):42-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/42/40613/abstract-text/18446504/pubmed\" id=\"18446504\" target=\"_blank\">",
"        18446504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones KN and English JC 3rd, &ldquo;Review of Common Therapeutic Options in the United States for the Treatment of Pediculosis Capitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1355-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/42/40613/abstract-text/12766828/pubmed\" id=\"12766828\" target=\"_blank\">",
"        12766828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottesen EA and Campbell WC, &ldquo;Ivermectin in Human Medicine,&rdquo; J Antimicrob Chemother, 1994, 34(2):195-203.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83315 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40613=[""].join("\n");
var outline_f39_42_40613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841863\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841867\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841913\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841912\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841914\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160056\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160057\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841927\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841865\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841916\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841870\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841871\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841883\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841879\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841880\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841889\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841887\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841894\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841873\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841874\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841876\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841877\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841915\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841930\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841918\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841933\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841897\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841899\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/43/12980?source=related_link\">",
"      Ivermectin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/49/33557?source=related_link\">",
"      Ivermectin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/16/1283?source=related_link\">",
"      Ivermectin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/34/9764?source=related_link\">",
"      Ivermectin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/53/37714?source=related_link\">",
"      Ivermectin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_42_40614="Embryology of annular pancreas";
var content_f39_42_40614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Embryology of annular pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 622px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40614=[""].join("\n");
var outline_f39_42_40614=null;
var title_f39_42_40615="Treatment of menopausal symptoms with hormone therapy";
var content_f39_42_40615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of menopausal symptoms with hormone therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40615/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40615/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40615/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40615/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40615/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40615/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/42/40615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal hormone therapy is currently recommended for short-term management of moderate-to-severe vasomotor flushes. Long-term use for prevention of disease is no longer recommended. The treatment of menopausal signs and symptoms with postmenopausal hormone therapy (estrogen alone or combined with progestin) will be reviewed here. An overview of the risks and benefits of estrogen, available hormone preparations, and an overview of menopausal therapies for women who choose not to or cannot take estrogen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasomotor symptoms occur most often in the late menopausal transition and the early postmenopause (",
"    <a class=\"graphic graphic_figure graphicRef82933 \" href=\"mobipreview.htm?34/59/35760\">",
"     figure 1",
"    </a>",
"    ). Although there are alternative therapies for vasomotor symptoms, none appear to be as effective as estrogen. The physiology, clinical manifestations (including insomnia), and treatment of hot flashes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We consider estrogen to be a reasonable short-term option for most symptomatic postmenopausal women, with the exception of those with a history of breast cancer, coronary heart disease, a previous venous thromboembolic event or stroke, active liver disease, or those at high risk for these complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, short-term therapy (with a goal of symptom management) was defined as less than five years. This definition is somewhat arbitrary as there is no general consensus about the duration of short-term versus long-term therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1\">",
"     1",
"    </a>",
"    ]. However, short-term therapy is now generally considered to be two to three years, and not more than five years.",
"   </p>",
"   <p>",
"    At this time, postmenopausal hormone therapy, either unopposed estrogen or combined estrogen-progestin therapy should not be initiated for the prevention of CHD. In addition, postmenopausal hormone therapy is no longer considered to be a first-line drug for the prevention and treatment of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VASOMOTOR SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the WHI and the HERS trials have led to changes in recommendations for postmenopausal hormone therapy. The approach outlined here is consistent with the position statement of the North American Menopause Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1\">",
"     1",
"    </a>",
"    ], and the Scientific Statement from the Endocrine Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy remains the gold standard for relief of menopausal symptoms, in particular, hot flashes, and therefore is a reasonable option for most postmenopausal women, with the exception of those with a history of breast cancer, CHD, a previous venous thromboembolic event or stroke, or those at high risk for these complications. In otherwise healthy women, the absolute risk of an adverse event is extremely low. Thus, perimenopausal women should be reassured that taking estrogen (either unopposed or combined with progestin) for the management of menopausal symptoms is a safe therapeutic intervention for many women.",
"   </p>",
"   <p>",
"    The physiology, clinical manifestations (including insomnia), and treatment of hot flashes (including intractable hot flashes) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the WHI, the risk of breast cancer with combined estrogen-progestin therapy did not increase until the fourth year. However, abnormal mammograms were more common in the HT group (the majority of abnormal mammograms represented requests for additional views). Thus, routine mammograms and breast exams are essential, even if HT is used short-term. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration now require the adding of labels to all estrogen and estrogen-progestin products warning of the possible risk of heart disease, stroke, and cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adding a progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia and cancer can occur after as little as six months of unopposed estrogen therapy; as a result, a progestin should be added in women who have not had a hysterectomy.",
"   </p>",
"   <p>",
"    Although the overall risk-benefit profile in the WHI for unopposed CEE appeared more favorable than for combined CEE 0.625 mg with MPA 2.5 mg, use of lower than standard progestin doses, less frequent administration (eg, quarterly), alternate routes (progestin IUDs), or lower doses of estrogen without progestin may not reliably prevent endometrial hyperplasia and carcinoma. Thus, we cannot recommend the use of unopposed estrogen, or non-standard progestin regimens in women with an intact uterus. However, if an alternative progestin regimen is used, close endometrial surveillance should be performed pending additional data on non-standard regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link&amp;anchor=H256690677#H256690677\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Endometrial hyperplasia and carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who have undergone hysterectomy should not receive a progestin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hormone preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the WHI and HERS trials provided data only on combined, continuous conjugated estrogens (0.625 mg) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA 2.5 mg), a synthetic progestin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Estrogen preparations other than conjugated estrogens, and progestins other than MPA (such as natural micronized progesterone) should be discussed with the patient. Although there are reasons to believe that natural progesterone might be safer for the cardiovascular system (no adverse lipid effects), it is important to emphasize that it is not known if this preparation, or different regimens (ie, quarterly progestin administration), is safer for the breast or cardiovascular system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H4#H4\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Effects of progestins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link&amp;anchor=H150020565#H150020565\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Type of progestin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conjugated estrogen and 17-beta estradiol (oral or transdermal) appear to be equally effective for the treatment of hot flashes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/9\">",
"     9",
"    </a>",
"    ]. Although there are epidemiologic data which suggest a lower risk of venous thromboembolic events with transdermal rather than oral estrogen preparations, there are thus far no clinical trial data demonstrating a better cardiovascular risk profile for transdermal preparations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H22#H22\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Route of estrogen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to oral and transdermal estrogen preparations, estrogen is available as a vaginal ring, and as a topical spray, cream or gel. The topical spray (Evamist) has been linked to adverse effects in children and pets exposed to the drug via skin contact. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is not known if lower doses of estrogen or progestin have less of an effect on the breast and cardiovascular system, we recommend using low dose estrogen when possible (eg, 0.3 mg conjugated estrogens or 0.5 mg estradiol). In some studies, these doses have been adequate for symptom management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352147582\">",
"    <span class=\"h3\">",
"     Dose equivalents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies of safety and efficacy of postmenopausal estrogen have used conjugated estrogen 0.625 mg. This is considered to be standard dose estrogen; low dose preparations in general contain one-half the standard dose. The doses of other estrogens that are equivalent to conjugated estrogens include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1 mg micronized 17-beta-estradiol",
"     </li>",
"     <li>",
"      50",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      transdermal 17-beta-estradiol",
"     </li>",
"     <li>",
"      1.25 mg piperazine estrone sulfate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    Estradiol gels and sprays are available in different strengths and delivery systems (pump, foil packets). Dosing equivalents depend upon the individual preparation.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352145522\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For postmenopausal women with moderate-to-severe vasomotor symptoms (and no contraindications to estrogen use), we suggest estrogen therapy as the treatment of choice. The lowest effective dose of estrogen should be used for the shortest duration possible. Short-term therapy is considered to be two to three years, and generally not more than five years. Only the minority of women who are unable to successfully discontinue estrogen without persistent symptoms should consider extended use of estrogen therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352146120\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women ages 50 to 59 years with moderate-to-severe hot flashes are candidates for short-term hormone therapy for symptomatic relief. Exceptions include women with known coronary heart disease, breast cancer, a previous venous thromboembolic event or stroke, active liver disease, or those at high risk for these complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352146185\">",
"    <span class=\"h2\">",
"     Migraine headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine headaches are not considered to be a contraindication to postmenopausal hormone therapy. The effect of hormone therapy on migraines is variable, as some women improve, while others worsen or notice no change in headache frequency. In postmenopausal women who take estrogen for vasomotor symptoms, continuous hormone regimens (as opposed to cyclic regimens) should be used to avoid triggering estrogen withdrawal headaches. The effect of hormone therapy on stroke risk in postmenopausal women with migraines is not well studied. The topic of menopause, hormone therapy, and migraine is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=see_link&amp;anchor=H15#H15\">",
"     \"Estrogen-associated migraine\", section on 'Migraines and menopause'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use of oral contraceptives during the menopausal transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low-estrogen oral contraceptive is an option for perimenopausal women who seek relief of menopausal symptoms, and who also desire contraception, and in some instances need bleeding control (in cases of heavy bleeding). Most of these women are between the ages of 40 and 50 years and are still candidates for oral contraception. For them, an oral contraceptive pill containing 20 mcg of ethinyl estradiol provides symptomatic relief while providing better bleeding control than conventional estrogen-progestin therapy because the oral contraceptive contains higher doses of both estrogen and progestin (which suppresses the hypothalamic-pituitary-ovarian axis).",
"   </p>",
"   <p>",
"    Contraception remains important during perimenopause, as women cannot be certain of infertility until they reach menopause (ie, 12 months without menses). The possibility of pregnancy in women age 45 to 49 not using contraception is estimated to be 2 to 3 percent, falling to less than 1 percent after age 50.",
"   </p>",
"   <p>",
"    In our practice, when women taking a low-dose oral contraceptive during menopause reach age 50 or 51 years, we discuss stopping the pill altogether, or changing to a postmenopausal estrogen regimen if necessary for symptoms. If estrogen is then given, the same recommendations for use would apply (for management of symptoms but not for disease prevention). Because women at this age are apt to have hot flushes when estrogen is stopped abruptly, we suggest tapering the oral contraceptive by one pill per week as described for estrogen therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link&amp;anchor=H10#H10\">",
"     \"Menopausal hot flashes\", section on 'Cessation of postmenopausal hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of oral contraceptives is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H627283998#H627283998\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Perimenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     VAGINAL ATROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epithelial lining of the vagina and urethra are very sensitive to estrogen, and estrogen deficiency leads to thinning of the vaginal epithelium. This results in vaginal atrophy (atrophic vaginitis), causing symptoms of vaginal dryness, itching, and often dyspareunia. Both systemic and vaginal estrogen are effective for genitourinary atrophy symptoms, but vaginal estrogen may have more local effect without high systemic levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vaginal estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal estrogen administration (available as cream, tablets, or rings) is an extremely effective therapy for genitourinary symptoms. It is an excellent option for nearly all postmenopausal women (with the exception of breast cancer patients) and can be administered long-term as systemic absorption, when appropriate doses are used, is negligible. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISEASE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal hormone therapy is no longer recommended for prevention of chronic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2001 American Heart Association (AHA) guidelines for estrogen therapy, long-term therapy was",
"    <strong>",
"     no longer",
"    </strong>",
"    recommended for either primary or secondary prevention of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/10\">",
"     10",
"    </a>",
"    ]. This recommendation still applies based upon the results of the WHI and HERS-II trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], and is consistent with the expert guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, emerging data suggest that the risk of CHD events is largely confined to older postmenopausal women, with no significant increased risk of CHD-related events in younger postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H9#H9\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Timing of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is possible that other estrogen preparations or doses might not have the same negative cardiovascular effects as conjugated estrogen and MPA, it is safest to assume that combined therapy has some beneficial effects (fracture and colon cancer), but has risks that outweigh the benefits, particularly in older women.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although we previously recommended estrogen as a first-line choice for prevention and treatment of osteoporosis, we now recommend bisphosphonates or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the available WHI data, postmenopausal hormone therapy should not be initiated after age 65 years to prevent dementia. There is insufficient evidence to either support or refute that postmenopausal hormone therapy use in perimenopausal women is effective for the prevention of later dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"     \"Estrogen and cognitive function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     WOMEN WITH POF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the WHI should not be extrapolated to women with premature ovarian failure (menopause before age 40 years) in whom postmenopausal hormone therapy is generally initiated at a younger age. In otherwise healthy women with premature ovarian failure, we continue their postmenopausal hormone therapy until their late 40s or age 50 years. At that point, the same discussion of potential risks and benefits of postmenopausal hormone therapy should take place. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Duration of estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     WOMEN WITH BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although women with breast cancer often experience early menopause due to adjuvant chemotherapy, and may have vasomotor symptoms due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy, estrogen therapy should not be prescribed. The epidemiologic data and clinical trial data have been inconsistent, but the increased risk of breast cancer recurrence with estrogen therapy in one trial (HABITS) is of great concern. We therefore do",
"    <strong>",
"     not",
"    </strong>",
"    recommend estrogen for women with a personal history of breast cancer. We suggest that other established means of controlling symptoms or preventing osteoporosis should be utilized before considering estrogen therapy in these women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link&amp;anchor=H22#H22\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Personal history of breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANDROGEN REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The known decrease in ovarian androgen production rates and serum androgen concentrations has caused concern that menopause might be associated with a decline in libido. An age-associated decline in sexual desire has been observed in both men and women. However, it is unclear whether the decline in libido in women is age- or menopause-related, since studies in women have not shown a significant correlation between libido and the serum estradiol or testosterone concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials of exogenous testosterone replacement suggest benefits of testosterone therapy in some postmenopausal women. However, there are potential risks associated with androgen replacement. Until the beneficial effects of androgen replacement are better established, it cannot be routinely recommended to postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link\">",
"     \"Androgen production and therapy in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CESSATION OF POSTMENOPAUSAL HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women have no trouble stopping estrogen. Observational studies report that 40 to 50 percent of women who start postmenopausal hormone therapy stop within one year, and 65 to 75 percent stop within two years, often with no assistance from their healthcare provider. However, for many others, abrupt withdrawal of exogenous estrogen results in the return of hot flashes and other menopausal symptoms, sometimes requiring resumption of therapy. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link&amp;anchor=H10#H10\">",
"     \"Menopausal hot flashes\", section on 'Cessation of postmenopausal hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The implications of stopping estrogen-progestin therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Return of estrogen deficiency symptoms (hot flashes, but not genitourinary atrophy symptoms, might be minimized with a taper). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .) The North American Menopause Society suggests that after a failed attempt at stopping therapy, extended use of postmenopausal hormone therapy may be reasonable in women who feel that the benefits of symptom relief outweigh risks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1\">",
"       1",
"      </a>",
"      ]. In this setting, we make additional attempts at a later date to stop the postmenopausal hormone therapy.",
"     </li>",
"     <li>",
"      Resumption of bone loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"       \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decrease in breast cancer risk to baseline after five years (",
"      <a class=\"graphic graphic_figure graphicRef63013 \" href=\"mobipreview.htm?13/27/13759\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"       \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of estrogen cessation on coronary disease is not known but ET has been associated with no evidence of benefit for either primary or secondary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists, North American Menopause Society, and the United States Preventive Services Task Force have issued evidence-based guidelines with recommendations similar to those outlined here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. The USPSTF clinical practice guideline for postmenopausal hormone therapy for the prevention of chronic conditions in postmenopausal women, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    . For women considering extended use, a 2010 Scientific Statement of the Endocrine Society provides the attributable risks and benefits of hormone therapy for a period of five years in women ages 50 to 59. These data can be used for evidence-based decision making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40615/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/27/40370?source=see_link\">",
"       \"Patient information: Menopause (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=see_link\">",
"       \"Patient information: Menopause (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=see_link\">",
"       \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"       \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"       \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Most postmenopausal women, with the exception of women with breast cancer or known cardiovascular disease, who have symptoms of vaginal atrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasomotor instability are good candidates for estrogen therapy (for the shortest duration possible depending upon symptoms). The recommendations outlined below are consistent with those of the North American Menopause Society.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Vasomotor instability",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postmenopausal women with moderate-to-severe vasomotor symptoms (and no history of breast cancer or cardiovascular disease), we suggest short-term estrogen therapy as the treatment of choice (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with an intact uterus who choose estrogen therapy, we recommend adding a progestin for prevention of endometrial hyperplasia and carcinoma (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Adding a progestin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for women who choose not to take systemic estrogen, have contraindications to estrogen, or have stopped their postmenopausal hormone therapy and are having recurrent symptoms, are found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link&amp;anchor=H12#H12\">",
"       \"Menopausal hot flashes\", section on 'Other therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Vaginal atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of women with breast cancer, almost all postmenopausal women are candidates for vaginal estrogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with mild urogenital atrophy symptoms, we suggest vaginal moisturizing agents on a regular basis and lubricants during intercourse (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women with moderate-to-severe symptoms, or for those in whom moisturizers and lubricants are ineffective, we recommend low-dose vaginal estrogen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The use of vaginal estrogen is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=see_link\">",
"       \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Disease prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We currently do not consider estrogen to be a first-line therapy for prevention of chronic disease, including osteoporosis. Recommendations for the prevention and treatment of osteoporosis in women are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estrogen is no longer indicated for the prevention of CHD in postmenopausal women. The best means of primary and secondary prevention of cardiovascular disease involves attention to risk factors such as smoking, hypertension, dyslipidemia, and diabetes mellitus. Specific recommendations for cardiovascular disease prevention are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"       \"Overview of primary prevention of coronary heart disease and stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/1\">",
"      North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/2\">",
"      Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/3\">",
"      Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010; 115:839.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Questions and Answers for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women (Updated). file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135339.htm (Accessed on July 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/5\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/6\">",
"      Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/7\">",
"      Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/8\">",
"      Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/9\">",
"      Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/10\">",
"      Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/11\">",
"      Myers LS, Dixen J, Morrissette D, et al. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990; 70:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/12\">",
"      Lindsay R, Hart DM, MacLean A, et al. Bone response to termination of oestrogen treatment. Lancet 1978; 1:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/13\">",
"      Christiansen C, Christensen MS, Transb&oslash;l I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/14\">",
"      Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/15\">",
"      Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40615/abstract/16\">",
"      American College of Obstetricians and Gynecologists Women's Health Care Physicians. Executive summary. Hormone therapy. Obstet Gynecol 2004; 104:1S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7450 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40615=[""].join("\n");
var outline_f39_42_40615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VASOMOTOR SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adding a progestin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hormone preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H352147582\">",
"      - Dose equivalents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352145522\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352146120\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352146185\">",
"      Migraine headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use of oral contraceptives during the menopausal transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VAGINAL ATROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vaginal estrogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISEASE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      WOMEN WITH POF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      WOMEN WITH BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANDROGEN REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CESSATION OF POSTMENOPAUSAL HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Vasomotor instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Disease prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7450|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/59/35760\" title=\"figure 1\">",
"      STRAW staging system for reproductive aging women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/27/13759\" title=\"figure 2\">",
"      Risk of breast cancer with ERT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=related_link\">",
"      Estrogen and cognitive function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=related_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_42_40616="Classification and incidence of childhood vasculitis";
var content_f39_42_40616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and incidence of childhood vasculitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40616/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40616/contributors\">",
"     David Cabral, MBBS, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40616/contributors\">",
"     Kimberly Morishita, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40616/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40616/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40616/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/42/40616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitides are disorders defined by the presence of inflammation in a blood vessel wall (vasculitis). The inflammation may occur as a primary process or secondary to an underlying disease. Clinical symptoms vary widely depending upon the types and location of the vessels involved, the extent of inflammation, and subsequent vessel wall damage with associated hemodynamic changes.",
"   </p>",
"   <p>",
"    The primary vasculitides may be classified according to their clinical manifestations, the size and type of the involved blood vessels, and the pathologic changes found within the vessel walls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nomenclature and criteria used for classification of the primary childhood vasculitides will be reviewed here. The approach to the child with suspected vasculitis and an overview of the management of children with vasculitic disorders are presented separately. The classification and approach to vasculitides in adults are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33383?source=see_link\">",
"     \"Approach to evaluating childhood vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9657?source=see_link\">",
"     \"Overview of the management of vasculitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is rare in children as demonstrated by the following two population-based studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an English survey of family clinicians, the estimated overall annual incidence of new cases of vasculitis was 53.3 per 100,000 children under 17 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/2\">",
"       2",
"      </a>",
"      ]. The two most common vasculitides were Henoch-Sch&ouml;nlein purpura (HSP, also called IgA vasculitis [IgAV]) and Kawasaki disease, with estimated annual incidences of 20.4 and 5.5 per 100,000 in children less than 17 years of age, respectively.",
"     </li>",
"     <li>",
"      In a study from the Czech Republic, a hospital-based estimate of the annual incidence of vasculitis was lower, at 12 per 100,000 children under 17 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/3\">",
"       3",
"      </a>",
"      ]. The annual incidences of HSP (IgAV) and Kawasaki disease were 10.2 and 1.6 per 100,000 children under 17 years of age, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both of these surveys are likely to underestimate the incidence of childhood vasculitides, since they are based upon voluntary surveys of clinicians serving limited segments of the population. The former report is probably nearer the truth, since the Czech study might not have detected affected children who never came to the attention of hospital-based clinicians. In fact, other estimates of KD incidence have yielded values about twice those of the British report. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=see_link&amp;anchor=H2#H2\">",
"     \"Kawasaki disease: Epidemiology and etiology\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted in these two studies, HSP (IgAV) is the most common vasculitis followed by Kawasaki disease. Other rarer vasculitides in children include Takayasu arteritis (which occurs more frequently in children from the Far East and Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]), granulomatosis with polyangiitis (Wegener's), primary angiitis of the central nervous system, and polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/5\">",
"     5",
"    </a>",
"    ]. Churg-Strauss syndrome is extremely rare in children, and temporal arteritis is not seen in pediatric patients because a diagnostic criterion is an age greater than 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION VERSUS DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification criteria were developed in order to standardize clinical definitions of different vasculitides. The goal was to facilitate and improve research efforts by defining consistent and homogeneous patient populations for clinical protocols and outcome studies. Classification criteria were not developed to diagnose disease in individuals and have not been validated for clinical diagnosis.",
"   </p>",
"   <p>",
"    Because childhood vasculitides are rare, individual clinicians with limited or no previous exposure to particular conditions may use classification criteria to assist in the diagnosis of individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/5\">",
"     5",
"    </a>",
"    ]. However, studies in adult patients with vasculitis have shown that the diagnostic accuracy is low if classification criteria are used to make the diagnosis of a specific vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/7\">",
"     7",
"    </a>",
"    ]. In particular, failure to meet the classification criteria does not necessarily preclude a specific diagnosis. The gold standard for diagnosing childhood vasculitis is with either histopathology from tissue biopsy samples or by characteristic lesions detected by imaging studies. However, in certain vasculitides such as Kawasaki disease, HSP (IgAV), and frequently granulomatosis with polyangiitis (Wegener's), diagnosis is more often based upon syndrome recognition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary vasculitides may be classified based upon their clinical manifestations, size of the involved blood vessel, histopathology of the damaged vessel, or the presumed underlying disease pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. The most widely used nomenclature was proposed by the Chapel Hill Consensus Conference (CHCC) on Systemic Vasculitis. It provides the following framework for classification of vasculitides based upon vessel size, but does not include criteria for classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominately large vessel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Giant cell (temporal) arteritis",
"     </li>",
"     <li>",
"      Takayasu arteritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominately medium size vessel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Classical polyarteritis nodosa",
"     </li>",
"     <li>",
"      Kawasaki disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominately small vessel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Churg-Strauss syndrome",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </li>",
"     <li>",
"      Microscopic polyangiitis",
"     </li>",
"     <li>",
"      Granulomatosis with polyangiitis (Wegener's)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most widely used classification criteria are those introduced by the American College of Rheumatology (ACR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/6\">",
"     6",
"    </a>",
"    ]. However, both the ACR classification criteria and the CHCC nomenclature classification are based upon data from adult patients. Because the ACR system was developed for classifying the vasculitides in adults, Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and Kawasaki disease, the two most common pediatric vasculitides, were not included. In addition, using the ACR schema, one-half to one-third of children with chronic systemic vasculitis could not be classified under a specific \"named\" vasculitis syndrome and would be categorized as unclassified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. Other inadequacies in the performance of the classification systems in adult patients have been noted, and the systems of classification remain under scrutiny [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2005, the European League against Rheumatism (EULAR) and the Paediatric Rheumatology European Society (PRES) proposed a system of classification for vasculitides that occur in children who are at or below 18 years of age. Specific classification criteria were proposed for the more common childhood vasculitic syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14\">",
"     14",
"    </a>",
"    ]. The rationale of this proposal was to incorporate and build upon the existing ACR criteria by adding individual criteria that are more frequent in, or characteristic of, childhood presentation. Theoretically this would provide improved sensitivity and specificity for classification of pediatric disorders, with fewer children remaining \"unclassifiable.\" As an example, \"subglottic, tracheal, or endobronchial stenosis,\" a more frequent presentation of granulomatosis with polyangiitis (GPA, Wegener's) in children, was added as a diagnostic criterion for childhood GPA. The ACR classification system is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2008, the EULAR, PRES and the Paediatric Rheumatology International Trials Organisation (PRINTO), using a cohort of over 1000 patients collected from nearly 100 centers, conducted a formal statistical validation of the preliminary",
"    <span class=\"nowrap\">",
"     EULAR/PRES",
"    </span>",
"    classification criteria for Henoch-Sch&ouml;nlein purpura (IgA vasculitis), Takayasu arteritis, polyarteritis nodosa, and Wegener's granulomatosis. By consensus, minor changes to these criteria were made, and improved sensitivity and specificity were demonstrated when applied to the same patient cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with the CHCC classification, the",
"    <span class=\"nowrap\">",
"     EULAR/PRES",
"    </span>",
"    schema is primarily based upon the size of the involved vessel. However, it also includes a category of \"other vasculitides\" for those diseases that do not fit into categories based upon vessel size as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominately large vessel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Takayasu arteritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominately medium size vessel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Childhood polyarteritis nodosa",
"     </li>",
"     <li>",
"      Cutaneous polyarteritis nodosa",
"     </li>",
"     <li>",
"      Kawasaki disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominately small vessel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Granulomatous",
"     </li>",
"     <li>",
"      Churg-Strauss syndrome",
"     </li>",
"     <li>",
"      Granulomatosis with polyangiitis (Wegener's)",
"     </li>",
"     <li>",
"      Nongranulomatous",
"     </li>",
"     <li>",
"      Microscopic polyangiitis",
"     </li>",
"     <li>",
"      Leukocytoclastic vasculitides",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </li>",
"     <li>",
"      Isolated cutaneous leukocytoclastic vasculitis",
"     </li>",
"     <li>",
"      Hypocomplementemic urticarial vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other vasculitides",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Behcet's disease",
"     </li>",
"     <li>",
"      Secondary vasculitides due to infection, malignancy, or drugs, including hypersensitivity vasculitis",
"     </li>",
"     <li>",
"      Isolated vasculitis of the central nervous system",
"     </li>",
"     <li>",
"      Cogan's syndrome",
"     </li>",
"     <li>",
"      Unclassified",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CRITERIA: MAJOR PRIMARY VASCULITIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification criteria for some of the more common pediatric primary vasculitides, based upon clinical manifestations and histopathology, were proposed by the European League against Rheumatism (EULAR) and the Paediatric Rheumatology European Society (PRES) in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14\">",
"     14",
"    </a>",
"    ]. Criteria for Henoch-Sch&ouml;nlein purpura (IgA vasculitis), Takayasu arteritis, polyarteritis nodosa, and granulomatosis with polyangiitis (Wegener's) were subsequently validated and improved upon in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/15\">",
"     15",
"    </a>",
"    ], and are referred to as the",
"    <span class=\"nowrap\">",
"     EULAR/PRINTO/PRES",
"    </span>",
"    criteria in this review. Almost all of these disorders are discussed in greater detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (IgA vasculitis), the most common childhood vasculitis, is an immune-mediated vasculitis associated with immunoglobulin A (IgA) deposition.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     EULAR/PRINTO/PRES",
"    </span>",
"    criteria for Henoch-Sch&ouml;nlein purpura (IgA vasculitis) include a mandatory finding of purpura (commonly palpable and in crops) (",
"    <a class=\"graphic graphic_picture graphicRef63367 graphicRef72094 \" href=\"mobipreview.htm?26/46/27367\">",
"     picture 1A-B",
"    </a>",
"    ) or petechiae (without thrombocytopenia) with lower limb predominance, and one or more of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse abdominal pain",
"     </li>",
"     <li>",
"      Arthritis or arthralgia",
"     </li>",
"     <li>",
"      Leukocytoclastic vasculitis or proliferative glomerulonephritis with predominant immunoglobulin A (IgA) deposition",
"     </li>",
"     <li>",
"      Renal involvement (hematuria, red blood cell casts, or proteinuria)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A biopsy demonstrating IgA deposits is required in the case of purpura with an atypical distribution.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease is an acute self-limited vasculitis that occurs predominately in infants and young children. First described in 1967 by Tomisaku Kawasaki [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/16\">",
"     16",
"    </a>",
"    ], this disorder mainly affects medium-sized arteries.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     EULAR/PRES",
"    </span>",
"    classification criteria for Kawasaki disease are not validated; however, they are almost identical to the American Heart Association (AHA) diagnostic criteria, which are the most widely used criteria for the diagnosis of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link&amp;anchor=H26262883#H26262883\">",
"     \"Kawasaki disease: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The criteria for Kawasaki disease include a mandatory finding of fever for at least five days, and four of the five following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral conjunctival injection (",
"      <a class=\"graphic graphic_picture graphicRef78898 \" href=\"mobipreview.htm?15/1/15376\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Oral mucous membrane changes, including injected or fissured lips, injected pharynx, or strawberry tongue (",
"      <a class=\"graphic graphic_picture graphicRef68321 \" href=\"mobipreview.htm?0/2/43\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Perineal and peripheral extremity changes, including erythema of palms or soles, edema of hands or feet (acute phase) (",
"      <a class=\"graphic graphic_picture graphicRef72040 \" href=\"mobipreview.htm?25/12/25793\">",
"       picture 4",
"      </a>",
"      ), and periungual or perineal desquamation (convalescent phase) (",
"      <a class=\"graphic graphic_picture graphicRef53452 \" href=\"mobipreview.htm?5/29/5587\">",
"       picture 5",
"      </a>",
"      ). Inclusion of perineal desquamation is a modification added by the",
"      <span class=\"nowrap\">",
"       EULAR/PRES",
"      </span>",
"      classification to the AHA criteria.",
"     </li>",
"     <li>",
"      Polymorphous exanthema.",
"     </li>",
"     <li>",
"      Cervical lymphadenopathy (at least one lymph node &gt;1.5 cm in diameter).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with fever and fewer than four of the above criteria can also be diagnosed with Kawasaki disease if coronary artery abnormalities are detected either by two-dimensional echocardiography or coronary angiography.",
"   </p>",
"   <p>",
"    In some cases, children do not fulfill clinical criteria and are diagnosed with incomplete or atypical Kawasaki. Alternatively, some patients who fulfill the criteria of Kawasaki disease may have other conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11814?source=see_link\">",
"     \"Incomplete (atypical) Kawasaki disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link&amp;anchor=H26263419#H26263419\">",
"     \"Kawasaki disease: Clinical features and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa (also called macroscopic polyarteritis or classic polyarteritis nodosa) is a systemic necrotizing vasculitis with aneurysm formation affecting small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medium-sized arteries. It typically presents with systemic symptoms (eg, fever, malaise, and weight loss) and signs of multisystem involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     EULAR/PRINTO/PRES",
"    </span>",
"    classification criteria for childhood polyarteritis nodosa include a mandatory finding of abnormalities in a small or medium sized artery identified by biopsy demonstration of necrotizing vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef74893 \" href=\"mobipreview.htm?8/49/8985\">",
"     picture 6",
"    </a>",
"    ) OR angiographically with the presence of aneurysms, stenoses or occlusions not due to fibromuscular dysplasia, and at least one of the following five systemic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin involvement (livedo reticularis, tender subcutaneous nodules, superficial or deep skin infarctions)",
"     </li>",
"     <li>",
"      Myalgia or muscle tenderness",
"     </li>",
"     <li>",
"      Hypertension (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral neuropathy (sensory peripheral neuropathy or motor mononeuritis multiplex)",
"     </li>",
"     <li>",
"      Renal involvement (proteinuria, hematuria, or red blood cell casts, or glomerular filtration rate of less than 50 percent the normal value for age)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infantile PAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile polyarteritis nodosa generally occurs before the age of two years and most commonly affects the coronary arteries, often resulting in aneurysm formation in these vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These patients frequently present with heart failure; however, renal failure, severe gastrointestinal disturbance, and central nervous system dysfunction can also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/19\">",
"     19",
"    </a>",
"    ]. The diagnosis is often made postmortem. Infantile polyarteritis and Kawasaki disease share certain clinical and pathologic features, and are considered by some to represent the same disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cutaneous polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous polyarteritis nodosa is a more limited disorder than systemic polyarteritis nodosa, and typically affects only the skin and musculoskeletal system. Although there is no strict definition of cutaneous polyarteritis nodosa, it appears that this is a distinct form of necrotizing vasculitis in children separate from systemic polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No formal classification criteria have been proposed for this disorder in children. The clinical and laboratory features of childhood cutaneous polyarteritis nodosa include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous nodular, painful, non-purpuric lesions with or without livedo reticularis are present without evidence of systemic involvement (except for myalgia, arthralgia, and non-erosive arthritis).",
"     </li>",
"     <li>",
"      Tissue biopsy demonstrates necrotizing nongranulomatous vasculitis (",
"      <a class=\"graphic graphic_picture graphicRef51874 \" href=\"mobipreview.htm?9/32/9737\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tests for antineutrophil cytoplasmic antibodies (ANCA) are negative.",
"     </li>",
"     <li>",
"      There is often a history of a preceding streptococcal infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. As a result, there may be serological or microbiological evidence of streptococcal infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Takayasu arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Takayasu arteritis is a chronic, inflammatory, large-vessel vasculitis of unknown cause that primarily affects the aorta and its major branches (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64547 \" href=\"mobipreview.htm?19/28/19904\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62264 \" href=\"mobipreview.htm?26/53/27474\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/26\">",
"     26",
"    </a>",
"    ]. Ongoing granulomatous inflammation leads to stenosis, thrombus, and aneurysm formation causing altered blood flow to major organs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     EULAR/PRINTO/PRES",
"    </span>",
"    criteria of Takayasu's arteritis in children require a mandatory finding of angiographic abnormalities of the aorta or its main branches and pulmonary arteries",
"    <span class=\"nowrap\">",
"     (aneurysm/dilatation,",
"    </span>",
"    narrowing, occlusion, or arterial wall thickening not due to fibromuscular dysplasia), and at least one of the following five features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulse deficit",
"      <span class=\"nowrap\">",
"       (lost/decreased/unequal",
"      </span>",
"      peripheral artery",
"      <span class=\"nowrap\">",
"       pulse/s)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      claudication induced by activity",
"     </li>",
"     <li>",
"      Systolic blood pressure difference &gt;10 mm Hg between any limb",
"     </li>",
"     <li>",
"      Bruits or thrills over the aorta",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      its major branches",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Elevated acute phase reactant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angiographic confirmation may be performed by conventional radiography, computed tomography, or magnetic resonance imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Granulomatosis with polyangiitis (Wegener's)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's) is a systemic vasculitis with granulomatous inflammation of small and medium-sized arteries, typically affecting the upper and lower respiratory tract, and the kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/27\">",
"     27",
"    </a>",
"    ]. It is usually associated with the presence of mainly cytoplasmic antineutrophil cytoplasmic antibodies (cANCA), generally with specificity for proteinase 3 (PR3) (",
"    <a class=\"graphic graphic_picture graphicRef66748 \" href=\"mobipreview.htm?38/51/39742\">",
"     picture 8",
"    </a>",
"    ). Granulomatosis with polyangiitis (Wegener's) is a rare disease in childhood, with an estimated annual incidence of less than one per one million children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     EULAR/PRINTO/PRES",
"    </span>",
"    classification criteria for granulomatosis with polyangiitis (Wegener's) require three of the following six features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal involvement (hematuria, proteinuria, or red blood cell casts, or necrotizing pauci-immune glomerulonephritis)",
"     </li>",
"     <li>",
"      Upper airway involvement",
"      <span class=\"nowrap\">",
"       (chronic/recurrent",
"      </span>",
"      purulent or bloody nasal discharge or crusting, or recurrent epistaxis)",
"     </li>",
"     <li>",
"      Laryngotracheobronchial stenosis",
"     </li>",
"     <li>",
"      Pulmonary involvement (chest x-ray or CT showing nodules, cavities, or fixed infiltrates)",
"     </li>",
"     <li>",
"      ANCA positivity (PR3 ANCA or C-ANCA staining)",
"     </li>",
"     <li>",
"      Granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area on biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER CHILDHOOD PRIMARY VASCULITIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the following primary vasculitides were included in the",
"    <span class=\"nowrap\">",
"     EULAR/PRES",
"    </span>",
"    classification schema, classification criteria were not developed for these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Churg-Strauss syndrome",
"     </li>",
"     <li>",
"      Microscopic angiitis",
"     </li>",
"     <li>",
"      Hypersensitivity vasculitis",
"     </li>",
"     <li>",
"      Behcet's disease",
"     </li>",
"     <li>",
"      Primary angiitis of the central nervous system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Churg-Strauss syndrome, granulomatosis with polyangiitis (Wegener's), and microscopic polyangiitis are sometimes collectively classified as the ANCA-associated vasculitides. They also each involve small arteries. The most important reason for this collective classification is that the definitions and classification criteria for each of these disorders are not mutually exclusive. Thus, an individual patient could be classified as having two of these diseases, or even polyarteritis nodosum. To overcome this conundrum, algorithms have been proposed whereby disease definitions and criteria are applied to the individual patient in a stepwise approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/31\">",
"     31",
"    </a>",
"    ]. The definition and criteria for Churg-Strauss syndrome are the most specific, therefore they are applied first. If the patient does not fulfill criteria, then the remaining elements of different criteria are sequentially applied until the patient is classified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Churg-Strauss syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Churg-Strauss syndrome (also called allergic granulomatosis and angiitis) is a predominantly small-vessel vasculitis that is accompanied by asthma and eosinophilia. ANCA directed against both PR-3 and myeloperoxidase (MPO) may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. It is generally considered an adult disease and is exceedingly rare in children. Published childhood cases are limited to single case reports. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classification of this disorder is based upon criteria developed by the American College of Rheumatology and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link&amp;anchor=H28#H28\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Microscopic polyangiitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic polyangiitis is a vasculitis that predominantly affects small vessels without granuloma formation. Compared to polyarteritis nodosa (macroscopic polyarteritis), microscopic polyangiitis has extensive glomerular involvement, usually manifesting as focal segmental glomerulonephritis. This disorder also often involves the pulmonary capillaries resulting in pulmonary hemorrhage.",
"   </p>",
"   <p>",
"    Microscopic polyangiitis is thought by some investigators to represent part of a clinical spectrum that includes granulomatosis with polyangiitis (Wegener's). The two disorders have similar nonpulmonary histologic abnormalities and are associated with the presence of anticytoplasmic antibodies (ANCA). However, most patients with microscopic polyangiitis have anti-myeloperoxidase (MPO) ANCA present in a perinuclear pattern, in contrast to patients with granulomatosis with polyangiitis (Wegener's) who demonstrate a primarily PR3 ANCA staining with cytoplasmic distribution (",
"    <a class=\"graphic graphic_picture graphicRef66748 \" href=\"mobipreview.htm?38/51/39742\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78968 \" href=\"mobipreview.htm?17/6/17518\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypersensitivity vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"hypersensitivity vasculitis\" has been used to include several forms of vasculitis of small blood vessels, including Henoch-Sch&ouml;nlein purpura (IgA vasculitis), mixed cryoglobulinemia, allergic vasculitis, leukocytoclastic vasculitis, and serum sickness. However, the term is used most appropriately to refer to the vasculitis that occurs as a part of a hypersensitivity reaction to a known or suspected antigen (",
"    <a class=\"graphic graphic_table graphicRef81148 \" href=\"mobipreview.htm?2/22/2414\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4070?source=see_link\">",
"     \"Hypersensitivity vasculitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major feature of this disorder is vasculitis of the skin with palpable petechiae or purpura. Biopsy of the lesions demonstrates inflammation of the small blood vessels, usually with a predominant infiltration of leukocytes, hence its inclusion in the broader category of leukocytoclastic vasculitides.",
"   </p>",
"   <p>",
"    Classification of this disorder is based upon criteria developed by the American College of Rheumatology and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link&amp;anchor=H28#H28\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Behcet's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behcet's disease is a multisystem inflammatory disorder characterized by recurrent oral ulcers, genital ulcers, and ocular inflammation, which may involve the joints, skin, central nervous system, and gastrointestinal tract. It is a systemic vasculitis that can affect both the arteries and veins of almost any organ. There is no universal agreement about the definition of this syndrome. A number of classification systems have been proposed, which are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Primary angiitis of the CNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary angiitis of the central nervous system (PACNS), also called isolated central nervous system (CNS) vasculitis, is an inflammatory vasculitis that solely affects the CNS vessels in the absence of an overt systemic inflammatory process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Identifiable systemic conditions, such as an infectious process, a systemic vasculitis, collagen vascular diseases,",
"    <span class=\"nowrap\">",
"     toxin/drug",
"    </span>",
"    exposure, or malignancy must be ruled out. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific criteria for a diagnosis of PACNS have not yet been formulated. A review based upon 62 children with PACNS vasculitis found that headache (80 percent) and focal neurological deficits (78 percent) were the most common presenting complaints, followed by hemiparesis in 62 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/35\">",
"     35",
"    </a>",
"    ]. There are no reliable laboratory findings in children with primary CNS vasculitis, and diagnosis relies on a combination of clinical findings and tests including cerebrospinal fluid analysis, magnetic resonance imaging of the brain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/36\">",
"     36",
"    </a>",
"    ]. Small vessel involvement may be missed on conventional angiography and a brain biopsy may be required for diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SECONDARY VASCULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis in children may be secondary due to a wide range of disorders. These conditions seem to represent a heightened susceptibility to vascular inflammation, because most people exposed to these triggers do not develop vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40616/abstract/1\">",
"     1",
"    </a>",
"    ]. Causes of secondary vasculitis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious causes including parvovirus B19, hepatitis B and C, HIV, varicella, Rickettsia, bacteria, fungi, and mycobacteria.",
"     </li>",
"     <li>",
"      Medications including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , tumor necrosis factor (TNF) inhibitors, and anti-thyroid agents.",
"     </li>",
"     <li>",
"      Systemic diseases including systemic lupus erythematosus, juvenile dermatomyositis, juvenile idiopathic arthritis, sarcoidosis, inflammatory bowel syndrome, and malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitides are disorders defined by the presence of inflammation in a blood vessel wall (vasculitis) due to a primary process or secondary to an underlying disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, vasculitis is rare, with reported annual incidences that range from 12 to 53 per 100,000 children under 17 years of age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classification systems have been developed to standardize the definitions of specific vasculitides to facilitate research efforts of these disorders. They were not developed to diagnose disease and have not been validated for clinical diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification versus diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classification systems and classification criteria for vasculitis in both children and adults are evolving. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The European League against Rheumatism (EULAR) and the Pediatric Rheumatology European Society (PRES) proposed a pediatric classification schema for vasculitides primarily based upon the size of the involved vessel. Specific classification criteria were developed, and subsequently validated in conjunction with the Paediatric Rheumatology International Trials Organisation (PRINTO), for some of the more common pediatric primary vasculitides, such as Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and Kawasaki disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Classification criteria: major primary vasculitides'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/1\">",
"      Dedeoglu F, Sundel RP. Vasculitis in children. Rheum Dis Clin North Am 2007; 33:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/2\">",
"      Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Sch&ouml;nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/3\">",
"      Dolezalov&aacute; P, Telekesov&aacute; P, Nemcov&aacute; D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol 2004; 31:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/4\">",
"      Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr Rheumatol Rep 2000; 2:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/5\">",
"      Wilkinson NM, Page J, Uribe AG, et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 2007; 34:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/6\">",
"      Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990; 33:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/7\">",
"      Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998; 129:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/8\">",
"      Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis--is it time to reclassify? Rheumatology (Oxford) 2011; 50:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/9\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/10\">",
"      Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/11\">",
"      Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996; 23:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/12\">",
"      Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol 1996; 23:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/13\">",
"      Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/14\">",
"      Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/15\">",
"      Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Sch&ouml;nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/16\">",
"      Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 1967; 16:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/17\">",
"      ROBERTS FB, FETTERMAN GH. POLYARTERITIS NODOSA IN INFANCY. J Pediatr 1963; 63:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/18\">",
"      Ettlinger RE, Nelson AM, Burke EC, Lie JT. Polyarteritis nodosa in childhood a clinical pathologic study. Arthritis Rheum 1979; 22:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/19\">",
"      Engel DG, Gospe SM Jr, Tracy KA, et al. Fatal infantile polyarteritis nodosa with predominant central nervous system involvement. Stroke 1995; 26:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/20\">",
"      Landing BH, Larson EJ. Are infantile periarteritis nodosa with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? Comparison of 20 patients from North America with patients from Hawaii and Japan. Pediatrics 1977; 59:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/21\">",
"      Bowyer S, Mason WH, McCurdy DK, Takahashi M. Polyarteritis nodosa (PAN) with coronary aneurysms: the kawasaki-PAN controversy revisited. J Rheumatol 1994; 21:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/22\">",
"      David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child 1993; 69:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/23\">",
"      Fink CW. The role of the streptococcus in poststreptococcal reactive arthritis and childhood polyarteritis nodosa. J Rheumatol Suppl 1991; 29:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/24\">",
"      Till SH, Amos RS. Long-term follow-up of juvenile-onset cutaneous polyarteritis nodosa associated with streptococcal infection. Br J Rheumatol 1997; 36:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/25\">",
"      Sheth AP, Olson JC, Esterly NB. Cutaneous polyarteritis nodosa of childhood. J Am Acad Dermatol 1994; 31:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/26\">",
"      Brunner J, Feldman BM, Tyrrell PN, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford) 2010; 49:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/27\">",
"      Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum 2009; 60:3413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/28\">",
"      Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/29\">",
"      Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 2000; 43:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/30\">",
"      Stegmayr BG, Gothefors L, Malmer B, et al. Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol 2000; 14:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/31\">",
"      Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/32\">",
"      Sabl&eacute;-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/33\">",
"      Benseler SM, Silverman E, Aviv RI, et al. Primary central nervous system vasculitis in children. Arthritis Rheum 2006; 54:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/34\">",
"      Cellucci T, Benseler SM. Diagnosing central nervous system vasculitis in children. Curr Opin Pediatr 2010; 22:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/35\">",
"      Benseler S, Schneider R. Central nervous system vasculitis in children. Curr Opin Rheumatol 2004; 16:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/36\">",
"      Eleftheriou D, Cox T, Saunders D, et al. Investigation of childhood central nervous system vasculitis: magnetic resonance angiography versus catheter cerebral angiography. Dev Med Child Neurol 2010; 52:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40616/abstract/37\">",
"      Benseler SM, deVeber G, Hawkins C, et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum 2005; 52:2159.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6401 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40616=[""].join("\n");
var outline_f39_42_40616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION VERSUS DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASSIFICATION CRITERIA: MAJOR PRIMARY VASCULITIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infantile PAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cutaneous polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER CHILDHOOD PRIMARY VASCULITIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Churg-Strauss syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypersensitivity vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Behcet's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Primary angiitis of the CNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SECONDARY VASCULITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6401|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/28/19904\" title=\"diagnostic image 1\">",
"      Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/53/27474\" title=\"diagnostic image 2\">",
"      Takayasu arteritis aneurysm 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6401|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/32/33282\" title=\"picture 1A\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/46/42721\" title=\"picture 1B\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/1/15376\" title=\"picture 2\">",
"      Conjunctivitis in Kawasaki",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/2/43\" title=\"picture 3\">",
"      Strawberry tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/12/25793\" title=\"picture 4\">",
"      Edema of hands in Kawasaki disease - acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/29/5587\" title=\"picture 5\">",
"      Periungual desquamation in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/49/8985\" title=\"picture 6\">",
"      Polyarteritis nodosa (light micrograph)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/32/9737\" title=\"picture 7\">",
"      Cutaneous polyarteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/51/39742\" title=\"picture 8\">",
"      C ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/6/17518\" title=\"picture 9\">",
"      P ANCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/22/2414\" title=\"table 1\">",
"      Drugs cutaneous vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33383?source=related_link\">",
"      Approach to evaluating childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4070?source=related_link\">",
"      Hypersensitivity vasculitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11814?source=related_link\">",
"      Incomplete (atypical) Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9657?source=related_link\">",
"      Overview of the management of vasculitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_42_40617="Peer violence and violence prevention";
var content_f39_42_40617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peer violence and violence prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Robert D Sege, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/42/40617/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/42/40617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of peer violence and prevention of violence is reviewed here. Violence in the media, domestic violence, and child abuse are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violence is a major cause of death and disability for American children. Violence or witnessing violence has both physical and psychiatric sequelae, including posttraumatic stress disorder, adjustment reactions, severe grief reactions, and depression.",
"   </p>",
"   <p>",
"    Pediatric care providers play an important role in prevention of violence. Universal (primary) prevention centers on screening and anticipatory guidance for the promotion of resilience and the avoidance of risk. Secondary prevention involves treatment, counseling, and referral for children and adolescents who have experienced violence-related injury. In addition, pediatric care providers can advocate for school policies and state and federal legislation to reduce the risk of violence for children. The newer view of violence prevention, discussed below, puts violence squarely in the context of improving individual and family resilience, and positively engaging adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States has the highest youth homicide rate among the 26 wealthiest nations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/1\">",
"     1",
"    </a>",
"    ]. Homicide is the second leading cause of death among 15- to 19-year-olds and the leading cause of death among black youth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data describing nonfatal violence come from national surveillance systems and emergency departments. Local and national data are available from the",
"    <a class=\"external\" href=\"file://www.cdc.gov/injury/wisqars/index.html\">",
"     Web-based Injury Statistics Query and Reporting System",
"    </a>",
"    . These statistics underestimate the prevalence of nonfatal violence because many victims do not seek medical treatment or legal recourse, or because the cause of injury is not coded completely or correctly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The US Department of Education reported 188,000 fights or physical attacks not involving weapons, 11,000 fights involving weapons, and 4000 incidents of sexual assault in schools during the 1996-to-1997 school year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/4\">",
"       4",
"      </a>",
"      ]. Nevertheless, schools remain the safest place for children. Vital statistics estimate that less than 1 percent of child and adolescent homicides occur in school (WISQARS&trade;), and the overwhelming proportion of assaults that do occur in school are of relatively minor severity (National Pediatric Trauma Registry, unpublished data courtesy of Director Carl DiScala, PhD).",
"     </li>",
"     <li>",
"      One-third of high school students in the Youth Risk Behavior Surveillance Survey reported having been in a fight in the 12 months before the survey in 2011; fights were more common among boys than girls (41 versus 24 percent), and 4 percent of students received medical attention for injuries sustained during a fight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assaultive trauma recurs; hospital readmission rates for subsequent assaults and subsequent homicides are as high as 44 and 20 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/6-8\">",
"       6-8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most violence in the United States occurs between friends, acquaintances, or intimate partners, and the distinction between victim and perpetrator is not always clear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/9-11\">",
"       9-11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nearly 17 percent of high school students in the Youth Risk Behavior Surveillance Survey reported carrying a weapon (gun, knife, or club) on at least one day in the month before the survey in 2011 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/5\">",
"       5",
"      </a>",
"      ]. Weapon carrying was more commonly reported among boys than girls (26 versus 7 percent), and 5.4 percent of students reported carrying their weapons to school. The percentage of students carrying weapons decreased between 1991 and 1999 and stabilized between 1999 and 2011 (26 percent and 17 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RESILIENCE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the National Longitudinal Survey of Youth (NLSY) and from the Vermont Youth Risk Behavior Survey each demonstrate powerful protective effects of youth engagement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/12\">",
"     12",
"    </a>",
"    ]. The NLSY analyses demonstrated that parental expectations and connectedness with parents and adults and with school protected against violence. The results showed the power of these protective factors, even in the presence of substantial risk factors. Social assets can be measured on a population level using proprietary surveys developed by the Search Institute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/13\">",
"     13",
"    </a>",
"    ]. They describe 40 positive attributes that protect young people and their communities. The Vermont Department of Public Health used similar constructs to add to the Youth Risk Behavior Survey. Their work showed there was an inverse correlation between measured assets and health risk behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On a community level, the Chicago neighborhood study showed that among neighborhoods in Chicago with similar economic and demographic characteristics, improved neighborhood cohesion and self-efficacy were associated with large decreases in youth violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current programs directed at reducing youth violence are largely based on the positive youth development model, which has strong evidence of success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/16\">",
"     16",
"    </a>",
"    ]. Programs for positive youth development are defined by the National Academy of Sciences as programs that seek to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Promote bonding and social, emotional, cognitive, behavioral, or moral competence",
"     </li>",
"     <li>",
"      Foster resilience, self-determination, spirituality, self-efficacy, clear and positive identity, belief in the future, and prosocial norms",
"     </li>",
"     <li>",
"      Provide recognition of positive behavior and opportunities for prosocial norms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics has implemented the resilience approach for primary care clinicians, Bright Futures, and their violence prevention program,",
"    <a class=\"external\" href=\"file://www2.aap.org/connectedkids/\">",
"     Connected Kids: Safe, Strong, Secure",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/16,18-20\">",
"     16,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious violence-related injuries result when people who have learned to use violence to solve problems have access to means of violence. Law enforcement agencies traditionally attempt to assign culpability in cases of violence, determining who was the victim and who was the perpetrator of a particular violent act. However, from a public health perspective, it most often emerges that both victims and perpetrators are caught in a culture of violence. Children and adolescents who fight regularly are at risk of severe injury.",
"   </p>",
"   <p>",
"    Several key risk factors for violence and violence-related injury have been identified; they are complex, interdependent, and influenced by individual and societal variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/12,21-29\">",
"     12,21-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous history of fighting or violence-related injury",
"     </li>",
"     <li>",
"      Violent discipline",
"     </li>",
"     <li>",
"      Access to firearms",
"     </li>",
"     <li>",
"      Alcohol and other drug use",
"     </li>",
"     <li>",
"      Gang involvement",
"     </li>",
"     <li>",
"      Exposure to domestic violence and child abuse",
"     </li>",
"     <li>",
"      Media violence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children begin to develop aggressive behavior and violent habits of thought in the early years. In one prospective study, 8-year-old children in rural New York were followed for 22 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/30\">",
"     30",
"    </a>",
"    ]. Television watching and peer-nominated aggression (being described as aggressive by peers) were independently associated with criminal conviction for violent crimes by the age of 30 years. Another study reported long-term follow-up of children observed beginning in infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/31\">",
"     31",
"    </a>",
"    ]. The investigators concluded that children begin to learn to control their innate aggression beginning at age 17 months, supporting the importance of influences in early childhood on subsequent violence and aggression.",
"   </p>",
"   <p>",
"    Later in life, experiencing violence (being shot, stabbed, or beaten) among men aged 17 to 29 years was identified as a risk for violent behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/32\">",
"     32",
"    </a>",
"    ]. Those who reported more serious traumatic experiences, such as incarceration, witnessing violence, or carrying a weapon, had the highest risk of violent assault (odds ratio 10, 95% CI, 4-25). Girls too, are more likely to behave violently if they have been victims of violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Violent discipline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of violent discipline methods teaches children that violence is an appropriate means of shaping behavior. In addition, children whose parents are unable to set effective limits may develop dysfunctional behavior patterns of interaction, particularly if corporal punishment is used extensively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Dysfunctional interaction may lead to poor performance and social isolation in the early school years and, later, association with peer groups that reward violence and antisocial behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Access to firearms and weapon carrying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 million households in the US keep handguns, and one-half of gun owners keep their weapons loaded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/37\">",
"     37",
"    </a>",
"    ]. Handgun owners typically keep the guns for self-defense. However, deaths caused by suicide, homicide, or unintentional injury outnumber deaths associated with self-defense by 40 to 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/38\">",
"     38",
"    </a>",
"    ]. Teenagers are five times more likely to die from suicide if there is a gun in the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Each year, more than 100 American children younger than 4 years of age die from firearm injuries. The prevention of firearm injuries is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14921?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of firearm injuries in children\", section on 'Prevention of firearm injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The carrying of weapons also increases the risk of violent behavior and violence-related injury by providing a false sense of security that contributes to impulsive behavior. In a probability survey of more than 3000 high school students in Massachusetts, weapon carrying on school property was associated with increased frequency of physical fights on school property [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, firearms-related injuries account for thousands of hospitalizations in children younger than 14 and an estimated 3200 cases of long-term disability in children younger than 18 each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. It is estimated that approximately one-half of these nonfatal injuries are the result of assaults.",
"   </p>",
"   <p>",
"    Preventing access to firearms is clearly an adult responsibility, as child-centered programs designed to teach firearms safety to grade-school children do not prevent children from handling real weapons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14921?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of firearm injuries in children\", section on 'Prevention of firearm injuries'",
"    </a>",
"    .) Clinicians may be more successful in preventing firearm injuries when counseling focuses on characteristics of the child, rather than on firearms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Alcohol/drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance abuse, which alters the dynamics and decisions in violent or near-violent episodes, is associated with an increased risk of exposure to violence, carrying weapons, and homicide among adolescents and street gangs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Early onset of alcohol or drug use increases the risk of abuse-related violence that continues into adulthood. In one survey of more than 40,000 adults between 18 and 44 years of age, those who began drinking alcohol before age 14 years were 14 times more likely to report having been in an alcohol-related fight within the past year than those who began drinking after age 21 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gang participation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Youth Gang Survey (1996-2009) estimates that there are approximately 26,000 gangs and 775,000 gang members in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/51\">",
"     51",
"    </a>",
"    ]. Children and adolescents who participate in gangs are more likely to promote aggressive attitudes, report victimization experiences, be involved in fights, carry weapons to school, and use drugs or alcohol at school [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Witnessing violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The witnessing of violence by children increases the risk that they will react violently later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/55\">",
"     55",
"    </a>",
"    ]. More than one-half of the 6-year-old inner-city children in a cross-sectional study of exposure to violence had witnessed some form of violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/56\">",
"     56",
"    </a>",
"    ]. The children who witnessed violence had more behavioral, emotional, attention, and social problems than did those who did not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Domestic violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Domestic violence and child abuse are the greatest risk factors for violence for infants and toddlers. Exposure to violence and victimization is associated with subsequent acts of violence by the witness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Children who witness domestic violence are harmed cognitively, emotionally, and developmentally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31097?source=see_link&amp;anchor=H3#H3\">",
"     \"Childhood exposure to intimate partner violence\", section on 'Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Television violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents in the United States spend an average of 4.5 hours per day watching television and more than seven hours per day when all types of media are included (eg, video games, computers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40343?source=see_link\">",
"     \"Television and media violence\"",
"    </a>",
"    .) According to the National Television Violence Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nearly two-thirds of all programming contains violence",
"     </li>",
"     <li>",
"      Children's shows contain the most violence",
"     </li>",
"     <li>",
"      Portrayals of violence usually are glamorized",
"     </li>",
"     <li>",
"      Perpetrators often go unpunished",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Television violence differs from real violence in important ways. Violence on television typically is socially acceptable, being used by heroes and villains alike. Young children, unable to separate fact from fantasy, are more affected by television violence than are adults. Viewing violence can lead to increased aggressive attitudes, values, and behavior, particularly in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/63\">",
"     63",
"    </a>",
"    ]. Children who view violence on television are more likely to experience violence and less likely to intervene in tense situations when they are bystanders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40343?source=see_link\">",
"     \"Television and media violence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bullying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullying is the repeated infliction of harm on younger, smaller, or less powerful peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/65\">",
"     65",
"    </a>",
"    ]. Almost 10 percent of students in grades 6 through 12 report having been bullied at school, school activities, or on the way to or from school [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Both the bully and the victim are affected by bullying. Effects on victims include physical injury, difficulty concentrating, physical symptoms (eg, nausea, anorexia), symptoms of anxiety or depression, poor self-esteem, and high rates of school absence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Bullies, however, often feel powerful and effective. In contrast to the situation in childhood, the long-term outcome (at age 30 years) for bullies themselves is especially poor. They are more likely to be incarcerated and are less likely to be employed, married, or in other stable adult relationships than are their peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Community violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies conducted in poor urban neighborhoods identified a pattern of violence in which fighting and the willingness to fight are key components of a protective strategy for coping with dangerous environments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/71\">",
"     71",
"    </a>",
"    ]. Young people who are unwilling or unable to defend themselves are prey to multiple and repeated attacks in the \"code of the streets\". Some parents understand this culture and may actually encourage their children to become able fighters to defend themselves. However, parents can play a crucial role in encouraging safe behavior. They can teach their children how to defuse tense situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/20,46\">",
"     20,46",
"    </a>",
"    ]. Resources to help parents encourage safe behaviors are available through the American Academy of Pediatrics (eg, the &ldquo;Talking with your teen: Tips for parents&rdquo; and &ldquo;Staying cool when things heat up&rdquo; brochures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Certain neighborhood factors can mitigate community violence. In an observational study, a higher concentration of resources for young people and adults was associated with lower levels of community aggression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric care providers should screen for violence and violence risk factors at routine healthcare visits. The screening questions depend upon the child's age and developmental stage and the cultural background of the family. In most cases, children may be asked directly whether they have been involved in or witness to any violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/11\">",
"     11",
"    </a>",
"    ]. The assessment of family functioning, family stress, coping mechanisms, and support systems, always a key component of routine healthcare maintenance, also is an important dimension of preventing violence. Environmental factors, chiefly access to guns, should be assessed periodically. Finally, abrupt deterioration in school performance may indicate violence or a related health risk factor including bullying, depression, substance abuse, domestic abuse, or family illness. Emotional and behavioral problems can be assessed using the",
"    <a class=\"external\" href=\"file://www2.massgeneral.org/allpsych/psc/psc_home.htm\">",
"     Pediatric Symptom Checklist",
"    </a>",
"    or the Child Behavior Checklist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=see_link&amp;anchor=H8#H8\">",
"     \"Developmental and behavioral screening tests in primary care\", section on 'Broad-band instruments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, pediatric care providers should screen for domestic violence at all healthcare visits, particularly in the perinatal period. Pregnant and postpartum women should be asked about a history of domestic violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/73\">",
"     73",
"    </a>",
"    ]. Many healthcare providers post domestic violence hotline numbers in women's restrooms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=see_link&amp;anchor=H86601695#H86601695\">",
"     \"Intimate partner violence: Epidemiology and health consequences\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6393?source=see_link\">",
"     \"Intimate partner violence: Diagnosis and screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adolescent screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violence clusters with other high-risk behaviors in adolescents. In addition to being questioned regarding drug use and sexual risk, all teenagers should be asked directly about violence. The \"FISTS\" questions help to identify those who are at risk of violence-related injury (",
"    <a class=\"graphic graphic_table graphicRef57574 \" href=\"mobipreview.htm?29/38/30315\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fighting",
"     </li>",
"     <li>",
"      Injuries",
"     </li>",
"     <li>",
"      Sexual violence",
"     </li>",
"     <li>",
"      Threats",
"     </li>",
"     <li>",
"      Self-defense",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information is used to assess the level of risk for violence-related injury in teenagers because risky behaviors tend to cluster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/41,75\">",
"     41,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk &ndash; Adolescents who are in school and neither fight nor use drugs are at low risk for violence-related injury. These patients deserve a positive comment about their ability to handle conflict without fighting.",
"     </li>",
"     <li>",
"      Moderate risk &ndash; Adolescents who attend school with passing grades but who either fight or use drugs are at approximately three times the risk for violence-related injury than are those who neither fight nor use drugs. Many moderate-risk patients can be counseled successfully in the office. Identify specific risk factors (eg, trouble on the school bus) and help the teenager work out a strategy to avoid the situation.",
"     </li>",
"     <li>",
"      High risk &ndash; Adolescents who are failing or have dropped out of school, or who both fight and use drugs are at approximately seven times the risk for violence-related injury than are low-risk teens. Prompt referral to a social worker or other counselor is indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parents of all teenagers should be counseled concerning the dangers of storing a firearm, particularly a handgun, in the home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANTICIPATORY GUIDANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics and the American Medical Association recommend violence prevention counseling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19000?source=see_link&amp;anchor=H5#H5\">",
"     \"Guidelines for adolescent preventive services\", section on 'Anticipatory guidance for adolescents'",
"    </a>",
"    .) Children visit their healthcare provider frequently during infancy and early childhood. These visits furnish multiple opportunities for the provider to provide focused interventions toward prevention of violence. The provider can identify and attempt to modulate risk factors for violence. In addition, he or she can attempt to enhance the protective factors (eg, intact family structure, positive peer groups, self-esteem, and confidence). Pediatric healthcare providers can encourage parents to model nonviolent behavior, anger management, and conflict resolution for their children. In addition, children should be encouraged to participate in activities that are socially acceptable and build useful life skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some aspects of violence prevention counseling, such as the presence of guns in the home, media violence, or the need to maintain family relationships, apply to all age groups. Other aspects should be adapted to the age and developmental stage of the child. Conversations with older children and adolescents, for example, may be initiated by specific events or by a history that indicates a risk of violence-related injury.",
"   </p>",
"   <p>",
"    The AAP released its",
"    <a class=\"external\" href=\"file://www2.aap.org/connectedkids/\">",
"     Connected Kids: Safe, Strong, Secure",
"    </a>",
"    counseling program after several years of research and development. The program includes clinical information, training materials, and information for parents and teens. The counseling topics utilize the positive",
"    <span class=\"nowrap\">",
"     parenting/positive",
"    </span>",
"    youth development model described above, and the Web site includes training and implementation information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Firearms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the safest home for children is a home without guns, evidence suggests that there is incremental benefit in safer storage of firearms. Families who nevertheless maintain handguns at home should be counseled that the weapons should be stored locked and unloaded, and the ammunition stored in a separate locked location. Some pediatric healthcare providers in regions with a high prevalence of handgun ownership distribute gun locks (see",
"    <a class=\"external\" href=\"file://www.projectchildsafe.org/\">",
"     www.projectchildsafe.org",
"    </a>",
"    for information concerning one such program). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14921?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of firearm injuries in children\", section on 'Prevention of firearm injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Media",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AAP Committee on Public Education recommends that pediatric healthcare providers encourage parents to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limit children's total media time to less than one to two hours per day",
"     </li>",
"     <li>",
"      Remove television sets from children's bedrooms",
"     </li>",
"     <li>",
"      Discourage television viewing for children younger than 2 years",
"     </li>",
"     <li>",
"      Monitor the shows that are viewed by children and adolescents",
"     </li>",
"     <li>",
"      View programs and discuss the content with their children",
"     </li>",
"     <li>",
"      Use controversial programming to initiate discussions about family values, violence, sexuality, and drugs",
"     </li>",
"     <li>",
"      Encourage alternative entertainment for children (eg, reading, athletics, hobbies, and creative play)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Domestic violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric offices should provide information and support to women experiencing domestic violence. Social work contacts and referral phone numbers should be available to providers and other office staff. Healthcare providers should be aware of the strong associations between domestic violence and child abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Age-specific anticipatory guidance",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Birth to four years",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pediatric healthcare visits from birth to age 4 years typically center on the establishment of good parenting practices, environmental safety, and behavior concerns. These topics are related directly to violence prevention. Careful screening and support in the primary care setting is associated with measurable decreases in child maltreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H126011446\">",
"    <span class=\"h4\">",
"     Violence-free discipline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family discipline patterns usually are established as children enter the second year of life. The American Academy of Pediatrics recommends that parents be encouraged and assisted in developing methods other than spanking to shape the behavior of their children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/81\">",
"     81",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Some of these techniques include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/76,81\">",
"     76,81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintaining a schedule of meal, nap, play, bath, and bed times to foster the child's feeling of mastery of his or her environment",
"     </li>",
"     <li>",
"      Satisfying the toddler's need for parental attention by providing positive reinforcement and praise for good behavior",
"     </li>",
"     <li>",
"      Using time-out from positive reinforcement, natural, or logical consequences when the child's misbehavior requires negative consequences",
"     </li>",
"     <li>",
"      Establishing family rules to address potential areas of conflict",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The short-term effectiveness of anticipatory guidance by trained providers and written materials on the use of time-outs was demonstrated in a controlled clinical trial of 559 parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/82\">",
"     82",
"    </a>",
"    ]. An increase occurred in the report of the use of time-out in the intervention group two to three weeks after the intervention (35 versus 2 percent of parents). Video-based parenting education for violence prevention also is available and appears effective in short-term trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Finally, a large national trial demonstrated the effectiveness of the use of brief motivational interviewing (an assessment of family interest and confidence in changing behavior to generate patient-centered solutions) and of giving families a kitchen timer (to monitor media-time and time-outs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     School-age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families of school-aged children (5 to 12 years) should continue to be counseled regarding guns, television, and exposure to violence. In addition, the pediatric healthcare provider should ask about bullying and fighting in school.",
"   </p>",
"   <p>",
"    The parents of children who are victims of bullies should be encouraged to discuss the problem with the school principal or guidance counselor. They have a right to expect a physically and emotionally safe school environment for their children. School officials can intervene to control bullying. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Schools'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bullies often come from disordered families, and their parents may be unwilling or unable to establish clear rules at home. Effective intervention programs include a strong parent education program for the parents of bullies, helping them learn to provide a structured home environment for their children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/70\">",
"     70",
"    </a>",
"    ]. Given the poor long-term outcomes for bullies, this intervention may be the most important component of a bullying prevention program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teenagers and their parents should be educated about violence; in particular, they should know that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Engagement in prosocial groups provides powerful protection for adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinicians should inquire regarding participation in after-school programs, athletics, or church-based youth activities. Adolescents and their parents should be counseled regarding the importance of engagement during the summer with employment, camp, or volunteer activities.",
"     </li>",
"     <li>",
"      Skills-based intervention conducted in school interventions have been shown to be effective in reducing violence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most violent injuries occur in fights between friends or acquaintances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/10\">",
"       10",
"      </a>",
"      ]. Teens should learn how to walk away from a fight. Parents should know their children's friends.",
"     </li>",
"     <li>",
"      The carrying of guns and other weapons encourages impulsive behavior and increases the risk of injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adolescents who are identified to be at increased risk for violence-related injury should be counseled according to their personal situation and risk category. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Those who are at low risk should receive reinforcement for their ability to avoid physical confrontation. Counseling may focus on their progress toward independence, with a focus on positive peer and social group relationships. They should be warned of the dangers of carrying a weapon, encouraged to avoid dangerous places and situations, and cautioned to use nonviolent conflict resolution strategies (",
"    <a class=\"graphic graphic_table graphicRef81769 \" href=\"mobipreview.htm?38/48/39691\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Those who are at moderate risk should be told that the risk of injury is real and should receive education about techniques to defuse tense situations (",
"    <a class=\"graphic graphic_table graphicRef81769 \" href=\"mobipreview.htm?38/48/39691\">",
"     table 2",
"    </a>",
"    ). These adolescents, who may not yet be able to think abstractly, may need to generate or be given lists of appropriate ways to react in tense situations. Making the list in anticipation of the situation provides the concrete-thinking adolescent with alternative behaviors before the situation arises. Moderate-risk teens should be counseled to evaluate their own risk-taking behavior. Their existent nonviolent problem-solving skills should be reinforced, and the clinician may provide support for their abilities to solve conflict without violence.",
"   </p>",
"   <p>",
"    Adolescents who are at high risk for violence-related injury should be screened for mental health problems (eg, depression, posttraumatic stress disorder, drug use) and referred appropriately. Those who do not have mental health problems should be referred to a social worker, counselor, or street outreach worker. They may benefit from community agencies that offer adult mentoring or activities.",
"   </p>",
"   <p>",
"    Adolescent health providers should stress the importance of follow-up to the high-risk teen and to his or her parents. Involvement of the parents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the extended family of the teenager is important. Parents should be taught to ask how fights started or could have been avoided, but not who won. If necessary, follow-up visits can be scheduled for another medical matter (eg, acne) to monitor the patient's progress.",
"   </p>",
"   <p>",
"    Violence prevention counseling for adolescents is based upon a behavior change model that includes precontemplation, contemplation, and resolution.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precontemplation &ndash; Teenagers in this stage do not recognize that the behavior is a problem. They should be informed of their own personal risk and that other young people from their communities have managed to avoid fighting without losing face, as in, \"I am concerned about you. You haven't yet learned how to avoid fighting, and some of my patients who fight a lot get seriously hurt\". Clinicians embarking on this approach should understand the role that fighting plays in the lives of teens, and the real and perceived dangers inherent in being labeled as a \"sucker\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Contemplation &ndash; Teenagers in this stage recognize that violence is a problem, but they have not yet begun to change their behavior. They should receive information about nonviolent conflict resolution (",
"      <a class=\"graphic graphic_table graphicRef81769 \" href=\"mobipreview.htm?38/48/39691\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Resolution &ndash; Teenagers in this stage have adopted new behavior patterns to avoid violence. Those who are trying to use nonviolent techniques of problem solving should be encouraged for their efforts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Counseling may involve reviewing specific skills that can be used to defuse situations of potential conflict.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prevention involves treatment, counseling, and referral for children and adolescents who have experienced violence-related injury. Children and adolescents who have been injured in a fight are at high risk for further violence, and crisis intervention is needed. They should be asked:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the fight over?",
"     </li>",
"     <li>",
"      Do you feel safe leaving here?",
"     </li>",
"     <li>",
"      Is there someone who can mediate if the fight is ongoing?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Referral to a mental health provider may be necessary if the situation is volatile and cannot be resolved. When a specific individual is threatened, healthcare providers may have a \"duty to warn\". Also, the police should be notified. The child or adolescent and the parents should be informed of the risk of serious injury and techniques for successful injury prevention (eg, methods to de-escalate conflicts) (",
"    <a class=\"graphic graphic_table graphicRef81769 \" href=\"mobipreview.htm?38/48/39691\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following steps are recommended for providers who care for children and adolescents who have experienced a serious violence-related injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask the child to tell you about the problem; listen without interruption and avoid judgment. This approach permits the child to express feelings of vengefulness and allows the provider to understand the child's perspective before offering advice.",
"     </li>",
"     <li>",
"      Assess the other risks (eg, weapon carrying, alcohol or drug use, gang involvement) and discuss the risk factors for violence with the child or adolescent.",
"     </li>",
"     <li>",
"      Develop a plan for safety after leaving the hospital or clinic (eg, staying with a friend or relative who lives out of the neighborhood and involving the police if necessary).",
"     </li>",
"     <li>",
"      Discuss strategies for conflict avoidance at the time of injury and at subsequent visits. These strategies must respect the patient's need for peer approval. One strategy of conflict avoidance is for the patient to tell the person who insists on fighting that",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      will fight them later (eg, at 3 p.m.) but will not fight now. The forced time interval may reduce the fury and make it easier to talk about the conflict.",
"     </li>",
"     <li>",
"      Screen the child for",
"      <span class=\"nowrap\">",
"       emotional/behavioral",
"      </span>",
"      symptoms (eg, using the",
"      <a class=\"external\" href=\"file://www2.massgeneral.org/allpsych/psc/psc_home.htm\">",
"       Pediatric Symptom Checklist",
"      </a>",
"      or the Child Behavior Checklist) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/87\">",
"       87",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Refer the child for support services (eg, psychology, social work, church members, recreation departments, mentoring programs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. Children and adolescents who are depressed should be referred to a mental health professional; those who were innocent victims may need posttraumatic stress counseling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ADVOCACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Youth violence is a serious health risk and complex social problem that requires broad-based public action for prevention. Pediatric healthcare providers, through the AAP and other organizations (eg, Children's Defense Fund), can advocate for social policies that benefit children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric care providers advocate for their patients to receive the care and services that they need (eg, mental health service, family support). Individual adolescent patients may be encouraged to discover activities and social groups that promote the mastery of new skills and that lead to membership in prosocial groups. Adolescents who have experienced loss may benefit from grief counseling or specific evidence-based treatment for posttraumatic stress. Parents of teenaged patients should be advised to restrict access to firearms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Schools",
"    </span>",
"    &nbsp;&mdash;&nbsp;School-based violence prevention programs are an effective means of reducing violent and aggressive behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/91\">",
"     91",
"    </a>",
"    ]. Pediatric consultants can help school systems reduce the incidence of violence. Middle and high school conflict resolution curricula have reduced the incidence of school fights and of suspensions or expulsions for fighting or weapon carrying. The Centers for Disease Control's sourcebook provides detailed information concerning numerous innovative curricula developed and evaluated during the 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/92\">",
"     92",
"    </a>",
"    ]. Peer mediator programs also reduce serious violence at and near schools and provide a model for nonviolent conflict resolution.",
"   </p>",
"   <p>",
"    Pediatric healthcare providers who serve as school consultants can advise school boards and principals regarding the importance of age-appropriate violence prevention programs and peer mediation programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary schools can",
"      <span class=\"nowrap\">",
"       teach/model",
"      </span>",
"      nonviolent problem-solving skills, focus on adequate playground supervision, and implement antibullying programs.",
"     </li>",
"     <li>",
"      Middle schools can incorporate antiviolence and conflict resolution curricula into health education programs.",
"     </li>",
"     <li>",
"      High school programs can use the school health clinic to provide services to students who have problems of violence, drug abuse, or pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Antibullying programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibullying programs are effective in reducing bullying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/70,92,94\">",
"     70,92,94",
"    </a>",
"    ]. Successful programs work, in part, by mobilizing the large number of bystanders to make bullying less acceptable. Bullying at school is addressed through increased adult supervision before school, during lunch and recess, and after school; and through the development of classroom discussions to reduce the social acceptability of bullying among the majority of children, depriving the bully of an appreciative audience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric healthcare providers can address violence in the media by endorsing community TV \"tune-out weeks\", encouraging schools to develop curricula for critical viewing skills, and working with local, state, and federal regulators and television producers to reduce the exposure of children to televised violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Youth development",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of programs that provide resources for adolescents, including after-school programs, summer jobs programs, and programs that find ways for young persons to participate in the community, are associated with improved outcomes, including decreased risk of violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/42/40617/abstract/72,96\">",
"     72,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Firearms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric healthcare providers can advocate for the prevention of firearm injury by supporting state and federal initiatives to mandate the provision of trigger locks and prevent the marketing of certain kinds of weapons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14921?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of firearm injuries in children\", section on 'Prevention of firearm injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Pediatrics counseling program,",
"      <a class=\"external\" href=\"file://www2.aap.org/connectedkids/\">",
"       Connected Kids: Safe, Strong, Secure",
"      </a>",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.jhsph.edu/preventyouthviolence/Resources/index.html\">",
"       Johns Hopkins Bloomberg School of Public Health Center for the Prevention of Youth Violence",
"      </a>",
"      provides a list of resources for youth violence prevention",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.mchlibrary.info/KnowledgePaths/kp_adolvio.html\">",
"       Maternal and Child Health Library",
"      </a>",
"      provides resources and tools for adolescent violence prevention",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.sshs.samhsa.gov/initiative/resources.aspx\">",
"       Substance Abuse and Mental Health Services Administration",
"      </a>",
"      provides resources for school violence prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Violence is a major cause of death and disability for American children. Pediatric care providers play an important role in prevention of violence through screening and providing anticipatory guidance for promotion of resilience and avoidance of risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that protect against youth violence include youth engagement (eg, parental expectations, connectedness with parents, adults, and school), neighborhood cohesion and self-efficacy, and programs that promote positive youth development (eg, bonding, social, emotional, cognitive, behavioral, and moral competence, self-determination, spirituality, self-efficacy, belief in the future). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Resilience factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for violence include a history of fighting or violence-related injury, violent discipline, access to firearms, alcohol and other drug use, gang involvement, and exposure to violence in the home, media, school, or community. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatric care providers should screen for violence and violence risk factors at routine healthcare visits. The screening questions depend upon the child's age and developmental stage and the cultural background of the family. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Teenagers should be asked directly about violence (",
"      <a class=\"graphic graphic_table graphicRef57574 \" href=\"mobipreview.htm?29/38/30315\">",
"       table 1",
"      </a>",
"      ). Their risk for violence-related injury is stratified according to other factors, including school attendance, performance, violence history, and drug use. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Adolescent screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American Academy of Pediatrics (AAP) and the American Medical Association recommend violence prevention counseling. Healthcare visits during infancy, childhood, and adolescence provide opportunities to identify and attempt to modulate violence risk and resilience factors. The AAP",
"      <a class=\"external\" href=\"file://www2.aap.org/connectedkids/\">",
"       Connected Kids: Safe, Strong, Secure",
"      </a>",
"      provides clinical information, training materials, and information for parents and teens. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Anticipatory guidance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary prevention involves treatment, counseling, and referral for children and adolescents who have experienced violence-related injury. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Secondary prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Rates of homicide, suicide, and firearm-related death among children--26 industrialized countries. MMWR Morb Mortal Wkly Rep 1997; 46:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/2\">",
"      Anderson RN, Kochanek KD, Murphy SL. Report of final mortality statistics: 1995. Mon Vital Stat Rep 1997; 45(suppl 2):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/3\">",
"      Centers for Disease Control (CDC). Homicide among young black males--United States, 1978-1987. MMWR Morb Mortal Wkly Rep 1990; 39:869.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Education. Principal/School Disciplinarian Survey on School Violence. Fast Response Survey System 63. National Center for Education Statistics, Washington, DC, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/5\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/6\">",
"      Sims DW, Bivins BA, Obeid FN, et al. Urban trauma: a chronic recurrent disease. J Trauma 1989; 29:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/7\">",
"      Poole GV, Griswold JA, Thaggard VK, Rhodes RS. Trauma is a recurrent disease. Surgery 1993; 113:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/8\">",
"      Morrissey TB, Byrd CR, Deitch EA. The incidence of recurrent penetrating trauma in an urban trauma center. J Trauma 1991; 31:1536.",
"     </a>",
"    </li>",
"    <li>",
"     Federal Bureau of Investigation. Crime in the United States, 1996: Uniform Crime Reports. Government Printing Office, Washington, DC, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/10\">",
"      Sege R, Stigol LC, Perry C, et al. Intentional injury surveillance in a primary care pediatric setting. Arch Pediatr Adolesc Med 1996; 150:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/11\">",
"      Slaby RG, Stringham P. Prevention of peer and community violence: the pediatrician's role. Pediatrics 1994; 94:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/12\">",
"      Resnick MD, Ireland M, Borowsky I. Youth violence perpetration: what protects? What predicts? Findings from the National Longitudinal Study of Adolescent Health. J Adolesc Health 2004; 35:424.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Search Institute. What are Developmental Assets? Available at: www.search-institute.org/assets/ (Accessed on May 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/14\">",
"      Murphey DA, Lamonda KH, Carney JK, Duncan P. Relationships of a brief measure of youth assets to health-promoting and risk behaviors. J Adolesc Health 2004; 34:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/15\">",
"      Sampson RJ, Raudenbush SW, Earls F. Neighborhoods and violent crime: a multilevel study of collective efficacy. Science 1997; 277:918.",
"     </a>",
"    </li>",
"    <li>",
"     Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 3rd ed, Hagan JF, Shaw JS, Duncan P (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2008.",
"    </li>",
"    <li>",
"     Catalano RF, Berglund ML, Ryan JA, et al. Defining and evaluating positive youth development. In: Positive Youth Development in the United States. Available at: aspe.hhs.gov/HSP/PositiveYouthDev99/ (Accessed on May 13, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/18\">",
"      Sege RD, Flanigan E, Levin-Goodman R, et al. American Academy of Pediatrics' Connected Kids program: case study. Am J Prev Med 2005; 29:215.",
"     </a>",
"    </li>",
"    <li>",
"     Connected Kids: Safe, Strong, Secure Clinical Guide, Spivak H, Sege R, Flanigan E, Licenziato V (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2006.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Connected Kids: Safe, Strong, Secure. Available at: www.aap.org/connectedkids (Accessed on May 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/21\">",
"      DuRant RH, Cadenhead C, Pendergrast RA, et al. Factors associated with the use of violence among urban black adolescents. Am J Public Health 1994; 84:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/22\">",
"      Sosin DM, Koepsell TD, Rivara FP, Mercy JA. Fighting as a marker for multiple problem behaviors in adolescents. J Adolesc Health 1995; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/23\">",
"      Valois RF, McKeown RE, Garrison CZ, Vincent ML. Correlates of aggressive and violent behaviors among public high school adolescents. J Adolesc Health 1995; 16:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/24\">",
"      Callahan CM, Rivara FP. Urban high school youth and handguns. A school-based survey. JAMA 1992; 267:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/25\">",
"      Cotten NU, Resnick J, Browne DC, et al. Aggression and fighting behavior among African-American adolescents: individual and family factors. Am J Public Health 1994; 84:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/26\">",
"      Herrenkohl TI, Maguin E, Hill KG, et al. Developmental risk factors for youth violence. J Adolesc Health 2000; 26:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/27\">",
"      Violent behavior in children and youth: preventive intervention from a psychiatric perspective. Group for the Advancement of Psychiatry, Committee on Preventive Psychiatry. J Am Acad Child Adolesc Psychiatry 1999; 38:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/28\">",
"      Cheng TL, Schwarz D, Brenner RA, et al. Adolescent assault injury: risk and protective factors and locations of contact for intervention. Pediatrics 2003; 112:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/29\">",
"      Borowsky IW, Ireland M. Predictors of future fight-related injury among adolescents. Pediatrics 2004; 113:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/30\">",
"      Huesmann LR, Eron LD, Letkowit MM, Walder LO. Stability of aggression over time and generations. Dev Psychol 1984; 20:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/31\">",
"      Tremblay RE, Nagin DS, S&eacute;guin JR, et al. Physical aggression during early childhood: trajectories and predictors. Pediatrics 2004; 114:e43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/32\">",
"      Rich JA, Sullivan LM. Correlates of violent assault among young male primary care patients. J Health Care Poor Underserved 2001; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/33\">",
"      Molnar BE, Browne A, Cerda M, Buka SL. Violent behavior by girls reporting violent victimization: a prospective study. Arch Pediatr Adolesc Med 2005; 159:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/34\">",
"      Patterson GR. Performance models for antisocial boys. Am Psychol 1986; 41:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/35\">",
"      Straus MA, Sugarman DB, Giles-Sims J. Spanking by parents and subsequent antisocial behavior of children. Arch Pediatr Adolesc Med 1997; 151:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/36\">",
"      Patterson GR, DeBaryshe BD, Ramsey E. A developmental perspective on antisocial behavior. Am Psychol 1989; 44:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/37\">",
"      Firearm injury prevention. American College of Physicians. Ann Intern Med 1998; 128:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/38\">",
"      Kellermann AL, Reay DT. Protection or peril? An analysis of firearm-related deaths in the home. N Engl J Med 1986; 314:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/39\">",
"      Brent DA, Perper JA, Moritz G, et al. Firearms and adolescent suicide. A community case-control study. Am J Dis Child 1993; 147:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/40\">",
"      Kellermann AL, Rivara FP, Somes G, et al. Suicide in the home in relation to gun ownership. N Engl J Med 1992; 327:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/41\">",
"      DuRant RH, Kahn J, Beckford PH, Woods ER. The association of weapon carrying and fighting on school property and other health risk and problem behaviors among high school students. Arch Pediatr Adolesc Med 1997; 151:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/42\">",
"      Eber GB, Annest JL, Mercy JA, Ryan GW. Nonfatal and fatal firearm-related injuries among children aged 14 years and younger: United States, 1993-2000. Pediatrics 2004; 113:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/43\">",
"      DiScala C, Sege R. Outcomes in children and young adults who are hospitalized for firearms-related injuries. Pediatrics 2004; 113:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/44\">",
"      Hardy MS. Teaching firearm safety to children: failure of a program. J Dev Behav Pediatr 2002; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/45\">",
"      McGee KS, Coyne-Beasley T, Johnson RM. Review of evaluations of educational approaches to promote safe storage of firearms. Inj Prev 2003; 9:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/46\">",
"      Sege RD, Hatmaker-Flanigan E, De Vos E, et al. Anticipatory guidance and violence prevention: results from family and pediatrician focus groups. Pediatrics 2006; 117:455.",
"     </a>",
"    </li>",
"    <li>",
"     Fagan J. Adolescent violence: A view from the street. U.S. Department of Justice, Office of Justice Programs, National Institute of Justice. Washington, DC, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/48\">",
"      Pratt HD, Greydanus DE. Adolescent violence: concepts for a new millennium. Adolesc Med 2000; 11:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/49\">",
"      Kodjo CM, Auinger P, Ryan SA. Prevalence of, and factors associated with, adolescent physical fighting while under the influence of alcohol or drugs. J Adolesc Health 2004; 35:346.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/50\">",
"      Hingson R, Heeren T, Zakocs R. Age of drinking onset and involvement in physical fights after drinking. Pediatrics 2001; 108:872.",
"     </a>",
"    </li>",
"    <li>",
"     Office of Justice Programs. National Youth Gang Survey Analysis. file://www.nationalgangcenter.gov/Survey-Analysis (Accessed on May 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/52\">",
"      Swahn MH, Bossarte RM, West B, Topalli V. Alcohol and drug use among gang members: experiences of adolescents who attend school. J Sch Health 2010; 80:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/53\">",
"      Taylor TJ, Freng A, Esbensen FA, Peterson D. Youth gang membership and serious violent victimization: the importance of lifestyles and routine activities. J Interpers Violence 2008; 23:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/54\">",
"      Wright DR, Fitzpatrick KM. Psychosocial correlates of substance use behaviors among African American youth. Adolescence 2004; 39:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/55\">",
"      Knapp JF. The impact of children witnessing violence. Pediatr Clin North Am 1998; 45:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/56\">",
"      Schuler ME, Nair P. Witnessing violence among inner-city children of substance-abusing and non-substance-abusing women. Arch Pediatr Adolesc Med 2001; 155:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/57\">",
"      Durant RH, Pendergrast RA, Cadenhead C. Exposure to violence and victimization and fighting behavior by urban black adolescents. J Adolesc Health 1994; 15:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/58\">",
"      Widom CS. The cycle of violence. Science 1989; 244:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/59\">",
"      Osofsky JD, Wewers S, Hann DM, Fick AC. Chronic community violence: what is happening to our children? Psychiatry 1993; 56:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/60\">",
"      Fitzpatrick KM, Boldizar JP. The prevalence and consequences of exposure to violence among African-American youth. J Am Acad Child Adolesc Psychiatry 1993; 32:424.",
"     </a>",
"    </li>",
"    <li>",
"     Rideout VJ, Foehr UG, Roberts DF. Generation M2: Media in the lives of 8- to 18-year olds. Kaiser Family Foundation, Menlo Park, CA 2010. file://www.kff.org/entmedia/upload/8010.pdf (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     National Television Violence Study, Federman J (Ed), Sage Publications, Inc, Thousand Oaks, CA 1998. Vol 3.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. American Academy of Child and Adolescent Psychiatry, American Psychological Association, American Medical Association. Joint Statement on Impact of Entertainment Violence on Children. Congressional Public Health Summit, Washington, DC, July 26, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/64\">",
"      Drabman RS, Thomas MH. Does watching violence on television cause apathy? Pediatrics 1976; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/65\">",
"      Nansel TR, Overpeck M, Pilla RS, et al. Bullying behaviors among US youth: prevalence and association with psychosocial adjustment. JAMA 2001; 285:2094.",
"     </a>",
"    </li>",
"    <li>",
"     Kaufman P, Chen X, Choy SP, et al. Indicators of school crime and safety, 1998. US Departments of Education and Justice. NCES 98-251/NCJ-172215. Washington, DC, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/67\">",
"      Wolke D, Woods S, Bloomfield L, Karstadt L. Bullying involvement in primary school and common health problems. Arch Dis Child 2001; 85:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/68\">",
"      Bond L, Carlin JB, Thomas L, et al. Does bullying cause emotional problems? A prospective study of young teenagers. BMJ 2001; 323:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/69\">",
"      Ramirez M, Wu Y, Kataoka S, et al. Youth violence across multiple dimensions: a study of violence, absenteeism, and suspensions among middle school children. J Pediatr 2012; 161:542.",
"     </a>",
"    </li>",
"    <li>",
"     Olweus D. Bullying at School, Blackwell Publishers, Oxford, UK 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/71\">",
"      Rich JA, Stone DA. The experience of violent injury for young African-American men: the meaning of being a \"sucker\". J Gen Intern Med 1996; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/72\">",
"      Molnar BE, Cerda M, Roberts AL, Buka SL. Effects of neighborhood resources on aggressive and delinquent behaviors among urban youths. Am J Public Health 2008; 98:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/73\">",
"      Martin SL, Mackie L, Kupper LL, et al. Physical abuse of women before, during, and after pregnancy. JAMA 2001; 285:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/74\">",
"      Alpert EJ, Sege RD, Bradshaw YS. Interpersonal violence and the education of physicians. Acad Med 1997; 72:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/75\">",
"      Sege R, Stringham P, Short S, Griffith J. Ten years after: examination of adolescent screening questions that predict future violence-related injury. J Adolesc Health 1999; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/76\">",
"      Committee on Injury, Violence, and Poison Prevention. Policy statement--Role of the pediatrician in youth violence prevention. Pediatrics 2009; 124:393.",
"     </a>",
"    </li>",
"    <li>",
"     Elster AB, Kuznets NJ. AMA Guidelines for Adolescent Preventive Services (GAPS): Recommendations and Rationale, Lippincott Williams &amp; Wilkins, Baltimore 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/78\">",
"      American Academy of Pediatrics. Committee on Public Education. American Academy of Pediatrics: Children, adolescents, and television. Pediatrics 2001; 107:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/79\">",
"      Thackeray JD, Hibbard R, Dowd MD, et al. Intimate partner violence: the role of the pediatrician. Pediatrics 2010; 125:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/80\">",
"      Dubowitz H, Feigelman S, Lane W, Kim J. Pediatric primary care to help prevent child maltreatment: the Safe Environment for Every Kid (SEEK) Model. Pediatrics 2009; 123:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/81\">",
"      Guidance for effective discipline. American Academy of Pediatrics. Committee on Psychosocial Aspects of Child and Family Health. Pediatrics 1998; 101:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/82\">",
"      Sege RD, Perry C, Stigol L, et al. Short-term effectiveness of anticipatory guidance to reduce early childhood risks for subsequent violence. Arch Pediatr Adolesc Med 1997; 151:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/83\">",
"      Scholer SJ, Goad S. Feedback on a multimedia violence prevention program. Clin Pediatr (Phila) 2003; 42:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/84\">",
"      Scholer SJ, Mukherjee AB, Gibbs KI, et al. Parents view a brief violence prevention program in clinic. Clin Pediatr (Phila) 2007; 46:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/85\">",
"      Barkin SL, Finch SA, Ip EH, et al. Is office-based counseling about media use, timeouts, and firearm storage effective? Results from a cluster-randomized, controlled trial. Pediatrics 2008; 122:e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/86\">",
"      Durant RH, Barkin S, Krowchuk DP. Evaluation of a peaceful conflict resolution and violence prevention curriculum for sixth-grade students. J Adolesc Health 2001; 28:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/87\">",
"      Anixt JS, Copeland-Linder N, Haynie D, Cheng TL. Burden of unmet mental health needs in assault-injured youths presenting to the emergency department. Acad Pediatr 2012; 12:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/88\">",
"      Lim HJ, McCart M, Davies WH, et al. Risk for repeat emergency department visits for violent injuries in youth firearm victims. Clinical Medicine: Trauma and Intensive Medicine 2009; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/89\">",
"      Cheng TL, Haynie D, Brenner R, et al. Effectiveness of a mentor-implemented, violence prevention intervention for assault-injured youths presenting to the emergency department: results of a randomized trial. Pediatrics 2008; 122:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/90\">",
"      Stringham P. Violence anticipatory guidance. Pediatr Clin North Am 1998; 45:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/91\">",
"      Hahn R, Fuqua-Whitley D, Wethington H, et al. The effectiveness of universal school-based programs for the prevention of violent and aggressive behavior: a report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     Thornton T, Craft C, Dahlberg L, et al. Best Practices of Youth Violence Prevention: A Sourcebook for Community Action, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/93\">",
"      Kelder SH, Orpinas P, McAlister A, et al. The students for peace project: a comprehensive violence-prevention program for middle school students. Am J Prev Med 1996; 12:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/94\">",
"      Vreeman RC, Carroll AE. A systematic review of school-based interventions to prevent bullying. Arch Pediatr Adolesc Med 2007; 161:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/42/40617/abstract/95\">",
"      Sege R, Dietz W. Television viewing and violence in children: the pediatrician as agent for change. Pediatrics 1994; 94:600.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Community-Level Programs for Youth, National Research Council, and Institute of Medicine. Community Programs to Promote Youth Development, Eccles J, Gootman JA (Eds), National Academy Press, Washington, DC 2002.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 593 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-124.240.187.80-4AC29DC90F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40617=[""].join("\n");
var outline_f39_42_40617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RESILIENCE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Violent discipline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Access to firearms and weapon carrying",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Alcohol/drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gang participation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Witnessing violence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Domestic violence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Television violence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bullying",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Community violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adolescent screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANTICIPATORY GUIDANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Firearms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Domestic violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Age-specific anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Birth to four years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H126011446\">",
"      Violence-free discipline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - School-age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SECONDARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ADVOCACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Schools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Antibullying programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Youth development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Firearms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/593|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/38/30315\" title=\"table 1\">",
"      FIST violence screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/48/39691\" title=\"table 2\">",
"      Conflict resolution",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19000?source=related_link\">",
"      Guidelines for adolescent preventive services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14921?source=related_link\">",
"      Prevention of firearm injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40343?source=related_link\">",
"      Television and media violence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_42_40618="AGEP 1";
var content_f39_42_40618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86911%7EALLRG%2F68610%7EDERM%2F86912%7EALLRG%2F56807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86911%7EALLRG%2F68610%7EDERM%2F86912%7EALLRG%2F56807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical flexural accentuation of AGEP",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthemous pustulosis (AGEP) detail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Nonfollicular, pinhead-sized&nbsp;pustules on a background of edematous erythema are characteristic of AGEP.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Werner Pichler",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 371px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFzAkADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDPic7vlIA7VZSMhcAnk/nVS0jJwWKBf7xNXb6W2igUJ81wDyQePwrzD6d6Ow0ko+BnKmoi5YsXVmYnjHanQySeYXfByOCelT7/ADZUVioZuDjikg2GQKrZ3DAP941KpWJh2Ibn6U+/uoYVhiiXiPjd3qszht3J3Nzu9RT2BXerJp4yyPKrYiJyBn71NRgXDhQF6D2pnlyPujRiqAbhupsRCqckAg9qNxrYvXQZ1jZRtDd+maSISmbaI3CD+EetVyzSuigttJypzxU0c4W/3SEg8Zx6UyLaWLE8LjYxx8/YHpSPIUtnTZ949Txz7VHc3YeeVIS2znjtSPKcqGMeNuePWlpfQST0uMtQ4DbmAA5Cv3/GpbnyxJGNyAeqnNV8sy5lXJOCM9DRdsjXC+UiwgjcVxxn0pbF2uya3hl84OXQg8nPB21L5nlsWJ3gHOM4yKrQT7HIjdVA6knqD2pbzAC/MJIscMO31p3Jau9RbmYeYG8s5HJIORtH9aQIksbnzMAcp8uM0sUUc1yizZ2lcfL244NRymRmQMy7IyUU46ikXpshZZm8xJAxyowqgdPY01J5ZflO5lYEDjNPZjHmDam/cCG/rQ0r2sm5dokHUgdT6/SgFr0JFYeSBK+JGGQSAQfTp0qm5Jy0a78KS4UHge9X7e3LzPllWFlDMyAZP0z3pCZY5HALASfKVCj5x2PoKGJSSehRW0QCN5mXaWyMDPyn696vQRqRJHEXQ5zk8bSO/wDSqkzMsCl4irRHbvI4U9sU26kkNwrty5UAgHqcdaEU7y6lqS7WdVWZSCmeR3/+tVRJz54USKc8c+n0qOUOVjMh2hshHx1FRJazNcKxHzt3PViKTuNRikal0zP5WchwMHP+entTTbTTOMvtj3bcHkbvTFSQb3GHjP7vgg8n6fWpw4TeHJY4wvuPU07LqYczWiGGzEsUe84dvlYDqD7+lWLeEC1YF03KdyknOfb/ABpgYyY8qPYzHdznDfSor64ONqxn5SSfc+tO6QrSloQvIzo5DMDnBOfXpT0uStoIYlbbj5lIyM9/wqCF2SUsqblK84GKerOoV1ch2YjGcYHcEVKNGlsPL/JuYLj7rrnv/eHtTmUSsW3hsIXDsO49D1qGONPN2/OeOhH5g/hUwMexQqrhW2g4zkf1ppCemwvnhkgkjUIQPnYdCcdSPeo2i+VG24DkqGB4z7+hFWAkQ/dzJiOSMgMOQCOmKrTyMjeWkmRj73UNQ3bcleRfi8vZMC3yFdrgkcH3/wAaq2Eu9Cq8OM7STwwHamMry26ozKG6KAOCMcfXmrM9vBDBHLC+JVX54nYYyRyB6UydFv1HSCVw4QgcbiGP9e9VFlJm8wL+7YY69+1RNI0gwpLNt4w3bv8AjVqGCz+zvHM7rLt3DJxtyKFrqNpRWos3y24lPQgAZ/h560iKLudyX8pkX8Hb1FU7udPsSQKVffxIwQbt3qP0qKESERxK5VHyB2KketDlqPk0LTIJI8NId5YhlAxjHQn3ps0bROEOzcuCQD/nrSrCYGSfzM+YMEZ6MOhHt9adLJ5kkZkiQZbBIOetBOvQluX3kxkAngpjt7VBGCY2jUJvj68YpkjxxXDRscAcbSOR9PanKpWRZcna3ysOppk7IfHGUh81cMp/SlnXIV1OA3UVP0+UHaobABpgKiZosgnPGelHkQNjk3MqH86Z5qx3LRnj3p7rskODnvnFQTqHYSryTzTCyZJ90tzkVExBOM9amOJIlx+Yqu8bKxb07UncLCOg2kEVkX2nxzowZRk1ur8y/MMGo8KOGFNaENXPKNe8NYZ3RcEVxt1bPbyFXBHNe8XVsrlgwyDXJ6/4bSZGZVBrWE+5zTp9UeWY6c/rQBk1raho81oTlSRnj2FZpQjqBx+larXYx2I8A9eBSkHPrS7fUUuOlO4EZHr0puD61KV4zzRjmi4hqj/ClAwOT+NL70Y4ouA0/WnRHr27Uw8cDmnp2oAmJ460inimufl6YoHApWQyZWHen59agU8c0/dj1zU27juSc468Uo4+lRbvelDdxSsB7nGyszhPnFBQM23K7umKigLAE7csT1FSs21SHJDHuOTXNa57jZKFK5zz2Y56VKYcRlg2RjqvaoEzsBUEmno8wJVeM8c9KAuNtoFnmy0pXA4LDrVgToqmNiPMB+/61V3MPu4LDg56U825QAuSHzgrQU9dy5FLKJgY1BYr909x/jVRZE3vGwKuW59hU+6OOESeZtlGO+MVSkPmzMGb7xzupCjYsReX57ISSg5zmh3RJNwLPkEEelVrePy5GGdwHYmrnyqCo2liPT9aE7g9yeBrddOaR+H3dQefyqqzBm255ByPpT3tY/soYs2H5A9/ekjIhhMexHY9W7j2oYK2rRPEzwzAgJJwQA3QVFHEZJyJ8Jt5+X7oodEaHcWOcY2jvSxCN4ZG3MuF6Z+9SHfQn821ZmaJShA6LyBTZbRxG8gYCNgO3T8Kp20Zdjt2hSvOeM02KacpIiScjPyn0p3Dla+FlkZh2b13dCoz1Wku9SJPlwJtT2H50ihBFD5T+ZKTgZPT6Z6U+KKSZ1VF3zE4K9M+9HoTpuxLQSzyqpIw+FZs+tXb2y8iBpC6/IdoXOciqm0Rlk4DLyvbiorgvIygOzA9V6AGjZA7t3T0JftDCSMPEjKowccZBpq3Ukce7zGLxttXjOB6GmHc7JGcAJ8u49B9atQF4N7RRqwfCnjhse9CTYO1ikZpGygIOSM56n60n28SX5e6+aPGw4GP5U+e6L24WRQMuSCRj6iqkcCnLMCvPy0rvZGqS6otQyxG5XncOmVOBjp+BrTjPlzPCrpzhldhnkdM1nR2+6cG1THB+TqMUxpnjtvKZWMRbj29RmndozmubYu3N5L9rV0OHUdAe+elSz3IeVdvO5dzE9z3BrPhQ7Fk2swxnPUgd6twwrLK0RwBIMBvT3+lCuQ1FfIs7iDGu8LERnj+E9s1BcPKk8ityv8ATFRShhlDhmRcbT0z7U5hllMSn7mRnkn1/Lmh6gkRxOQAMBWVuc9KkZDJgAfPkgDNT6cUurxBNEXhaIqwztPs2fam3s0ccxjDIskI3qwH3vY09EtQb96xIkVzdqqbN8kaje4647Z96baYeURqMMSAwYZwfWm20zSTZikAScEYDH5T6H6UsMYtNREdw7rK/IboUbOcfj0peZO10NvGjidVDNkcYznHuKhWJt7SIApDZbngHscenrUV+d13MicDG4+p74+taMJtuEk3b2QHcejH1+vbFJajb5YoluysVjHgRmXdyN3Q+uKoTyplyYxMko5zwQfb6VKqxSW9wrkh143Z4z2FVYP3iA4znjaO/vTerFGyEs4yC0YIR/vcnpgdKkuopJQVKkxN0OehPvVu0iidn3nY/wB6NiOfb/CnT3Akt28hNpTDEKcqQO3/ANanZWHztyujOispESRwBmP+HHYdx6/QVe1SIRsLhJAVJDOV5Ab1HtVO4unSRXQA5w6lT2P+cVeuPLax3QRkg4dQDyjen0oTVmglzJpso3riRggIWJlydhPOe/tzS2l1FBvW4AYbcNIByKqWgkkLyOpWPdsJA4U9utaCW/k3Ecl0oSJlKnJyG/8A10LXUJJJcrK4/e3QXcN8efLD9wexP8qspIY4yhOJME4BySO4qnqlvC6NNbiUqjgMrsdwXHH+FRkMZY5RtVThQM/1ouRZSNK3IZyW2nI4Gep9aWbDToRgMwwcDoarqOEdRs2nDHOQG/8Ar1PIGjnDpuAYZIPOG70ybaiJmaI7mIeM4INQMzhDGFwM/iKsQgL5nmhQrccDkGmyq0E7nALAd+4pdBrcjRmjKIRhelSu2QQeGH60zeI7ZePMcHIPt3zQmDG218k8gimQ9xJELKGDYIqBcsTk5xVlGVl2EjPaqvl/vCyHBHUUmDRLKgI5qpKmGI6ircEm4OrjnsajKkEK4HNVfqQ0YOp6THcxthRmvPdd0R7dy6Jx6V6+8Wys7ULKO5Uh1ANWpNGM6dzxBkIbGMU3ac4xXb654e2szxrg1ydxbtC5VlwR7VspXOZxaKe30xRt49al2449aTbn3oERYx70hFTBPajbQrgVyCB0pyjPsKkKetOVeOadwsNK8dKaAeKmK03GM0rjsRjI/Cn496AO9B6UdAEAx+NAHGKcB3oOeM0gse7RRSSklQyADofT606NXRiWhyo79qhWSV3JBZQRzzwKcbtliaFRleuSa5bnt6iqRkh9yjqPapI2DSkIzNxxxVZQ5fZ1/GrunTQ2zNI+QcY5NCYMjndl4EascdQKiiebO4btw/SpPt0HnNsX5SOeKntgs6NsABHIJHb0o3ehWy1RRaNXbMrHL+3ep44VEKsF3AHDE80uM9/l+nSlkiby0MLMoyQTjigGx8ZSEyFiDvHTHFSTPDHJF96XcO1QxOY0ZpVY49qij2+aHYe4x2oFYthY9p3sVbOPofpUbAKOCCMZ6cipb6S3lxLEQuRg7u3vVZZA0qFiGXoeeCKTCLurjmVHiBL7R1A9/enBYBZA5/e5OARw3tQzIjYA7/dx1FRCQG48sDcuOAeooKWozzfkVTgjGFBOcetC2c8yM+0BVIHBqLaXkIHzA+2KtTLLbR48w5B+ZQelLzZTdtENmt08sOkmWXGFAwRV+CW38sruO6IZDt1bPaslZJXkEjKSG6ACjc7lSByOmaIsmSvo2WLjUPMlQ8kP228KPpUomEkgKrnb0IGMgf1rOjglMxlkUBieFzWssccscZWN1ZOXwe1CT6ibS2GpPGLncpPlvjOeoqFndTJHuKqWLbh6eoqbUEFqzKpQiUAhivIqBYpJY4XjJkKMQV64pii1a5KCuoKsTcSLH9/b1x0qvEvzgbsBScoDxUkZlVH2ZEY+82eQfam2cBkhMgHyq2WbuKRW3oXrdBbXME0mNhOGKnkA+tMu4pEu5IkbzFk5QnoT6VDeImVKurE44XoPerkyxoUdnzabcqqn5lNO5m9LMr2StJIucpGnBIB4HcY9asXk1tBaIkJ3SBsq3Qn/AArNkuMPMIXLrLzsDYz681XeeW4uQhTLIQPl6nFJz7F8l3foaFrIil2lYlH+XPOQfWpr6UwToUfO4YyOnTmm2xje0nRkJmYbuvU/41Uhi+1rkzqj4z+8bAyOv6U9dkLRu7HW9y1teq0o3R89OMZ6/XiiS6gXUSSEZXTaTjgHt9a1tE8topgyB9jiVGI5BFZWpLbTakjQlSj53KD0+lKSskJTTk1Yns72wtmFwRuKk5UnA+oFP1iaPUJY7iJ9iEHJI6sOetZFzHEDIsboUI69d3tTvtRXTUtpYyUIOKV9LByaqa3LG8xTRMkLpcpneM/f981ZnEVw6rD918Mu48qe4/Oq1rFKDayz5fPyjd3FXdsUVwskiuFUYz29j7iqSfUTeuhCYBCD5xaNy2Gz0PvVp7WWzKvhWjIDISeWX0NPuTOsisjidJUwD+vPv71n3OoyGzCkEsj5RgPfkUaIS5pWsX2uYi3nF98fLKnQgd+npTbqBYpEMw2hvmQhvvEjjJHrUKPFLl4SqO/IjzwD3CmqrCcJMDuJiOSo5wQetA4rXQtyIZLcqY2We1Hzhj95fp7UWRXesUsUiLKR5coONjdjSajqG0Qz7SxfB3Kvy+4BqC8e52NJblTA6EgZ4B9P6027CV2rPqQspt9RljnzLGWyMnPzYx+dSz3lzNZCMgKFbdGX/iA7Z9apC7EzxSbP3gYFiRgMelXL2cGEwRfMnVww5Rv8KhbMppu11qNe5eVlZyWV02/Lwf8A6+KrwGRIxwzbG6Hv9fyqe3VBHucHk4x3Vh3q4w8xt6r85GGAAwc9Pzqkib2K7ZEqupADrl8Z79vwrUhuSYQh2sWXYUPG4jofrVGREEpBJkQjI2tja1RzSS/OPl3BQ5z1B9frQtBOPMh0d+XIRotpYYJzyCDwanjMl1crJcH91HlJOxz7VU+2D7RMFXdHIoz8vRu/0pbeR3YAyssgH4H2o9QceysTWqH7WY1yHU8MejCn2se24mjJVck7SeB9KpGYtIgI2A9Dno1SyB5BuLcsfm9iKcWS0+oBm81g64IHap3A+Vg2NwyDSQEBi0mwkNuHHUUEBiUQrgHGR2o6Ce45CMAAc1FJIfNAxz2qw/loBliSF7DoaikQMyjcDkZBz0o1IHTEGLjlhVZnSSMHvVnaFG1jyehqG6syBuTiq8xWRQuoFkQqwrk9c0QSAsq812YXCAsefSoJyuQCvX1FNOxnKCZ5Dd6fJbudykgVV8vPUV6fqOmxTqSFGcVyGoaYYHJVeK1UjllBxOfMZHbmm7OuavtFgngioSmO1NmZVKHkHrQAecVOU4xSbfaquMhPrimke3FTFKZjHakgIiMfSm4xyetSH0pvI7Gj1GA7Up4OcU0HnkUMevFHmgPbt6sflGBTShbnI606RlZiAO1KqjIyDg9hzXKezcaAVY5wMe+adlJFwRweMntUisN+ZFG3uMUDy2kwhwc8cdqATIbeLE6jeqKDjNX5ZjZAxwAOW6P7VU8qQySkgkDrgdagk3CMt1B4xmjYrfckV5E3F0Lc5Izxircd1LGP3agpuDbRziqEty8doFAz2IpLN3ABQFWxxzxQtBtX1Zc1DUDdSbExjrnpTIGwqlGO70Iqlb4FwHcBhnkY61bkkWO5PlbduMil5g0lohsmCpWQhec59antIzJHuRAygflTFQ3KhFCgqC31q2ke23EloSrkYdaaXUlsqjKguAd4OF9qfEkhDzFlEykDFQQSMkofBZ1OSvrU/mR3AkmlymD0XpSKZPaW7sJHj4Zclj61DcQlWjkdgYnPPPSrEs8CW2+3kLOq881mGWaRMhmYAYwabsKLbdy9LbhpFSNztIyPSkjTbGCFUsD+INRwI5spJmnAJG0LnqR61HZ79hkPIHLbqFuNIsyzRCMZDebnO7+lM+1+VKJIAQcZZagYA2rzRg5Dcg057aWF1MucNgbsUtWGi0HXFwl1saZ2WINgtjJFO89bedDAMgjGc+tRy2yxXYUFCjjueM0iWqwXQ+0SfulfPyjgmlawJxtpsT2yuVnWRwpHOOufpTRcbY2+bbg8j1pk8oS/zHn+8CPSoXl+0T+a0eD1O3ufWjpoNK+rLNvBNMpW3UYznk0x4pAhSRnGOSPepoZAkxe1BwRyD2P+FOsZit0xuXK9z/hQkhXe5QWBS+7IR1Xjce/rS2c0scvKZWTjgfe/GrOovbGXEPcY2joKuXyxeXAbbLApkqD3x1FOwOW1+pUik2IjDKyBiCew9KbLcQtcBFTCuAGI7HvU094yWaHCeT/Fled31qOwjhnguZJEDMMbVIwcdQaOor2XMy3FfQ2d9sXcIiuxs9j/AIVQtRFBqqyj96u4/J35qv5v7rOBuB6nrj+tLaM0W9NuGYgqfcUhctr2EkMf2p2iX5c7gB+oq8jFrV4ECOobBO3kA9waS7s1idWRX3ykHn+EmogTGr/MwZTkAD86aQK0kaMiXNtZLDOS6IvGOSh7j6c5qWyYSmMFmIKGOQDkD0ptxfxvuAbY2BjnuOo+lVLe9eBBKo2pxkjHHoRVN6kJNx21G+W7ag9rLKyJDlgE6NjoR9ahuWClVQ5t3cAlhyre3tUl/mbVbFrclY3UguD3qvqZQl4x0XkHOOfWobtuaJ7Grfxotu8mnOHKYIGOQB1x71Tt7qSGVJoi7xSjbJv6E+5/Sq+nLNezOsTiKfGee/vUkAe3t1yMpKSsiHGNwPOarfUm1vdepYG+a3a0lJWRHysZ6MCcj6fWiBDbxy2Fw5QscowOQD3xTYROdQ85VVmtyPM5yCv9aj12TffqYnJRlyR6j3o8yd3yi2sUUZeC5Rc8sjHoCP8AGtmNbRoorqFQ74GSO/HII9KwY/OuAu05lTHBGApHr/KrVw5t7AtAnlksGYjoM8Fce39ad3awpxvpfUZNcqEleFHCgnAA4UdxVgTvaXCxKEOxPXO4Hkj61Z0O4aBjZyx+WjAlM9//AKx6VhXwS31FvJ2jcSSM8qR3/wDrUnpYIu8nBovJM5u3aIq2ZFZdvOCen+BqbVHCSqAqruO4joR6qfaq2nJu1BNrLmQMvzcDdjOfxq5f2Fz58c8rovmZQAHOxh0/Ajv60JOw7pSSZW0+1M9zKYhlIxvZemQe1SJH5CwzqPMj5X5+gIPIqxp0LW81tI5EazRssbHOCewYds+lZt9MbK7kjTeyS/MY36K3qPak01sF3KVkaurLALdJoY43LLjJ7e496z1dQ43E+W+D6fWs2JZpIlDOQpkzt7A+n41pxrCHaLY0KSLuTeOFYdqerEo8qs9SdpFhLMuN8QJweQyGqrS/v1eID5vT+VRwIroCiljghgDztzzT4olG8biQoypX9KTbCyRdjYsrKpy5GP8A6xqiGaMvHImCrZXNWN+AsgAAfCtj+E+9Vrwu04kblQMZHem/IlLUuSSmZFMaBQvvRl3Ux5wCOtQwyCOQRrht2OlT6iBCiyRsCmfmHpR5snbQoyBo5cE59aQhXT5+D2NIGEm4pTXVgoJHQ0waIHTGap3Vkk8ZyvNapQL1Gc1FKoyF9aexjJHE6lpZjLFV5rClhKkggj616VdwKyAN9KwNR0kMCQOK0jI550+qOOZOgppQ9q0Lq0kiY8ZFVGQ9xj+tWmZWICuc9qY0Z61Pj6Yo2evNMCoyDPIqIx9TzVtwOagkPXHagCuymmMfapHyScVGRnNUkB7ai5+ZhgdyauQXcVvDtbnjnjiqQyRhgAP73ajyx1baRXHsevo9yRZBKSVAA9zTkG7kIxC8kgVA8QTGwhj2GKmiZthxnI6knvQU/IGnlGRG5APUYyaj8zKIgTB7kd6kErxrkHJIx15FV4CXuC5UDnoe9D3KRO6wPH+9jYMOmOQfrUc0QiKqQhBHBqSWRgpGxl3Ht0p1rGjZ3sN4HHvSe4XsQKoyNvGeop8si7VXaN4PJFRSgeaV53Z7VObVlQOoPI4460bjbBJNnzrxjgYpZXlCrcBtueOO31pFKhP3nBPc9KZKQ0ZXBP06UMQKtwpaVuCeefSqqNKqOvBVuMZq1DayzxNIu75Dg5PBpRcILUwumGDZBxiiw0yq8mYUwwDdCo71YjmCIFXjcMN6ZpjQgIjgAI3v0oUKCQQMn1pWG2OXLng7YycHPIFXZNPlS1aQyhc9gc7qgd/s1s6bSVcDAzUDyS/ZtyXHAH3Dzz6UxXfQnvLlUS3MDAYGGB9anv7393mdvndecGsa0hkmlO8ADrU+yMBvOzvHQ9alq4NIIkaSKJjkktn5j/KrUNq987o0xVgMqrdzUNu0aRfJkOTgZq+JYbeUB8hlXg9Mk+pqtOo230H2YtTdRR3ivnaUIBxg9jVe5hSG8aNHIQj5WNRQNFPFchm3OGyrZ6U65hLNERIJFznJONtK5O0tydAY5y4byx90+1MnDC4RTGcLyx6E57k0xZgwARMoBsJpEmkhLK4Zx/ePNN2KT6loCHyJSiK6Nkbj3+lUdPvXt3JKnOCmO4qj5sjs+xyibiR7/Srtn507FUhVmUZY5xSQNWTuJ9pci5OBtJyFP+FQQvK37x5GAYhWx3FTeS00jKwYueM46H3p8MTQxkyZOOG96LBfoT2q26wzszkMpAiUnBbJ5P4CkIUKpDjBO5SR27GnQzMql40UonQkfpUTuZJW2ljkZAp3EkT32oG5tgHO2RBxt459aNMja9jcPIvnbMj/AGhREkcm2LBBbnIPGKuQwbNJjvUhcEsRuQfKv19PxoS1IdoqyF0wxvcL+6Bk6NnkY9ahu2hmh+zwgfJkAHoec4qsuoJFcs+w/vCN6noKh1GTbdrJEDjdnIHf1+lJsfK+a4wSOIQ0IXMThyjHlff6Uup7Tcxqke8zHduHOc9qrtE5uWLYy/3tnOVqzEskLxQSDdDvDAkcjmjluVbW5Z0vMM0ctwNrZ/h6gAYOf6VpTCJ4MZDb85OOrVV1aHEMvVGYbm56eh+tU9PM13p3lWyF5FGUBYKPqc9MUJt7GT95cxK0iyITHkS4wSDyB71RsvLRkefdt3ZHHzD/AD6U66KW+pTNGW8tvkYHr7H35qtbyu0jSthBkcgcg9OBTV7lLY6HzTcyNeQFTE48uQDjn3qnPdbLtfNQmIths9s+o9DT1nNjZq7rmJjlwvP41Best5ArW+3Jbl8/rTe5EVZ+RJqd8kuz7MwH2flc8HaOwpdQsrOaSO4hXbICH3A/e+vrVN0t5JWYSBE5QlgSMdunNLb24+zKqAm7yVQbuHXHUenFJruVayVmODH7RIHxtZgyleAO/wCFdFJMNQ0t4pSQy43vnkeh+ornJmt7a5h8nKKygMDk845NaNlcLah/OOyP5ULe2OmP601omgmuaKfVEeoajutkhcbnfg4PVh3/ABqvJem4X/SlVZVXG7bnp1NV7yM29yjR4aBZPlAHzKOoFa88Mc6xzb1AnyC38JPQZHUMale8mHuxSHaJd+fayQLApUdxjOOxqjfStMzQRAZQ+YyuDkN6Umm+bBJMtmDKYzkYXHB6Z9s0q2lxeSyS3D+SyuBKuOVwOGHrVboVkpNk1viKSGVQBASDu69etKo8vzrcuCyMCNvIxU9pAlxcyWbuIQUMkfcMe49s1myn7POMxsoU7TnnOe3+FLQE1J2LzYBUuAVUYI/vDtTLiSS2McijCZIXcOvtUqKoBjmXLKMoHPGO4NQTK9xZAt/qd5EUjHoR1+tPbYRFdIsCRSxqPKkyCB/CfSpSoe2xKflj5H+0KihxPE+5xtUgsi9yO4q7aW/n2cjyHBJ4BHzfUe1JCbtuZ0LiK6MeDtbpirDuAWjGM45B7UAQNOYpmMc2MH0B7GmKFcPE5xPnhj3prbQl2K6SMUKn/wDXTJtzOCAeKRyRIqrxg9KsN8pbdkEihCaK5+ZeaYAGBDDNSwIHPJ6U5wA+BTRm10Mi+05JAcCsK60kqSQK7LYd3tUM0IdsYGapSsZSgmefzWLoemapyxupIIxXocmnBj90c1Sn0ZWBwv6VakYuB5/IDjmq7Z/Ouxu9DPO1eayptGkU/dP5VSkieVnPkD3pu0D3rUmsJE6oaqPCy/wnj2p3HY9mtyMBXwqkZ3GkKqWIQ5z6npUTL8oHIPqKiWMjJx8vqa5z0yYxbACn3+/PFPtZJELqFBLAjBqBhzgHAxnNOIYKSrYwOCOuaLDTuM3EE7hg56Vaimjt41DITk5YHjNQo0cq8nZIBk570ht2ZAXzg8g5palvzHzXCXDtt+TuBUUcbSISm1SOck/ypHh2ruxkHjkUIjLyMlv4cd6Wtx3tsSwxeWVefa6Pzx2qxPdhIFhhIMfX6VXgt2fc9xuVeenY1GyoFLI3fGPWh6C0e45cvub+HoeKXaPl27uOuKdBIUbGAqNxTmlxNucYGfvCmFyW5vkjtlSKM+4zyfeqDHIMqurFh909qmvpY7hwFAKoMfWopbZIgjLyW9KnrccbIjkkPlABGwOhzViIxm3IdfnH8VRiMtwwIx61oBkFg0ciNgnAx61Vrajcig4En8Y+lM8pGU9jnpSxRSyRkogCjnOO1PQqPlzy3Q4pIH5ErPCsKJtAdh1zUHkZUcjB5HPWmTvHDcAFvNFSWWyQMXQmJOmO1O4Wsrkv2UxBHlUiM84749acjBJ3glHySYIY9QKjMjXAQnzZI0bHA6Cn6rLArRiBRuH54pXFfoUbqGKO6KxE7cdKke2cRJlsA8jng1K0cPkxSMrCRj94jg0kzgoigZIzwOgNA+Zsd5D2ajeflfrg5/GrVy5/spQVGHbAcetZzOJLc73Pmdu9aiy20+lRrMNjLwT7+tHkKV1ZspeVGlpuVgJM/MD/AEq1ZwSP8yMElHIYn7wqGy8m5lbzGXcnQsOGHpVq7W0QhYpGiKp8mGyM96egN9CtJK8F78jFiT1I7+lMMjyTsGOCeD71Xst8t2csWJORnpn1q1MzXGpACIDaPm29CPWla5TVmNTegYAEqfU1A0hR3O0gONuPSr7uLZpIXUZA6n+L0qvbBJbWRmzuRsjPTB7Gh7hzdRpkZYxH5mVyCvHIPf8ACmOsk/mIZfLkUEk7sBsfw475qSCOFzGZ3KoDyR1wfSlhVJLposkQMcBjyR6UkO9iBrcf2f8AMAJywY852jHQ+9WrURNbG4eTlQVKA8D3qo6rFdSpEvyoenXNOeEOjSR8lPvr04ouweq3JoJ0QMNoJL53Dirl5OsoiWNczKRtUcH6VmTGMW6Mn3sYZT/Opp5JFMcu3GV2+54oE0r3LWs3XkM7s+6R8fI3b1qG3MQtJ7SVEImbcinjI9KoRQtfymKWThfmJPJNROskt2+5vni4BHUgUk+xPKkrF7S97XE0MkjiB8hZOpBXoKYGeB5IsKxRwQ/fr3qnsntwyZxuPyk9jVq1h8+7hVTh3G193rimO2t+hLqF29xI6KTtPVVPANTQ2U7WTx28MjybQFEYJ69ge/fipJLaK3hExcrcRtzzxikec2s0sbuERj8rKSoJx7fWhWJvpaJFY2qhJVuo7mORcARqoVs+pLdcelWoJIra/hQxNGjsP3zSktjPpjjPfHWsyOWXzD5jSSE8K7kk+1PuxcN+6uUKlPmyeh96pOw2r7mzqGmBtTuDAymX/XRqR8sgzyp9D3FakFhaQ2ZnnIkR4eEb7yE/1U8fSs3QrySTVLc3HWNSpLKOcjGMVsmaMTSJkEFeCfarvZXRy1JTjaLZxupIwv4zJJgMuVVDwCP85rRtWI0+dpI5GRiFbAJ2uB7dKi1dG+2rbqN3mNvRj0X1q6k0ukb2K5gnw6pu6EioirLU2crxVieW6dJIp5IPLu41w4boRjn9MVnajffamM9oxDqNrgf3T61BrM8l9bRyrHJgNjbjBweMD15qmtrJax4YGKUlgpbjI7ildsIwW73LgtWDRtHIfmXfGCecjt/9ao7x2zbzM3mJJwy5wc+/vU9jZzXGmboJMSW752tzn6VNqdpDNAtzF95uWUcYYdRQ0PnSdmT2NslyJriWR8jIkUnDYIGCagupYbKLCs8kEhyq5ztNRWtw1tNHJKFaGaPZv68+9ZMrm4uXWJSYlJIPr7/SiTvoCTb12J5HYuyyFUlDcbe4xWhpk1w99bRFBIYwRgnBb2zWfBbveKkEca7nbMeT0PpmrdpG9szPK7x3EMg49s9acY2CVrWIb+CV9R2vDJErAjc/r9afHFLDIJWlBZDyD6V0mpTrcwEgDzAcFff/AArk1kluLlmG0LgqEY0WSehnCTktdC7bQieaRQ3z53Lmnywkgu56cYHakiTMHm2oLtCQGPTB/wAKqXLy+YXPyRlsbQelDHuWLcDaW4qSRUSIE8571EAyR8AZbofapGU+XtPIHOaNSGiNGAII6GnlADuFIkbEEAdKTLBdp70LzIaFYHGRTo2U/eGadCNyMKgVSr5p3ZDRbNrHIvFQyaUjDgCrELDA7VajbildoVkc5c6GGPCVj3fh7Ofkr0VFDjpSPbo3VaalYlxRgzICMDIUcUxXReAoLdOelILhGO18bQOOO9I6BB/rAD1POTmnc7rEvkADJC+vB/Sk2YOY3Az2zVVshtzFgO1L5p2nofpQFgVEkUiThieMjGKd5kjptVQwTgH0FJtzgELkjqTSfPCCE43DFK+g7k5CkDnkfw9RSkADBwD6VXjJHLY49alMhEIPDAnpQhWHtL5cLKDuVuNveqcigH5cgds1Za6DOxRAiMMEGqszGSXEJYoOgIpMtEiSMDyox6YzSSIfvHP0zU0Koqky7jkcEdCaHchVGzj1x3oEVzH5ZXzMDJ7c064myUyGCr0xUhiYH5gylumetDhPLIIDN2x2oHcJrlZNpTLHHIp8t2sliI4v9YOMkdapRHYGJDB+3FOIR2APGBk4oCwnmzwgQ7sAcEDvT5WQRL8xPt0qNmVX27y4fndjpTpY9s2wuCuMg0kFxskoktmTAjcdWHUiktZGiJETbeO/enMivG8bMuPvAmootqgHIbj8qB30LEUlxGWK/KG/I1GsL+cpfA3859aezttCk8Dmp45P3e87f3bZ+tKwrhDBcXCvECMJ8wRh94e1V2SVA0QBVupI649Knku5lmS5Vt8Y4wO1VWvGe4aQHhvlwad0NXNjSLG1nsne43KegHT8az7ifyrpopVDKnQY4x61HDfS24WNVzHnuahvJlluUmxkAhX57UNvYFfmd9hglEMshi+YHoPSo97Tyhc4ZRuGf5VqmazedXt0VfK5IHJzWXMfOneREKqM5PvU9S4yv0NHTZY4GLSgheobHep7DUYrTU2ZQCjcZPp6VTM+bCOIrtI6e4qubcBwAcZ6DvVehNlK9zT1sBnFwrZjJAC+g+tQhtiIvljZIc9OT2xmqRnaKMwSqdjHKn0p9xcu0mVdiVGQSO9JMFF2sWdwa3MbxHcGIUgc1Zt7ZpER+CknDYPQiqkt2fKjQzDAXg45GetNhvfJV0UEKW4C9qHLUdnbQmZI7a+iKnK5wQf4vXNWJLeO4uCLYnYBknPIrMuFmFzmaNs4yoz+tSNdlHjljQrJjDL60K9tQafQluLQph13eUD9/HT14q7Zq0EjJcAmOUYiZx0/wzWYdSneJ4H+YN056e1TpJIfLdcsyL/F3HpTTTE02rMjliU3coiONvPB65qTTrNZZjGHKSRncD3PtVhYPMLPaFAXAbGcAe1UEfM6yoCGzjC9SaV7aD3WhPfJ5d2sTOrR5DEHqPWn3MaBHnhlC+WRhj3Pb8anuBGwSaWEGdeG56+maW3nFxayW6sg4JRCOhoTV7EX0Mxt97IxdiWKk8c8jtWhZwG9t2WSVQyAMu5c5x61RtVlZxJGuzyzhj0INWoygnYDc6FCCV43N7U42HJdiO5kt/PjKBgqHDAj/D3qZrlHEXmlgjHbuLZKnsf/AK9UY7kxTzL5EbJIONwyR9D696dLLGfML7ssRyRwMUXG4mrcziPUbVlK4PG7Hek1DUBBNvyCByD2z6H61UlsTJaJcw7jkZweuf5VR+zSyQOY8kNjcD/9em9rEcsWaWrXCvbAhsBcMjA8gdqqC+nvNMaF2UmP5gejYzVFVD2iKkjOo6p6+mau6U4SdGk2BImDEZ+8D7elJdgUVFehs2d15+nxkLudDsVVPfqOv41V1VLeJC8hYxyncCckxyemKffWxi1BxaFY0mOdvoRz+eKj1yWJ5oTlSGYNtDdTjrz70N31IitU11JrO9axtVudwaKYfNGfUcHn17/Q1UtnmvLuZYWMb/eRQBhuehPr6VcgtozbyqAzqCNyscj8/aoNOaERzMiuZ4HwFHdPTHtTbux6atbkDxkwuhBKlmUx4PyHPf8Az3pLZVhPmupdoiDgDj3BHrjpV52mvXa6tlEc0YBkDfxjP86pyXomnc7AvngnBJO1u+B60XsNXehtQyW63UN/bKAesqY6+/1HrTPESKZILiNwVcYL54dT05qBLhbS0QyAjaNkm4fMCR/LpioLKZb6yuLRj8indEAOVpuXQy5bPm7Dbi1uZLb7SkpAY4K+oH+FZNx1WTaEk3Y4rWMlwLcNFMAquFkV+x7E/WqSzRPezrcL5cTHpn7rdiKlu5cWzQgmWzUPD86SjDg1nyzidwkYKx5zg9M1ci/fS7IUMULYDEtk78dR7GqlxA1nOiBgSDuVyOvtQ1qJJX8y2ryxnkqFUZww7e1TBlJTZkHvnpQd13b7nj5jGSw64oSJY2jcuTDIPlY/1qyQlQwyb1YMGPBFRMSGIb8qjuZHMRj43Kaajloxkc+tTfsFi3Au5sg49abMMN2pkTY+6CaVnyRR0M7aj1ygHoeasxOMZ71FIgeIMDg1HE+B9KCbGvA/T0NWhzWdavkVdibkA1ImjkpYCQC+VB6cVXd5EOPvY7nqasNJIUEbggDnNC27yYKMpboQaux2p23GRXWEKyKST90+lJEQefXrTZYgGIfKkHoO1EXQnkKOuaAuThTk53Z7VIZWbauOnXFLF90eWcE84NIW3SNI/XoSe9BG4FPkYKdvPIJ601FQYDnaV7j+I1YtzAZQZSfK+mTUF/s80BSdh6YHIodil2IXUuRjGM8c0x1cAsgwB1qe1iaKWJpGAjY/epb4mOduhjbuKGrjvrYLV5lgMgKsE/hPU/SltHNw5LqcPwBnAFO+VrQKScZJX1FZRlYSg7ipBxxS0Gle9i/G2y6EcwLZHUnNSJ5QuljdmMRxnHGKqRJLMzbTl/Q/zqJyYlKs5MucNzRsBuX7WsSEpyenvWdIioyOV+Rh2NU1BeNnG4ketSiRXni2DB6HPQ0NiSsNdFclVyoPQk0qhyMAbwOpp97GIickMM8CiyuvLmTaC3+zjIo0uHS6FW0MiE7sY7EdadbpEjKzHnuDVp75ZEMQjJI/CqlvH56sMgMDjmi+oXdtRd8fmHeuFHQVM8MbTbQQVcDJz0NVpNoYqQFZB9c0yMuVLqcYPzCgC3JE9s8iblwBkjPUVnhFKOxO0g5APerF5cqV2xjcWHzZ61EZ4/IMbKS3Y4pFK+5OqJ5Clm+UjOR/Kp0063uLKSZXKOOgqHS7RJJwl1IyK43LjnJ9Kku0NoXRCpXHTP3qfmS3rZPUrCD/AEf7RA5Dr8rD1qK3neKN49uc89etWY1j+yRyMf3ZOGUHmnTWwiUSKHKbsZI6iiyKv0YqmOVYoo1PyLljVa+u3jnjePgj9Peo03KxMbYk749KLOJbq82yE4I4OOgqWrsaSWrIJpXmjBdskHv61sSyC4sIm8kjGFLgcA1RnsDDKVfAXsc9a1hIp0rMGWkU/MtNKwpSWjRCNNSXThL8omUkcH73pmq1psJjRoiXBO4eopBdSC0Eqso2rtK9PxqTSjGkS3DHMiyYZT6GjRsLtJ3J7B3XUwxGYwpUbh0B/rVTVMSXgEZJYjkVo6ldBg2MDcMDb69uKqaTJDFE/njFwDyzcmk2mSn9oppAMgp8wBxn1rSmkaO2iVo1KA7lPf8AGmWbwtqJWQhUckrjoGouH+xznA8xDkbT2NPoXe7JoIhdwO1q3lv/ABgnofas6d5DAIDCVkjPJ/rSwXYiR1YlGY8MtRXE7pfxuxJBA59RS6hrcnDOrxqH8xJANwPbPX8akurZYZQ0Q2bCMMT6GqjzQrdSFl3RODuHvT5bo3UZiVGLkdc9SKVuwtd0Sfap1up1wdr/ADbSOc+tWdIES3aNcyfKFLKOucc7fxqRIYprGB1ykxTLkHO7/wCtVaEl45lhT7vzN6Af57VVrBdNNDo5Irt5FjgiQAZL4OTk9f6U+L7OIJkvCFY4KsD1HeqyuI2DlCBjY39Knjk84PsiULEAMsOgPpTS6Ayywa4tTbWbOGUKJVLYAb1H14qCd7qOIxupaQLli38IAxVS0naG8wjsATjcD+v0zTdR1N2I2BTjl/c+tTJpq5PK72RFEriJVdmCbiRkY696vptluYklHlwuPLz3Ddifas+3vggdXQlZCQMdB7Cpt6m2DruDZHfI46000U0y9qXn2UnlE5aJg6ktk1QKNeSSsiEljmNRzg+lSz+VN++jB3tJwvoP8KuaKypcNG22MOMZJxnnI69KaWovhV+o61uPss+xczF12ugJOw9/riqlhdfYdQlmkO6AsyMfUetW9O8r7XcTXEh2hyAI8bs465PrUQSKNWkaL5mHzLnPHt/ntU3s9SdFdGrZW00kbPJmJmbBCnJMbchvw4/OsTVYEtJ0ETErncr+4q/YXbW1qiSvgkkqCeAPQexFVNalVogUIMBXcB6UTlroSm1Idqc0d+6vGSocZdenIqpDJ9injlhO5HwD65pbeOQXCQoynzFDISOg9a0RYNc2j42JLChwBwXA759qpIptRVuhRe9H9oyKD+4nXbIPQ+oqKO2ffI06nYh2N2x/db6VMUi+yiWMvhSCNybSX7j34oupJjbibcu2UbSp5JHrRZLUVrbD7+abeImGzCKSfXFPuHDQRIJvNY/OjHse6mmajiNYA64iIAEgbnHcfWnzWXlRrNbrtY/Op35IHp9aLXuJWsjVgIsFC3DATEYJ/hZT/hVe4U21rcWUrKShLwsp+Ug89akE0UmiW8uR5sOUDsOh7Vm6pcrPYxMeSMbucGiTM0m2RwS4kDA5yOc81Jbv+8dCPlPIzVW3ZCsRjGGY/wAVXo8yu0cS5aPkDNFjRlpEUodpCnHeqQbcg55pZJiIyH+/2I7exqIyMCGbgdSKTsybFuJyAEPSllQxsCPumm85VuoxU+QxG77lOxNh0TlHGD1rQjfkHNZDSoZNqnpVyCUHAJ5osQ0ZN7sDhQ5bPO4jFR7pAAwAIB+8O1Qndt5JI9+1SF1x8oJHTB7UzovYFBaQlmyWOc1JEZY92zbjuDzmoF5YspAJ7CpQ7KAFHzdz3Io0BjlDhMtgBj2qSOIzkISMrzjPBprZIX5gSaax3dtp9qAuJIgGVOOTjIPFUyrRyhwTlTxmrFxJ93KhT7Uzz5TE8SDdk598UWRaYl9cSy4VyuOCCD0qNnuZ12KM45Papfsm2FZW5VgeB2PvS28U5iYhg8ajI3A8+1JoLpLQijecqy7dzEdAeRTbZo4h/pC5Y8gZ6VCjskpfcRIew6fSnXETA+axDluMAdKLA3rYnku1jiUw/K5OCfUVXcL5gLsWDck46U61fyh5gRXXphuv5UXM73k6syEAfLgDpQxLfQkidY8gOSvp6ipbwxSRxvF8g6elV5o2iO3KkEdRzTLiRpECFWKKeoFMOt0So8QRTKS7A9Cc0kjGGTCseuVKjpVXeu0DaVZTxkdauW5iIXOQ5OD6GlYb0J7ncoiYry45cd6mazEUKSRTDJGWFRTQsUZd4G35sdjVGSRiqqSwA6ihiWq0JXO/dwQxNTxo6YDxkHHcfrVRQ4cgbgOtayzzeWvmkfKvy5HBFCBsimtVEkW7hnGQe1EVo0zsigb07VTa8k82OTqqNkA1ee9Z0aS3ZUY8tkUXQO6Ibhfs4IPJx8pz901CjNLPEZAXyeeM/Wo5DLIS8gB3d6fDKYdzn72Mj2pLUrZFnVbeOOYfZs+Wx456Vds7uQxlZSGnIwQewqgNTOR5qgbOdw6VBLcyLdSTwq20gbgRjNBLTasyS2Pm3bCNQGU9G70kttPbvjGHHOVP6VXuUnidbhvkZ+Rt/lTjPNcyAEkY5PNBer1RYkla5ssFCZkwcip4xvtxJCu51GHweo/xqgszRSOkbbVfjmtOyl+zvtTYYGTJ4wSff1p2SJl7qMYsuDjcoJ4FSQStuYseX4J9RUyJbyyTgtg8lT/SmRINgCgHBzzSSKciV+DHtlJj9+31ql5bzzSHOSCelXZrVZofMRmABxg1XjULdbY/mGRwaVrMSY+3G0I2zeAwx7GrmqbTcTPJmPK+vr1xUl8iWcwRAAsn5ZrNvGkmhVnU5Q43e3bim1poCd9SzLaeVZxsTuZ8AE+n+NQ5nmcQytnHyjPbFMlvm+zLA0bEofkOM8imrKz3O8gB24x6UBr1Fhj8q52P8yg9R2461KGjjliCrvJONo9+1AVY1YO26RmAx3+tV3ZUlDRMw5PI7GlsUtTSuJEt4kJJymQUHGf8mqlvvLSMiBQCCRnpz2qBI2kDMzFlPJzyRVl4me5dIyVVAN+30+lFmLbQtosZs5GLZIZiucDn3qEGJrYKwZdxzvz1PYfhUc9s1qAH2kuM8HvUhVlgD5VBgHAO7r39qe4vQi8pRG28Mm/5QWH6iq9xbSYyqs+BjcOma0Gugs8XnBSMBjkk5P41szTJBaR+WgdZMgL9RSVktROo4vY5iARLbDfgHkAH19qt2KWstoSrkyq2GjPQjHr2qpebFDdVLHcpI5HtUUALgsykjB3Y7/lSXkVvqaUCGJvPiXJiOdj88YptxdxSgO6gSA4z1BBqKYTBQRITvXt3HpRdiD7BB9nVjIOJCe3r/wDWoeoupO9usrIyOWMp27ehJ7HFLYo9vfi3kDbZBt2scYz1x61VgbNqz7/3sRBAPfFTyyvfslxIdhVcgoOQc09Ad9nsKIQJTa3rExBWETjsR0H5VUs4RPYzw7yzg5QZIA5qeQT3MkUrSqRuwCODkdzU9ojRIbuJlMsTEbCOMd8015ivZDG/49UilGLq3+4f7w64rYiCGK2KSMrnMiN0z6r+PpVG+niea1mfEUgHI7kHpUdtdv5ClyTJDN5hUdFX/wCvTTsZtNo0NeiigiVrf/VOoYD+f41SsWkkWONEjYQAvh+N6HqKZqt/G9syIQfKORz0B5FRWVy7WJEEQ82Ibjk9V6H+dSnqxRT5dTRuIoV32HBQ5aIjH5VSNyVso4WXe0AOWzwVzWVPPK7CVTIFif5VP8PtWhBMXWaMj58BgPU9x9CKViuVpDZjuQuAwhJA2A8exqpAXKyW5UkMOAO1aFsYZLbduBB+X5uOKmgth9l+0xMpkiPK46j1qtGx81tCkkQAXkEEjbnqPrVu03LiYZAVsNt6kVJqMQ/s6KePDoWJB7rn+E1HG8lvbxsv+pmGMnsaNLk3uhCjtcuZOAWAz1xmn3CLE2wdjhs0++ZIGj80YlICkjow7Gm38BRC8j5bgZB4b0NGltBbmhCEitv3eGOMj3FULe5Dh0IwM96ZbyvFHlQG3dM1XO43CttwT1pt3Eo2LDqoZSvLVPA5WQhh15FOW3EiGQsFcdvWkmUEo6H8KLWJbKaxFgcsFGf4jioyORg4xwe9LM6EAx4D9Gz0pI8A/Oo56EHvTNLaXJoo1ALMvPY96RiABwxPrTvO+TlMZ745oSVcAOC3YUyV5iADaSM4HBochQoyOehpdynB25x6mnxr84wASeAGGeaLDIpo1KZYbjjO4dRTIrXdF5yOGwclTwfzp1yHR2BXZnqAagkkdMhOAeCMcUFK42eZZoy8RZBn7h5/KntfGFFWGTchHzAioPJZj90jPtimm26KTlmOMClqVoPuQ10VdItigev8qrfMkZZXz7elWLmzmgVVd9qsOx4piRlFOcEDvQF9CP7OxhEqhsZ6471JsDNGhDKx6kVYJmNoArp5IOCO9RsCJFSJgzdm7UCuQSsXkKqwbbwCe4qMMQjeWTvz644p20iU7sBwe9ORii7WjBUng9qNhpkqoqxRrJGSGOSQP0zVq6Fv9nDQSbSo6HvVS8kmXaGxx6HNRW6gyEuhbNIN9S1Ywy327MwCjhs+lP1OFbWQINroRjI61QSaa2kkEa7EPY9velWSac7y6/J2Y9aBa3v0LFnOkEhd8kAYwe9ST3jzLhBsjU5A9qrafA93K2VzjO729KJWMP7kqu9D94d6YWVx8iK7gxqSuMkGliTz5XG7ZxwBxRHKotmGMt0GaWAmKRftUbeSw5OKNwuyKO4eKTMjKSo2gYpBK804AjwZDj2q5PZxNErxkY649apPdNEmxUXcnT1+tTsWmnsSy2yfZmJYCVTyKS8vpJEC+3J9abDGb6FpS2JlPPvS2BjEcvnoCmOOOhpifnqXNQhJt7RopGZSBuB9frVGYNDMwGWB6HpmrNjPHFbyb8nBwO+BVi7uYPIKKFAHI9qGJNx0MxY5RhQm7eOB1OaltYpJLjy5Ny4+8M4qzNPCmySIAHGRj1qvHcG6uw5BXd3HrS9CuZtCusdtcBNn3Wzn2qWaQFg6INoOBVN2d5txBwvGT6VqwWkLW2ZnKyfeVQe3vTJlpqxwwLJERRukBbI7D3qlPCi2yyggzBstg8gfSnRJ58UgWXaqHgdqILdyMtko6k7u30o3EtCvdXrSSkEcY7/zpJJ2MBBblhzSyWTCNnTkLzmn3MXlW6vlSGGNoqXEu8divHPGE2Fc8cn3p1oAWlUIX+XIAHIPrUEMO4fLyxycDtirsV15EhkdCj5xtUcYx1oQ35D7lQyQlFAmHUYqsMNdgyYWMn5iBwfwp08rrO8wAUsOmamcj7Eo2DzF+bcKEu4bIsqEgijmjYnORJkZxVKESCbdEQu75SewoluMxiOMZPXIHBqE+a0BUk7VOADVbgl3Lr+ZNbCYyhwh2YHXioreQYYkHaOo9Kks4JSFMbAkDDIP4v8A69M+zvEzZBA5H1NK2oabE0sTu6SZ3jpnPTNTXcc0UDxCYbE+ZM/y/CoA7R4XjayZ5BGf/wBVVp2lmUbm4Xjd0z7UeRNmyIPJOitLyScccjNWrPPkssZ2v/FnviqyBolCA43AAnoB6VJG7IG55Pt+lHoNjYJSZGDsWTkkZ7U9ZnikkUEDepBA5yDT7C3ZpmQR5c/OPw6ikndZ5f3Eflsh4UrwT3Umk0kgvqKLYfZhcbgwJ2lR1T39xViSOSKLzAN5PzFSabbwM5g3LiJgcsD/AD9xVa4knjhJGCFO1jnp/wDrolqgvfQfHdOwXEa53cDPfrUsymC6MUo2xOyuw7jNQW8DoscwUupOMEdPp61eupl85riaRpCy7cv3I5FPRCdk9A11EcowwQOAeuV/+tUFjEvls7mRF+6rKR8xxwOf1qtcP50wIkOw5fC84PfHpVoICgKKNqAuME5I7k+4oQlorFae13vI0jBZFQFQe+Ooq0vkxzWs0aHDxmORCO+O1QqzS3C/Jyo54z+FTajD9kcoxZ0YAr6gihbBvoyqMSXJVMkMQMEd/etabTIxLJvlBRV+UDg4+vtVaGRJX8mNCwcbSy9j1Bpl0sj6cskkrb1JXYTjHt+NC0Qm3e2xXjVQysw8yNBwOORnp9auWHnG9MMRyZRxzjp2oBgnjsiMpkeU2B0IpbpTZbwD/pEWHif1HpQDd9CtczXEYltSu1S2WA5x7+wqzG7vai0IyxO7B7cdaqySzzyLdFeJQY24zUtpcbG8x13OrBee1CESXG6aCMvkFPldSf1qS3nM5WC4U+SFK57+1QXodH8+UfK/y4B6N71LDdMyCKZFZCRtZQMiheYbofaTIl3sbaUHGDTryQyzoiIQ4bAGOoqrdgQX7DKuuc5IqSSVpCpZc+X1I6gU7k8vU0rWJXZopG2u4+VvQ+lUZRLbyCGbqOpqd4Jfs0csLBoy3zEdVNRarJIZEaQDIODQyVuVJLcHDZK/VeTRECuM4wPfrV2UKcNEwZTwADyBURKINrEdM4HSqsXcaqlWAJDZ6EU9lYM2V3D1x0pIdrygJkHqM1KZNh2MfmzyDRoTYYIHaPeg46ZPT8aZE86xlAAA5xk9M/Wprie4jhdAAwPU56VQUttVckgnOM0MpLQCHZmZy2QcEj1qRVlz8hXIOeTUYU7iGOT71PHjgKRn+IikDdxcOineu5T+Iqq7BH29cdG9Ku3DSvFtjUgd1UVnkeuQabGkSi4aWJo2DPjkEHpUMMw2ODGue+fSlbAiIAIfsR0psajHOPrSHYa+4rgHg9hTUUjDA4NTqAxB6elBHPzZKnrjrQgFuIlWVSWEiv3A70+UBVSLI29cdRUEDqJyQxGOme4q0GhuYQnlgXWeo6Ypk+pHc28MEkTFw8bck+hqee9t2tjDGE4Gc44+tZ0qGKYDhsH7vrViExKzo6oUl6ED7pouNrqyhcSSM2JFC+hxjikEMjYUZXJxVi8AjfbLIWQDgY5qS3uooo2G0tvXr6YpId9NCG1llsZSUPfB96t3MDXNwZkHDjcecYNRWTCYyxyKGLcqzHpUdxHLbRFRLuyfu46UB18xxjeOQ/JvOAaSZriUiaRD5a8hh0xSRXDMgc8OoP8A+qn2V27o0DxszZ6D39qL3DVaiJOygByoSQkjnpVeXETZT5i/41bdY/INvKipJ1BI+Y1NDZwR2zlMMynJJ/lSa6hzJamfHvjCtEdm84Iz1NaenWzxhxKgKk5yTxWS5VmVo2JbuPQ1blnmlfykILsO3emnYcrhOYodSGAQjDlR70+fSvJm8123w9SB2FI7o9t5Tjy5U7nrVjzZF8tSwcEdKQuZrYowwK7ERNuxyOeta1nDFBIGYEMV3qp5xWLbO66hLtUHHbpxTorqaS6Xe3yqc7f6U7jkmyWedmu5k42jkU+VovsSqcrMDz6mqU423bOud3XBFSzhpNpfrn5SP61Nx6aE7QLhfLk25xuz1zUv+kLtgDJ/s1UUh5ym8ADg47j1qFt4udgfKj7uT0+tNAabTrAkkYnWXgrx696pWkqhJN4O4425OR71XlSZ/MkLJ8nfOM/SoYnYZ457560vUaWmhfSNvN/ct15GO4qZYVNtKkmVuFPCn+KobaQxzgK2Fx1PapJ3UXUWJN4xyR1+tMBbXT3lthKrjIO3azfnULK0DEAgqf4TT55HhlIVhsc5/H0qQW7iFpZ1wOoPepepV+rK8SuyAyMwI4UH09qsEGLDxjA6EMM7vepEEwhdhGuzbtAY8n6VAzxhI5A5JXAZSaLivcvrN/Z4Rl/eRsN24joaqeYvmu8jurHlABke+atEPLp7qAShOVJHasu5IaCMr94fe9qH5BFXNG/mikkiaInYAOM8j2qGVNjEk4BPTHQ9qoxA+YGIzz0rTvZWkRWlxtYYAHUEU076sGrWRET8irhQ5wCRyCfU0gDNbMy5xGQXA9feorVYxcbrjBQjlT61LFL9kaYbMpKuULcjB7/Wl0C1thyzYMTxsYpQcMRzj3qpI0sNzIN3zMT7gmpprd4HQHJjA3Lx1HfNQ3GVaCR4wqkD5vUU/UWhYhlle1ZCcMGLgjqD3ojnP2CS1faxkYnf7e9QT+TgeXKSuclMEY/GmfuwilSGBPToRQyTVtLtpNLED5JgOwemOoIrFMjTyOz8c9ugqzbSrb3BL5ZZVIyDUDFbWaSPG7OCgHr6mk3rqNKzdidNohZSeSMAYzyfSn20kiwlMuAoKnaf4SKhDFpGYsMnnnkD6VdjZVmSVxuUnBA6ketA3sMDEwqudoxgFev4+1F7cNOkYlyRGfvZ5PvTnC+Y2zlCflz3FRMU2svl7Tghuf5UWEkXdJlSC7R3bMcgwwPBBqHVJv3ksYbKOAcH17EVLbwIgkjfacx+Yrk8jjt61DHG0sTxmFi4AG5jyB2x7U2Tpe5YgsPOsibeXMqDf5Z/u+o/HFN1GONrWC8ikeTKhXRjyD3A/GrJumjgiuWQBG+SVVPIUHr+BqjrEYhvwyH9xKPMHpnPIoYk22MjeWOJ1TBDEHO6liKIFLgFGB3YPPPQ4pkEi/aP3PzRYyR0JHr9at6ZDFJcSW8rgmRCVOOSfT60Demo+1/fwNCWX92Nyr/fP0qtbOVLtGAoyQAeSPalgkktbrfhPNjzEQRyR7j1pkbq1xI+Nqs+MfX+lFxWJ7dBcXLedkPjAxwCasW6+bbbwQGjJ3DpuANQkCNwbgMDnnHp6iki3IkijLoTk57Gmgtc0LO6QXIhjOIZOGB6D0qn4iEsV4I5MYxw3rUNtG28hyEzwcd6k1l55ZbcTIAQBgjuKT1QctpXGSDyjuUEZqNXLBw2SOu6rLN5rBVII96UxIsZdGKzKcbT0q7E37kUazrEpdSIC3DU2dlSUADIx35zUkt60kPlyFiOxByKrElidxzkdfWkil5k1zdb2UxMGIGMt2qurDPzDntQUz3yR3B5p8SDBJIz696LBdWJtxdVIBUDhu5pWjRW2rljjr609UcjEa7R1PNQpKqudy49MnjNMlaliO+a3QpsDE9x3FZ6sXnJC4zzj0qaVd2GboeR34qEKSdqglfypNFKyJpWklUMVX5ONw4J/CmMwYjYuMDOeuaYQZBlVJK9adGj4+V+R+lAIGwylieSaspdRQ2pCrls8g/xfhUMkLeSCZAFzlRjOTVYwkkb2Kkcc84oCyZKzM0TuiERseCB39KQxeTGkrE57e4pv2iWOAwgAxnj6UlyhFurhhx1WkMS1KTXQEnAY859KLi3BnZFGAhyG9fSoAdwwMqx4pDLMSYy/bH1FPYNbllJoXDPIq5IwQxziqrFJZh5eYznAHY01Yy+c4yvUU6eF4QrMQ8ePvL2p2EkkSRExzN5pwBwSB0qG9kYsgZ2Kdc1NbxvP95woYcH1+tOjcIskLIpPQkU33C9ncW6tY441lR924jOOhzVy1iAmYg/vlX73qKqR2RnscRzksPvrjjPtUUiy26IdzbgcFlORUk76XG3ck8kxMqjCMRn0q3JLGtgJIDlwcEf3qhi/dp5joWikHzDrzUcU5i3osZ67lyMYoY99h9rjbi2AeR+DGaEMcRUPuSYHGBUCMy3RlhI8wDKjHX1FOu7pWEc2BvByB/Oi3UqzuXZraOK8X7aWkDrkEdjTLiTzrYxpAyTJ91jxkVE1xLM8UuDvHIPbFRajd+eybFZG6Z6fhTsJJ6EsKFVbMoUH5mPr7CqlzH5L7o5CyfeyOtQxPJBJgDcc4wefyqzBE9xI5JG5Rnb/SpVynpqXJ7V2iWcyowZc7hUU9tKHjjtw7FwCAe5qC4E0NvlSRG/YHiprAh0JEjC4Byp3YxTErpFmxhMdzIk4UM6lSG6g1V+zbxISygI2MdyafdQ3BLTfO8q8lxyDVRZySXAOG9eMmlfsNX3RatoYgDJMHcqxGD0NFyUaORwArj+6McU5yTan++3zAfSjT4I50l805k25xntQ092K/Vk/mgWOzgnHBA5zWX5jBgxzvU4z04p8e9ZFjHzBcrwOtJCxNz88eQeNpqbXZcdBsju7hlBUdMmtSa7Kq6NhlVRg9qg+zqknlsfU+xpLcARSORlV+U5p9NBNpkLy3AcoGPI4XOajJAjI2HcO9IqyBwdxA/pUkMTyZOc/N82BS5S72L8F3JFaglCIjxmnDbDE7SRkxzLwfQ1XhikcfZ3kKRtzyM4p6vOqyW5KOVXjnGQP609iX5EcQP2f5RyfXvirF/5TmPy+CyjOOxxVVUMcuw4JI7HNSTmSThsZTqVFA+tyRYxIcIDlRuBPB+lX7gQPZQcAbk+X2NUVnRbTy+r8nPeiKOaW2dE2sFbO0+ho3VkTJdS1Z3Ymt9jqd0R6kdqyrtTvMatmIHKCmCUI0iZdSecDin2kZKyuW3bcZ/GjcVuV3EZTs+7nPOfepo4RsYbcnhh7U8EK5Dcgfqals0d920EMi5I7sKaQXHzwx/Y8KoR/vjnP51QdI2gV+RITnjvSzodyZZ/Lb7rAc/SpraIkCM42/3/AEJpWbBaDbZB5bqFz90g9cDvUjx+XciMKzKeV9ajy9vMyP8AK/KEDv71OWkYQyucMozuX19aHoVcY0p8gW5XDofkLdhTrebY6u+clcbeME+9QzxyNLtPzORksPSnxRMkaFgN3IHfmlcWliWRlhtZH25U/Kqnqinng+tMivpf3agjcSF39RjHFVHebL4I2s2Cnp+HpSRJvJGccZHbmizbBx7lmeRhBFGW/wBbneo6r7YpDLJvhW65WD5Tg+3/AOqoirPICFYZIJNT7TDdlZfmKhSwP8hTSsIbayH94kC5wSRxntzVy+a2jhtpYPlkyCWHr3qG3MMF4OcpISrew7U67VkY7YwyEGTYxzgd6Lq1hdR92ds2+dcJcoCeOjDjI/Sm2yjyp/OBLsuFyM/N2+lMklWaNUZTuQ5LdfYVZdoonjeMnY64Y9cEYOaFYPIYZGlhVpiD5fyOo7A9DU4cpbGN14YDBPf0INGovA1yGiCruBztq1JcQiwtA20yQEfeHUdxQhX0WhVklWbYWUiRQAcdABVieM3kETg8odpz61VMhj1CYKu3dnGT29KsQLMLGZA4EZ+bGejULYdraopICVOOQevalcbyPm5xUkZKYK8N6etKqgoBn5jz7D2FWZ3KxQLwenfBqUW25ASBgjK5PWnkKMkjKD0PNQSOeFUMPfNAK7HpDzjaQ+MgZpihtxzlT2X1P9KZ82cyMcAce9TRyoVUMMADrnqfWgpgSVfJZgc8GmbyZiZh5gJyQ3GTUxy4O3DD9ajkQAbsgkDp6UEpkEWQ2Q5Cg9O4pxIYNngjjHr9acSysGAG7oQTUBIJyvXuKRW5JFK8SNsIye470mV3EqflPPuKVAc4wBkfnT1TcCOQR19qAuQyOwwC2QDng1PLKyRxRfLJu5BPr6VXkUggNznr71GzAj/WMrKeF9PxoHuS+XuDHuvDA8YP0oUW0kRDbxMDxjp+VQBsJIDgyH1H600zyJGPl+ZTkMD/ADoCzGtcH5VdEXaeuME/WrUdvLeo726ZSMbhjqKjt5IpfPmmjV5sYVG6L/te9OtZprVl2DBPBX+9QN+W5AJDE5YkiQHketSRbxaSO2fLJ7ckfhT7gE3STXC/I3VR61GGjFwyRSP5LDGAc8+lBL1RTgkYSyMjcddpP8qSZxnAc7R07VpH7NblZUH3fvK3UipJrizuIowkSZY4wODQkPm8jNsJXt5WYZBkGD6UXTyNI25gQOflp1xE0E7I5G0H5T6ipbbbEpOMoxxuPb2oG7fETQYEEc5baAMFe31qrK5mUyby2G2++PX6VIgadPLQjK5BUnqKhEEw8wxhQ0X3wT1FAloyaJ4rW4clCxxwSf1FMS5iuGiikiwgbBz2pqx4tFlRg2CSwPY+3tUNrIYzIuwMZOMUajtfUu3eIJYRET5BboDyv/1qSS5iy0UYGPvKewPpVdwsJUSJtlTsexp1y0d2m+P93Mo+ZSOvvQTYgOXk+ZSr5yc0/ky5QMvYEUQh5G8x8v2IHUVaeaNOIY1RWI2AnJPuTQX5D7gSmGKB49ob17e9VYo/In3FiDH69DVmF51AmMZMBO1mPPFJqB4KoAynmltuJaaDZ794chACrfxA1GFUOu9l5+b1A/Cq8kTKIwXz8uQDUvlOsTmJwyjjLcYzTsh2S2FW8C3iS4DBc4HtUj3LC6EsKAFgQF9RWWSwkzIMY9Kt2UaGTbK3yjoemKIhJLc0baBDIjFmHmnJ/wAKabZmlZIAWZDnP+NRWoeScLEfmXJXJ4+tNhlZLiTeM7uoJ6GlclJokQDdIbh/3i9RnrTLjfI4aNSiMOB2ao5uLljLh1YZwOMGlN0/lomeVIwfb0oRXmSKAWVpckdMA4x9asyZtJW2FTvXOB0qu00mQ4Kqu4Hjk5pLgPaS71JI6H8aGNalpbiLyhvQq3QmqkhlhldWVtp+b1yKYCs4kLMVY8jnqaDNJcbQxOVGM9D+NK2t2O1gDKCrISSD0Har7XXlskm0gYwxA/WqMaIzMVZRgD73GTUjsPLYdQw4o6A1cJ5PPmd0KgAcZ4zinSXMiyq6ELuABzUdn5YJ89WK9Fx61bea2aEQkqQBgEc4o6CdlpYqiEvC9yw5U56dqlt5FSb7gKy8Fe2KltWiELgMCHGCKowp94MQMA4PXp2FHoLe9yxx57JuAXtnjFOikeNy8Wd4H14qMqHVGH3vYcfSppWUQxvCxCuQJFzxkdDTAgR3wVcnCtuHGanuZotiTQrh1b7vtSZNnOXlUMpHbnFK9sS+PlVZCGXnsaELS92TalLHKiPnLuo575pA3naa5TblCAecE+tVXiIUxgEyKcHnpTtPgNyRAr7W5BPqPUikOySIknlRVkK5GcZq1cSDylOSh3A/Q/8A16ikDRLJBKeUbOanvpolmjDA4RB8meWHahIG9dCtJLGbqNyDsbtUvkSPIIoY1BKFwe5UdSfeqkCK8hzIqITuG7gk57VLNcMFxk8nY/PUelFxvyLDoiCPfuMLjjbgkc9Oe9IZGMyHzCSvG4dVHb61XtuyBC5LcDPr2p45jkVxhwdp9qW4WFuIQvkyLIGZh8y4OQR6/WrMH7yUmUkB/lVu2aju5jLJA7lFlYfeBzyOmR2pNokVimAynIz+dMV9NSOFYvPImyVGQcHsO/vVmeeE3b+RA6QEjYkj5K/j71GQROkkSqI3yVzyPpj86VE3hSck5HB9KWtrIe+o0Yk2yxIVB4HPerV6qi2SaEllbAck8qfT6VFJGI4QYy5yvX+6wPNSsFOnlfLYTg/N6FT0NV0FfUbbrvdGd8uAckjr6VeO+IeaqMsLOEcdeapWwYGPfkDdggd6uTXmQI32r5/3lx6dKWlh7sIuhJ5AHftTSQefzx0NJyEG3k56dMU7b8oYEEnqAOlXucxG6qRlcq3t0NACjIkB3Hn0IqZQF4YAMB2pjgkEK2c+/Q0AmV5FVmLEls9lqEx8EkjaBmrYiI5yD9Ov5USKrbgw2/ToKCrkMEZcgIWL+3GRVi6haKQrvDNkH6VGyFFwCCOxz1qvLM8jjfjj0o6FbizFmY8e1NjhLcr61KMYBYkL/Kmd22nbu560CuLho2yPvAc4HI+tMMm9syn5Scbh2ppllZ2yS5PvjP1qHIOQ3APv0oGixJGsYYOct27hhUYwzhDGAQO45NIqbgDuJX17UkSoXCM2NxxknjNFykgji+cIxXGOGPapPs8f2czIw2g4Ye1NlspVLEA7M4yDxUE08oJVgFBAGMdaV7BvsyS6hFuqzo+3dwFBycU22gLsJo9zLnluhFRCV9oBw4Ixhu1SRyNFZMOfKYkjPUH/AAouPWxYuiVLC3DEAfMCcEGsqORlPycMp3H61bhvEkUhcbu6n/HvVVkeOVmdSFbpzmhbiWmjLA2XlyJbhQYwKmeygly9o4R1OSp5qKFXhkAZFKSjox6/SmISly0kgKccYpifkyPdLcMd+HEZ5I9Ks/ZRI0awtujfkgdh70xZS75idUlPBGOCPWomh2u+3KsvXnjPtQh3Bj5FxiNSrL3PcU1Z5FnMjHI7r2xSzBJESfecHjB6g06Pygmx/lfufagY6WB1h3jARjkKOOtBVYkRo2HmN94HtT9TbZEixfPCMYb39KfdtavbRNG2xscg9c0r2EuhFcz4ljaSMeYMZPqKk1OZDIjqAG6jA6ioUgkkAXcCzDIJ5z7VWuWdQY2Ayo4NA7K6NG0Klnmh4b7pU1VxH9s2SFkQjGM1Wik2FcggjrTo5SLkMwU5GMH+dDYWs2XPOe2EkDLuXooP8QqKZXEW4Lth/hJ7e1K11HM6LOvCjG4H8jSec728kKHMacgt1IosIZ8shiIIBztNTXU4icwqw4G0kDio4wRalo1BIIO36VHdzrcBQF2NnBGMYFIe7I7dszBQm/jFShgWcoCQPyqsilJlDHapbr7VbtpxaySK6bo34zjqKZTJbRZTIuz5W6hqr3QkinYMwLN3HQ1PLe+XsROcdD0/Oq8shnlZ8bVP6Ur3Er3uMVeQVLEnirCKoAZyAOgwKkheNEZJMFlGVbHNMzHPGSg2OvBGetGnQW4twoiRNy4B5FJNKZ4WwGyMVCWZkYSNwOzdaYkvJUKTjof8aVii1bvsClY/nxwTTWmY/OuARkN7+9RiTajK44PQ+lJ56eXt+YkLgZ9e9DGABZnyQGIyKmt2EkjbgCdvAPFNVSFjZkYxtwMDqaW0jWSVkcYDDgE0NBfQbuZVaME7S2RTS2VBIwV6U+NEEcyscSIePemFg7Atk5OD/wDqosFxVdg6iHp6+v1qaRHjKs4UFWHQ5qMoV3beMelPuSSxZOmA36c0MRJHciOZ3VQe+DVq1iW4iw77TMDt2jofSs23w0iAYw525NSOXtZQASGVt2M8GmkJ+RPco1nOY7jMpxwfUf40yIssu6UMyBfkPUD0FGqXn2p4nUYwuCKhjlKMqtlVJ5z0x3pWBXtqWS8sjiRsKkxAP1qecx2F0kkQLEZGM1UlnQSusRDQv91T2NQoxkbaxOT1J7UmHqWby8WWbzkQnKFH96rzs7ssjsCwUAH1HpRIp288gjNCIzrsC5btjqc9BRYa0I5Dk7ccZ4+nrVggvCjhWBUkMe2ainjCOUc/ODg47VNHN5cClQCrt8yk5wRTsDemhLAQY2GBvOVGf0A9+tNlMarlS4ckZBpCSEVjkNndx6+tRnBRpHdd5IAGeee/0pAiYISjELyrctU0OHwEHzfdyTTBcMtr5bDGec4+96k06BMIyY4Jzn+734p9RBE4EXlqp3K/yjGetXYI2E33GIIyfUCq6RyBzhWOV3rzx+NWNQUQKsiSFJH+YbepyOuaWwN9CCWRfP2xMRExJ2gcA+n51JBK0SblwFdShB6VBHNJFH58LkMh4OOSDwf0Jqw/k5CwgYCgbTx2/wAKbCwkKvCSr7uPmUkdR7U6aIy4IAJzkYHIbrUhd3y5kGEXAY9x6D60Szh3t0gUq6cBh37ikNXLCoh5LAEduuaRhg/KSMdqsGIJkNjJ6ZPSoXU4yAevUmtTkHBMn5wNw5O3+tMlCFVxy/UgHj/PtS7dy/Kd3fjrSGL1GM/xGkFxqvhCWLhz0YdhTAWxy3y85A9KeyquQ3JHQ9cVCFkILIVwBg47UykRSuTjgcDGTTSAeAMcd+9Ep5+6vQHgUvmIw5HzZwT60rFjAMjA55+mPwpWBIG7GTx0FSja3RW5GAP89aiGT1APYcUCG+UoJ3EE+3SlS3G0Sqw+U7Tnn9KklQiM7SoYnkEc/hTY41Ay4ZZVwcnlSO2aCkxB+5LY8tsjoe2arsOCGAwe9E0vmTM5AX1Vf50szZ2qWLoo6kcikyrDPOnhTYrEIDkA1HJK03zOehyADjFSrsKMSQD0APNRS5ReU+bGQaLANDBWQ5yGOTgVLfSR3DILcH5BUQjcQmVkOwnAdemaWOQqCwClzwRTsD7ldoR5e+NWwDwx9aDcurruTtgg9xV63uoo4WjkUEE5KnpSbkkimT5WUDcOPu0Cv3RQ855Y9jAhQcqc8gelSRzSJLGXJZV5GehqPejSDZlTjrjFWV8toHZmG7oF7fWmNqxFOYbmQsAUfHDA45+lMFy/k7c73P3s9KaqoXPmEBiMr2GfrTrVAZGWRdoI4xSDRCJ5yxEldytzjrU13JHKiMpwcY2ntULwSBv3ZLHqAO9AIlUO8YEaDadvB/8Ar0BvqXLSWJbRlyGDE5U/yqOOSImWFYwOOCR1ppsJBbrPbnKMueOv0qrHIYiSQMH1HWi2orJ3sSGbIV4ziRTwB2p94425HDHG9c8ZqokTSs2wDpu64qV0Z4SxUEdS460WKsiNBKCJChwe+KQK8gO3nHPTjFTzPs+SMttwOSOoqRY4zaFs4cHPB7UttR30K0OxZdsmQpGami2pc/uSSBgrz+f4UxQrr8w/HPSnRFVP95MHIzg09xMe8ZaVgjBTnjB4NQiNUuQrOrc9e2aRXWGYH74PQZ6GklDOfMaPCsaW2wLTQJDh3ydwBxU0KvPbvGCoKfN83BIptokTzfNnY3r+lIf9HuCV5weOaNh36IZHFv3c4Krn5jihd+Qfy96luSJJN4CgnjinCGQQrLwVPQDtSdwv3G7XUYfqOcH0qSKGSX51XAztJFDRho/MD5OcEGm2zyJJhAhY9C3QUxXGzKYzJFIBvJqLYQuTwB2zUxfzZGaVcq/AYdqaWRGZST7NSsO5bUk2ZiKgKcDJ9fWqk8DI2CpxnPFSwyJJtSRjyQOnfNR3juZ3jJLMDx9KH5EptMb9pfKMS7TKMA5wAOx+tMSVvPzGCGHJyaVdmRxyOOe3vRMp8x/u4PUjvT6XLuh8KGWZgVJZufl5pXXYuOd3cY6UkTtBKkignb/CO4qXUbhpGPC7HwwI/rSdxX1GbtyEgnceuKYRkgYIHpnvUtnE8ySFBgKeSTj8KZt2vhgQc5wRQFyWJigDbc4x+FOvZRNcMVHAxgjuKdGg80CR9qH+Ki6lWNdkYBYHGfUUN2EtyNomKrKWHlvxuPY+lPuFXycBSGGCW9PanQTNKkkBA2v90ehx/KqrYGwEMCAcknJNFwF4kSMqoVgc57mprZPNZgvGOSKijbbKoK5HYVNbXYhiZdgw3fHIP1oGxN/z8qBxnB9qlkk/1DRqFkxVfzA6xgYyueDUqtD9kIZCZQTyP0pbgJKuSxf5X4BA7k+lNjAk3JkADgD0pYGiMUpkkZZcZHPWn2si+chkSNkfAbsB/hTQMkUSPDuJJAwpPv1phiD3AiYYJHP1qeMwxtcAH5MgopHDHPr6VSb95cMVIxnCkdOKXUETx7yiuIwfL9RkGrXzK/mKFZXydvoaqeZtCAEhT95c9/Wnn5RtP+sGDg96AJmmfyQsZJ8s9frUU8jyCPzCSi9+/v8AhRE7B3C4O5cf4GpkgV5nidtqD7rUINERkSBVDqSm3dyeg9qu2iRBCJ2B3ptzn7pHpUUkIaENHwY+MgfmacywOUwCOzjORx3FFh9CMuW2ngoSUOOgqaLhg4AG1uv9aISh024t1jDkSb1fuD/+qrLs93eY3q29VCnGOMcDApWHckJk+8Seex70oZcYPDZ4P+NOWNhhuWHXIPQUix5bBYEj1FaHIxI5Mk43Ae1DyDJLDtUkgjRAFOQR+FQ/KozgN6GiwvMiI/u5HuDUMhbJVgD/AFqxkZJ6E+g4P/16jO1ySxUMB09fxosUmV5JCRjPT16inRhA+19pBHYZ+tIcg57D0xUS5VyRlQaZdy3AqMp2AOy8rzjj61ATiVTuKsD0JxTU3KRtPA54pyDbIWYBgevHalYV0SgkcPwD/E3OfaoJpPkKIDjoCDz+NMLkSEKfl7U2YqxXauwj72T1oKRHs4DxMQQPnB7VZspt2EbYGXLDcM5qvtKjJzgelJIRIRwo47f560bDvcdehJJWclIm6bVGSfeowucEj7vameUFJIPy9sjmp40JcKGAY8ZNIL2Q6ERm4VXIaMgg7uMD0qN443uHWAsccjiiZGBfcM46+lLDctACQ3z5/A/WgLkZhZ3EMm1WPcnOKrtC8cjrFlitSzytNLkbVINJI8m0t8o6g47A0DVxsoXZFGIQkuOq8g0xkxwAfXnqKliPlhPKkRlA6Hp71LHPG1wzTRqNy/xU9hXsVHjVYyQ6uMZ29xUgklkiRXDggYJ24/WrUNpFcW08qgAq524HUVEkkkMROVZTjC7snHrTsK9w0qZIrlzNhm/gYjtVe8nE9xJ5CMQ3XHH402NSTJuUZ7ZHH4U/cxO6FBE2MlscGkkO1nckhluLa1USAPE3K46j0qpcQ/K0rkcnoOKlSR5QEOSD2B6H2qOSCRHAH7zA3EjkEUrdhrRjY4/MXKnaw5HOPypVd40xng9R1q09t5t5GhdQJFyNvQe1Ne3O114Yj72Owp2C6ZHFIHhZZQDsPDd8H09aYkoQOjLkk/xdhTTETkKwwASpPGRUqsggGM+YDkPjnNIZZsQjXrRLgqVJXjqaguwqzMoYtnj3FMhcG4jdm27Tu39D9an1b5pxKACr85XjNDRK0kQyrI0MZZRsB2hwvWq67wChY7T2PSp/OBiMbCRo8cKDimxtGwZZPkU8gAnFBQke5UI2jnv6UHczHfy/AqxZSxAMkuCScqTxkU26/c3StHtKkZUCkJPWxEi4kCSAjnvUpm8nekZ3JnI+tNuDI0iy3CgLjgA54pInVDJHHhw4+ViOlAyGQ5AIbLnk04koykHnOaaY2QcjpVhI1MTM2CuMgj1p2G2QSyMBgN8uc7fSlDDymQqGLDIPcUrydd6ZOc/hUSE7j29MfyoAnaMhQUO8ooJzRJIGZZkOHYYYf1puCmGYEZ4z0FLchVkDKcjA796CSJcK3A4NSFHZWCjco6nNOEeHDLxwGBolysG5iS0gOcev0oaHcgUjy8ZwR3p9sF80A8jqM9/anWrRmIfaVQMRxtPzY9xTYwUyc4I70rFXJFeSIssJBBPXGefWpLiTcInYNuGcjOce1QoobJLqg7jnmhAqvuYcdxRYRcFzmzMO0Y3DaRVSaNt7BgVYc9MVJE3lEBgD3xTrmQyN5h4c8cdxRYFpsPgD2rpIhDB04IGT9Krsd0rFvlzkipUZ0CvuyvQCo7mRGBJB80tk0WQdRY8b1Pp2poIwGHrj8amjRAyuwJHORnqaYRklgrKjHcMDOKLCuOcLtUDg8kmnWuJLhIySATwRVd8guqvvXqCB1qeyDC4TaeCQ34UJA9iSWIW1yYlw24FcEZPNMA4OASuOuehq5q6wq4uITgs3zYPY1SkRopAARjhlIpAndXEmeR4kVlXYCRjdyMdqjjlC25wBuVt1TSx4jEnGHz3qMqN3H3CNuTStYd9CVVZ+cfKeMgcZNOiRgyvJzztPvUlvJtsZNxOUbIXPGR3pLudZJv3JwuAT9abt0Fd3JZMLM2w5VTj+oqwTtj3gfMrE89xVFWGck8P2q7EGmRNp5UENngCgNtxQ7WjESElWXGPUUxonjzsy2zHPqD0pWhDs8LNlkXcrA8N6ioI7loHfGSCNuM88GlYq/YvWC+fKIjtG4ZB6YNCNJpmp5L/cb7wGcqe9V7iYLdmW34OQwPbnrTJp5J5fNmG584I6celA1r6Gxu3Lx35PFGHVuCOeKrIpznv6VP5jKmd/Hp61ojmsPmG1QoyPbOc1XXII2de5p7HcB1x3Hp70r7AoC849eDmnYSQxsZBCspPYc5+lRyEE/dwRxj1qPeScbjnrzxQCeBkMw5HPNIbQhj3Hr7Dmk2hT2Y+n+FTx8Lgg7mPAIqMgZbghvSnoK404Yjao6YIpTngjJ9PWlSPex2kZAzSvnjk+hpCKwwZOQM55zT2iOwk8gdSP0oK5G1QN3qPT2pCXSMhXJV+NvXFBaI3kbaB0A46YFRMxJVsEE9DU6yKwVJEBGMbh1qtJH5cgBJKnnGaVy1YmjdY4x56eYGJKkHke1QFgeRuA7U12xuwo2k9DS+W6n5gQw6ZGcU2BMkwyBKuQBg7T1qB9pyVBC+vtUoAZRgfMD/nNOZAqZzlsfSgkYlqWYqm0uBnr2qJj5Yyud468ZFTNEwj8z/Vr/CSe/pRbsw4hT7w+beOM0DRXVVKF8AAegwfyptzC8eBKCFbkEirEkjHe8bBVYESL3H1zVZruQwrE/ROAT1oBXGxTPBkI52EfNjnirMNvbKBMz+ZH6e/bNMNm5iDKyqSM7fUf41UUMD8vAPBVhjNHoG+xZluCj8ktnn3/AC9KRbaSdBJaF8MSGycDNQEiO7EjqGTH3ScVZtbvy9y58pGbchAyFPpQkh2aWhXj3xsQo/eL2xTbyWbekxXYVPY9auakZTcRyhQ6AdU/WqTSeazIu5jjncOpofkNa6li5IuVE0YChSAWU4/zio4/MZZQsmCPn56n3FRwh/s7KH3DqyjsPSn+UrWokQt5nfnNAJW0GFt+DJ8z8AEdAPenx7y5RT8pIJX1qEqygAghuuD1pz+UNuwytgc7uMH0GKWxQ2UrvJU4UZ6VJJHMsKb8+W3K0lq6wuWdA6v1B6/WraQNLbgS4Ef8ILdPanoJuxTUAAls7eOcfd96YPLXzQxBI4TAyT7/AErQhSNrd4lBLjJ5/i+tZqqA5Vtw9KNwTuWvLhFtuyrPjJGeDUCHn5iduMrQgjD/ALxWKkdAcHNOETMhOAMDPP8ASgW25MqSbFM2TERwQeRVc5XdtYNtOeOtSxCSaFdjg4PIJ5//AFUiIWvPmUAEYIz/ACosCdiIM7Z+YktzjtUkLMuE3YRmGPUfSntk5ghXJU8HP6Gq8zDA+Qq68MtJD3LF1HJ5pjckuOE9CKiUEFSpwQevpS3lwJFiyCHTv/WmEMVwDn0NPcFe2pLI0jqIyRgc/WmpjZtYgg8g+hFK2xiCZAQR+VRQY3AOSqsOCKV9R20LEbsf3I6fwn2qMyZ2iQ7SnpUpt1eFSjOGGWJxkfT2quo83DSnYTwp9aNyVYIITIpZPXvUu5XQBBhxyxz19KS0aQiSNCuQc7ienvTWUo5z97v70XHfUczH5Sfz9RTkYLkMAQe9OmRceZFkxjHXsaJ2i2DykJ4yTnt/jQx7iRjBZW4Zc9e9G5nwGy2w8CmHYZFEa/Lt6+9P3Nbyq4HHv3pAEsgnuEVV2AnG3tmmFA+7zGxx+dP5kmeZUGFIYrmn3UqTsohTBxwBQK5XDsItg57gjsauQXarbbJByp4z1IqBDGGYI7KBgjjr7UTyq0u7YPlwcHvT2E9dB9jtRl3nODwMUsyj7TIIG+XqMnBGTTI73y74TBMKU2n/ABqO6lEt000Y9CQe5pXHq2SkjyWhdcNuzk9qFDDyyxzt6BvSnbvMExhRijqCSR0Pt7UzzGYBGHKngikx3JssYWUEMrPwP89qI4me2bB2yIfun2pjoydeMHBx3p6E+RKmzLFgdx6UXF6EaN+5fJxluB396HAAQrw4GGpHBU5AwxORTwAFbcvzHofQ0DuTO6mLy1QZX+L1qSGZ4iehDjkD1FPlRJIRcocbv4D2PeoI+Iif7p6DtzR6iTEWSTzfMZsMc9KW3crIpLYIJXJ7e9PjLoXkjQsFxk44AJ70xmbdK5ALMdwPpRaxZYAjVmQuXULtQgYzSIPlGTyR+ZpnyoY2fDAHOPapesoCAjLbRkdKYjSUkrgAcdxSEZ5POfWnHATgEn9KQjd16everOVMj53cfw801CXbGPXvTyQSMA5PGc0oXb1LA9RxigpDWKhyM5Ueo70+aRWhRAw4JO3A71FNjOTjJHGO1REngHj6mlqMmGO5z75pm15HG35mzgZ4NJnBOf8A61A5wOAe2KZDHHdvA6sODntSPuyrHv0pWIDYyTnuaazHq3IPegBjjAJHY5+lR4y2V/Gpcsx4AJx0J600demSKTKQZXyyGGcHII6g+1V0d4jwcc5+bpVnAPQZHc+lV5QQuWAOehHajUaGySiWQM0ar6DqM0ZdGysgOfl57CjsR2z+VKUIyDgZ9aB3GFzHL/eU8E4I3VZMTvbGZGQqD0zg1WJwx35bjA56U1hIQPmKqenoTQPcdJhl2mRlYDJXqCfaq5Zwm3d36VLKJC2JQCw4wP50iocrgF8dh3osFyHeZJUWXpn5tvBx61NdGKK53W6hiR8wf5hTDh2HbscjG2myKIiwJDkHhx0oDqIJm27QflA7/wAP0pFCGZQjEHGctyM+lWXtGeOMqFYMOCpyfxqpLBIrbTtz16/rRYFZkUsZI+TbuU4ZS2SPoO9IIzsALdDgY7VLGc5+UbhwQf50wITLtVsKePagu5OkhgZo5ZsEjPTIP+FQTIZZ1MbBmxk56GnywNG+yXGc8e9Nb90drK2c9+KCV3QK2ARHxv4Ip8Uht5G3IQcZTJ6D0ohiWQ/KwUYzzVdxuJDMWxxnrQO19CWQF38zgmQghQamvIszo8Q3Iy/eU8ZHWmLO8qxQSqsgA2Rlui0xkZVeGSQq68rtOADQAtssYuPLuTsQjIxx/wDqp4Z/NktVOCOVJPOPWgETIsmxQeBg85qGeRTKAT8yHA29RS3HuxpjkWTEZCFSD97v61YvJFDI5UM4wWTHX6VVaQE7nOX6E9sU/dKwSdtoHXJ70xW1uTSosrKn+qJG4AHg1WebcihSf9rPPPtSfJLJ8pOMbmJPGfb0FN+7kn5kz3pBsSwBmlIiC5Az14NII5JmLorZU5bBozgqVBCn8xn+lTefJEgVV5HUf3h70wdxlvceU7FwTngnvTHJuJcs2ACQGx/DSDM0hzt3E4pxZ4/3JZSo5z6UvIOpEYwApjZTnIKg5xipIA+z5ctjqAe1MRljjYg4kJ5UdxSRO0b5QkYHbkUyrk1vEkokJPljG5c9/WpEh8wKJTtUcgjuahnmV3UxghWxuU9iKfO8sSDYSqnovU4osS2xskhMXlY+ZCfmB4aoXABAOMdc4/SpkCTI7btp28DpURGQuASSP84osCEjYpKzRk//AFqswsBIzSc7gc+9RLsDHGSDnHapFYMqdBjgmgbEZgF+XOw9QaASufTNPSUgkbQd3XimIMsRk4PApAhrEl1AOF9+gp3nSMvl4DEjGNvNI2GGOnP5U5YysAkyCpP5UhsWJ3iIdPuv29akjHSWH5fL657io2JbAA+XqOaltolcyR+Zz1B9R9KCWyKc5l3BgVcc7famFcsccg0qrsGD1zinQssc6+YNycimIlWFDaqCh8134Y9DRewfY2icAHcuG9zUPnO6CINhQdyCnTO9wm4uWCdQeoNDY1e5JaBXhYOwVd2CBwR6fhTUOHGOmT+NQoBkdgwwSeakAKllBBGccUrDZLIQsmAd2RSSy8oQSFIANI27CnGBn9alcwmPZtJ5yW780CIyWD5k+8P5f4VYjj8w43BV3AFj0GenFVgSACze2c0u8EAYPpQMRWKnHIGeRmrMYIRn2kIzEc9qr8FvbrzzV20YeXMhORt3AUkhtk9tlJZraArKJV4JOBiq6q8hNvtVHjByfU+pqMusKiSN2aRVBVl/h9QaSFmec7mIL8FhTC3UleNT8vmKVx1pYgWyTKFfG7Pv6UxgYCI3ypVucDNThUN6UaUeXt+Vun0pMdzQfKtjkH17U1z83U88HipZQVJ5zTcbm4XA/nWpyXIyCD1zTWcMuH3EjgH0qZx1xjH1qI5LA447kUFJjEJ6HtTjycE/gelDL8xIo68HrSsFxxUMMZwe2KaIxxuwp9aHyvH4U5WOMcfQ0EjSmOp+lLsH07Uo4HIOP1phYgcf/XpAtRknyEjOTj05pgJxyDxTmPykMM9gT2pVb5cNkZ9KDQQkAY5H0/rURwykevUYqaSIhcjLL3boKj+UjJ6e1ABsAwBycZAHOTTXOT36d6acgELkGmgNJIq557k0DsOUIzfOSBjr61C0WRuzhcnAz1qxIjRtsDBs9G9famFGjOTxxzx1pbgQo2yQMRwOoJqNpWD7439sD09KsHyzKMFdrYGT2NNmsxhy52ADIbqM+lME11IcCQyNI4WTGRx96nWIhkdhPkY6KDioeqBDjPWnLEZSMA7ugA7mn0GySWW2UsYxhgMDaTj6iq6DzyzJJtcep5NPjVonOYSWXsOq02SVQweEg7sllIpDXkBJX7jEtjB9/wAKsKbee02KBHKAOvHP1qC3XzmZsiPA455zUMhaR23AZJ5A7Gi4rXJZWIfbcSbsqNjjsammuftVsoRcyAgEetVtpuCiRJiVRznv9KYirFLGZPMUHlh/WhjLFxEsTRtA5O442t1U+lRXNtNCwMylUbvnvVxVijuVlkfzYn5Vjzg+uf60zVroECIEEEgnApEqTukUCMLgkYz1FI4MrAu25umT1p4iJR5DjCcYYdTTYwFlG48ZwaZaY5JmjUoy8Y4PcVLKVeFUjCtKTycYOfWlh3GVsR+Z/CMfw/WlmKlWBJjnQ56YNDEVH3I21lG8D0qaWJ4VRC4KONwz6+lVpdwn3b9xODkVKPMkG45fHU+goRTCNAWUE/L2x1pq7Q7hmO0nG7HH40qsNjDjB6E9qcyvIGlRNsf8WDxQIe7qEKH5lTgEc5HsafFMBtEp+ZPun1HoaZA6+UYpBhDyCBVYgbsZyvY0eorXHXcgZzhRsJGCOv0oQBnXzGOM5bvQSpQjHJ5z6GhWP3l445xQPoTPCi3SpGwKsOCTnBqOUNBKhkHHpmmuvyEAdORRIyugLAs2PvE8UbCQs7rJ93IJ65HWj5hIPMO44/CpbRYJHAkPJ4GTgVFIMSEA7gjYB9qNh36A2xWbIJQ8jjgGmF2IAPK44FWFlYoUPTGAR1qBcthOcr6UvUEG1DB1O4Hoak371C4wQMfWmhWK7sZ29aVSQuWGew56UnqMk4RlZGzuGfpQpA4/HmmAjjGM56+tKoDYcEZzjHoKABVy4DH5c8kdqVlXLBT+7BxtJ6mnKTGSNuec7T3puxiGcAY3flQFxRnAXqTSmYh1ZRll4J9aWd/MlLj5SfTsajAy2X/Md6e4hjcocdOop5cBSJFyDyGzSsq4KjuOfY02Ax7cytjjjjqfQ0ACnCZIDFWz9ammRVhWRWAHcfWm2mQcbcxs2QPT3pk7L5zADCZwKQ92OeQtGEwPl5yOM1PFtaX91hAV6N6iqgDbSdpK4p+0bGyTxyKAsWH/AHsjCQ+WSuR9aUANaSyFgGBHFRNuLJvXBAwOMZFNbGOPXrjtQA5FyDjr2q5fPC0KGLAbaAwPWqxcxkOB0wcUy8bdMGP8QBJUdqLiSuxT90FepxTo2VUBBYzHJ9gP60qwkQRyHG1sr9KX5BCGPDBsED0NDGJCTG4bkK3J96lVSzDaOWbgU14wRtUk88H0qaNcO+47SOefWkO/Ua4k3lZfvZ/i6jinFVZgzcArzSxkyTFnbJYgknjNOkykvlsMHPQc4FAGsysG579/SkOQRnjA7GgOWPPWmtnJOc+lbHKhrHPpnpTQOTv6jsaRupypz7UAZyWP51JQ4dM9R1pCB0o+Y5xz3oxn8qBBnJHHOOx4pxwoBIyaCCByMUwEscHGPehgOU7ue57DvTXBLZIOaehAXGMU12+brx2ApCW5HIxxwOe3ammQhdvbPFSgBhkkbfpwaZsX3I7UF3GFnA2qcA8YxwaRTjOQQw6Gnde2RUbnpnpSYbgUKjkcHpRtzHjk44A7ijPUDpSHKk9z2PrTAadx+8d3v3pHBXGGDDuO/wBKUvyGIwe9IcZ+U/nQMgkRJHbam3uOelMM0+1lVnKOOV68VMVHQj2GO1IpeN8xnBxR6lXIkfAxJGGDDH096eHaAAtgp+oqElXfL4VSeSO1LlgpG7K+uORQOxIu9rhpIizdRnjn61WkA8xgcgA5Ck9PWnsgILDc3OQ3ShULOX3HgckjcTQCHvB5UUc0UuQ3DD0NRkFeSGDdRnvSLsUqQ6shPzA84pzS+YVDkbV4H0oEKVARZIm/eL1HT/Iply4nAwpWXvk0jjrs6470sa7ydoO8dVpsPMSzkWGfMgBjP3lx0/CjUvLLK0a8tySp4oldQ5ViFboOM5pypLC7HyCycb8jIA9c0Bs7ieXG9tvVm3bdxOeD/wDXqyWh+wIpiClR83rn1qg7AgLGAmfmyDnNNUAHfuIjzgjqR9aTFYkmbyWRoXweCRnjPv7VNc3kdwm8KVkAxyM/Wm3iq4EqMoYdc1XlWMRrNbj5QfnBPINCHo7Mb5OMK+5dy5zjgfWmxOwUorH0IqxBdMQ+4GRSMHHb2quY/LPz8djRbXUpPuPhCPlZQwOOOcYqW3nkty6YUgj7pqTZEo23ClJP73Y1HKilBJFu44JHRfagm6ZACSAx4I6inu3mHdjC9hTXAByAduMims2CM8L/AEo9StywhVYjI4Vgei9cH+lMi8tnYSHYpBIwOKYGKv8AuCBuGDkcGkUFl3kYAO4Ang+1HmSKNyggjaMZAPcVJ5xNqIgq8fypJJEcudjHIG0Z5BphAyNucEdWoHcjU8AFQQenv7VMoxkdweQaRQCSpOM857g09Bj73HHegGwOBtznGacQnmjYx2juetNUKJNj5K9cHuKUjDkEfMDjn0oAUhdzAEqCOKCAFULyWBz7UpwM7GyB0J6mmnoCAevOKQEkQL70A+Yj5ai2lWxgg1P/AKp1AYMp+YEDpUczeZKzKAp9PWgEwYl+ScnoKQghVP8AeHQGk5DcnigrnkcjPUetAxHwEGwsWPWnKDhhjryDTAzBwyrtx1HrTkYCUM6ZT+6DijYAb5JM4APoRRAYm+SRcuTkY4zn/wCvQ7M7BmbIPGTST7WZHRAjD72Oh96LgOVnSOQsx8z7vT9faoQCx7E46nvUjRgS8t8h7g1K4VlUKCFU4z60rgmOjuSIyu0H+77A0jSB40QqARwSO9OgiWQS5JUKuRjmoWGdmOOMH3p7grIka4LRpuGVU9BT3WNrrCELESOfSmIOMAcelSbeByDzikIcY8nGd2AfyqIR8ZxyeOanjULkuWHHykVIBA0a7iQ2csT6UDK/mMtqyleGbcD6HoabtJwwKkEDOf5Uqrk4HTkZ7Zp4jAVs8DOMf1oGSQQF/N5PmL8wHQYpWIYZAPI/I04ENEXcHzVb04IqIErIXRcc5A7Y70DJ4o84+XBbGAT+dKy+U2CGB68ipoTIIslQcL3/AENLOHZFnYglvlPsaGCLvHGfzpOgPGc00Abu9PVcZANanHsQsM45INKrYGMZx3qbYQOelMZM4IGKQ1IgeXLAqNvt71IsvHPHqBTTGckkA5pWxgAgUFXuKX46k03PHPb2pp4Oc8e9OJGfQ/WlcBdykjGRmgjjGck0KnHQYphZ8DPSgEKCRx+tB3knPT1pFYZwKkGMd6VguRDpgYJ9ajfLHIwMCpWZT1BNMY9gOAO1BSI1GDxTseuO1IMNgH5T0HNBDISCMg0AI46+3vULFVOBk56j0qUqcckCoiCrDd35z1oZSFBwpJUEE/jSSbXJwvBpE68n8Ke/y445oBkDohiIZTuB4IpEcxHK4Ixg8damOSOB17etNgDLJuRFb/ZJ6/Sgd+5FJniQKVQ8exppKheGHJ5A4qaR1eNjGrIG+8hqGSEBVZG3g9R6UXAJYYP3bxMqN79GqAbCxwu0ZqykKlRFcAI+Moe9RrGzSMC43gcnsaa7AiSE2+8rcBsY+VgcUy4Q28gaJxtbtnqPSnRxK0hik3Lxx3BqDy33OsaF1XuOooBCXLRuirEhBHY9qlikkt08t97LnJGeQarEiXkEKwP3cdamd42VAqsG75Of1pWC3QhYAySSBQBncAadMhYK8JL/AC5fjp/9eppCEi2lGyOC68celQI6+UyoxJ7H29Kdx2uRbFmjLb1DDse9FtmBs7VII/i9aDHtVXUfu29OxqRUWQoGyQD34otcCHbgsw4DdQKMF2AY7896lkLIXRG3R9PUj8aQrhDnHuKQxzuSixMxBjyBupiIzEhV5HJA/nT1ALZbDH+EY4b2pDvicDG0n+XpT2JEUdjwwpJF3cEDj9KcuWXewzuPX1NKMsMcEj9aQbETLMUEnljy1G0GnSqixIYz7YzxmnIXAPQe+e9EqxYBRcFvvAdAadguQjd1Aznj0BqRGEcilkyuejVLKHhVA5DL1B6celMGC7BUG1uOeooC9x88SGMPECF6gdcU2SR50i4BKjAI60eUwOw8envS2xeOYbOnc4oABiUxne3mHhif6Us2Wc7iN4+XgYpsqOj4bqxyuKTqScEcc0APnTbCjqQQfTqtIw3x71OCOCo7+4pJcOF2qAR1HrSbmEaOE+TqPT/9VAxyjMAdMH+Fh6Ujgq4BwcdfpSpGwUsw+Vx973oUszKm0MV/Nh6UWAcxyi5U9ODTcc9Oo4oZy8pjP7tCenpThGpLRKfnzkNnjFTcBnHGAPehuH4XaD0HsacuAWU9R6U7Mb4DHa2MZ7cdKOgESjDbV59qcflbD5GBzQFy5DdOmRQExyeTnrQDHIDLkRgdNwqRQyYBGNwGfemA/PgAfhUiLncuT7Z7UmFhFzk4wM5BqJ87o8YAydx9KtKMsuQHJ4xUTRFnbHLLyBnr6imgBCXIAT5gevrVhQBJ+/yVA/hp1iI5olKuFkxgZOD+IpswEZ28FxknH9KQ/QjPVgOOcij/AJZnauTjPFWI1BETDGcggnkVKnljcGHyliRt4waBlSONiHU9TytTIu8NkkAkVNGuduMDPBbtS2yh52EhJBPOKPIQu1VEciYDHIKnkcUQx/NIrHA3AewpfLMbE7dzE545GOhpQGZ5F4GRnJ9qY7DvuonykZ6Ac5qKXBV8A7Rz1qWPzWYKow2MEg4/Wl8rcAu/GSRx2NSVsSZIPOKerFhg9Kj2jdzTgu48cVvY42yZuUxnNQkkYGDS8jjPNKWI6DNSCDcrdRimuenGTQxH8I/OmkZOcYFIB21CPT603Zj3pFU7sk49qVxjpRYY4dMdfehumDSAHjn8KeFyORmkIhwMUvXGDmgpjJBNBHvQNDed3OM0wrz3B9M1L9cc0hTnPUe1A0yEnoT26nHNIW4z1U9qeRzxxUe0Z/qO9BYNgleuB19qZIvPoP5U8kjk4INN5BJX7vegEJsOOcH2pwITqCR6UgbHbI/lTQQw5brQMaw3H5GwP50KucncFIHGc8+1BGAMn2oV0wQwDLnkUAQbcs3Yimvz1xnvmg4Ejc4Xt7VK8hVEyRuXqMdqGOxXZicH5iF4PtT4ikf7x/nAHKnv9KdyC7KR83X0pzQQvEDEGL/xA9qYeRHPKJ41RQQQ3yH27Utuk8LkupB25zSOgjOxxhD0J7UGXy5lE+ZUAxleo96QulkNklili8xl2SHk+hPsaI4xcWxKqd6/eYc8fSiYqQfKlUo3O08c/wBKW2maGMqmVB6Efypj6aEeZoHaJ2xxlQwzn6GoPLIUMBweCSatyNI1uXLptPTHVaromW27yqnt2pFJjmVX/wBQrbcZK00EIQ2AfUGpkd45fl2hlGD70+KSALJ5qAuSSpoEVyzDfswFbtU7LbJbo4b95jlc5qFBghscA9KUttl37BsbtjrTDcrbyCBzj2/nU7xySEhxufHGOmKfujTJdck9sf5xSKkjqXBOE4HPIpbjfciUBuCSSO1P5yDjn6Yo6D5jnnqO9OcgL05U0MTI5PmUcHGc/SgsrDoM4wcdjStz8wHP86dIsZUAOSfXpQIbFsJzKSy9OtO+UNgEn39KbhlAbbwepIpQQpBzx3NGgMWQliCecenpQSw2lcAjuO9OkUb8RHcMcUnGCAMk0CQ3so3HaOntSK20bs4boQR1FOYBTjcp+nahEaRGZAG29R3oGxpOeRwppEkMZyoBA4IPTmlIB5x1pFHBB6dv/r0IQ3LRo0bAkHkc8CiN/LZZUGcHofSlGUI6EjpxTrWXypCCMo/B46GiwBI5mJchfM65zTDyQfukinLjJ4PBPFAzI7ljggZGe9AXFjdosOn0PuKkldZbYRjCyJ3xwRUHqGz9acoIHbkcGiwxydM+nOKnZQSNpxjtUCZ6jOcdKmQExtIRwmMUgHQwmWYIpywUnHSiIkBVH8DEn60kUjRTRyKO/GR1FCZedyowGzgelFrlEuSdpwN2e1WksXeMzRsCv3dp4qvFEWC8gkc//Wp8j3BhRASE7Y9qNg9CnlYAz5Ktuw3t6H+h/OnwDdJuwSQfmPXNOEcbIdwLyMfmyeMGp7YNbzSwPyycr33L/iOlJjJ1CtaHaQDFhuvUHrR5YVg207WOVJ9abGs0sLFegUhsduakCOY8BunJ54GKAsIzAR7UBbjn60ixZXnuDjHUYp0SlhuQADJBOetOkby412jkZOB60DtqXbkM9vBLCAF8v58H8DVVZSqrIvD5BHuB2qLazjj0zj2qxDAXgboPLHOT157Urj5bD0jG0MzDL/w91PamsBuL5OCTjjpjrVhfKM0WGPzDJP8AdOKfJBtmaHfjDbmY+hFIZU3DPIpwwORSYyCRSgetdWpwCMcHrUZJzxwakYDPagEZyAPcVNi1YTg/d/Wl3HoR+NHy59PpS4HSps0BG7c4/wAik5I9qcVB/wDrUoC4FK4huSPSnZPenZA54+lNLD8KGA4MrfeprAYoIA6Y5phB79PWlqNIcACAT1pOgwD71Ee2DmnduBQPYRmwD0PtUTfoe9Sc/wBaYWIPcY49qRaQ1fLVssp9wDTPlJJUEexoYkMQQSvqaTgkEdKfkWSR+Uz/AL3j07fnTWAAz0B4IpMA8nmlKjkA0hEcgKqG4Zc4BqN/m5C7fpTwuOv4CgRgD5W/+tTGNwrIwcde+OagkUjG1t2P4cVYxgkU1lIAIOCKBXIUbKheh9qkUleRuDnoy9qhOA+DkE+tSI7RHPbvmi42htzLJKAXKnHHAxRbYwwYkMwwR7U5gZMbfnxzinTtuUM4YMOOccf40C8ioY8DIOQT6dD6VLEzIAj58tumOuaXacnd830p0ZDDt7gigbGwxOkjJOFXeO/f/wCvUUqeW7BCSqngmpZxyMOXQdCe1EZZAjOpeMHpQHmSpAktoSMGXrjp+FVpIWiBWQlWxnnv9Klupo50BjXBz9CKmgvoygju13MvRiM5oFdrUqRYKglcuO+elK7HYR0UnkHtU1yigiSI/ITTDkoxG0gHnnmgd76kXlFFEpGU6Uq5U7gSD6jvSo6q21m3RnnA7U5cAjJ+U9DSGxhBbIAzmnx20kgYjBwOhPNSRSGGQyABh0IqOdn8wygsI36AGn6kq5Cg5IBzjt6/Sl24zjn1FSBAY964wDjOaNy4PUMfShDYryOYxGw2kdeelMSPBAYfTNI2AQWJAxxxUinIHU+nNJCtYQptVXHI6Y701iucc57U/kEEimuvzfXsKaAFK5RXQAA5PvSTld5MXHHOO9BwUIzz296jyQQT93pzQFgIOAy9DyKsW6RuXEp2kjKnpUWHK7guVB5PpUlxC0SIxYMjdMdjQD1IAvO4EcevOaRoyGIxw3ze1SDOPm4/rTGzjAPvSsMNwCkEZOeTnrTGJD8nBI4IpVdAGBGcjgig4aFSBhx1JqhWsETdVzzSsWVQegz0ppxHlj25JxU9ztCIY+AV5INAdRtvN5T7tofqCD0OaceuCwKtyCP5VHFl02IMKPvE0hiPKI2GByO4pBsWGSZkZSzfusfKeODVhWYwbUiU4bAcHk5qPyZHieQPgYwdx5PsKhUuDuDFRjBAo9BqzLUbkSFWxuUnNTyXRmiijVcJHn8feqI3tIQRliOvvVyGN/L7DoST0Ht9anUrQesACMWGH4P4VM8URd42DMSd0Tr1U9wR3BqeOFVQktmSTng9v8ahR23F48b4vmoBK5FF5oWVYnKgDpnluasx2pmG0E7mIx2GacwBkNwSAkrdE6qfTmkUkptPGDwRwT+NLYq5e0xFihukliMnlnOMZKnvismNTcTjaoVOo56c9Kvr5lnCLpSf3h2sM9uxqC0MfnSNKDhhuXH15pdRpbstLCsKLu5OCSR1xUUcXmHdIG2BsAA8ke9WYSk8rHBjjGdq9ce1TGIRorAttMnB7GjcER332aO3gW23HAAfPf1+lQ+U6JvYAKykg7skc/54pLpYTIQZwTuXbxjIzzn3q1EluYmjnJMhYhQTnn+hoV2PZFIjimDknPaiiuo85DH4OO1HbPeiil1GhTy1OooqSkMj61KQD2ooqUNjcDaKhIANFFLqCJF4H40jfeooqmHUjfqKd6/SiipiPoMJweKYxOKKKC4kLH5qG4IxRRUssNx6Z4Bo7kegooqmCGgnax7jpQvzk7uc0UUkHUY4G/HYClU7l55oooQMlnjU2aMQN2RzVSTiJceuKKKF1BbEeTG4ZCVPTilVmZiGORRRTYxSSrYHTrT7c/vl9zzRRR1B7EgjQ+cxUZB49qps7BDgkYbAoooFEfIcCMjr0pXUfYy+BuB60UUCKYdhgZ4zUknBAHHHaiipWxoi5Ii/ZUO0VBGMsQemKKKb+IhDx0xUBOQCaKKBoa3epuoB7miigbFmJZlB5GKWP7oooqnsT0HEcGo6KKkAb7n60rgYTjtRRTYkRPI6ZVWIU9R60gJ3KuTj0oooZTHMxIUE8DiiUAQoQOc0UUCGSKABgd8Uqf6wD1zRRSYpbEqnKOTzkEGqUJPkqe4xRRQgiSq7OXZiSTUqgfJx1ooprYGSMigcDHPapI/mDbuaKKTDoNQkyMM8DpWjMdtqAvAIBNFFJlLdGnaRJ5v3Rwg/WqN1/wAfkowMZx0ooqWOO5GvQN32g1ft/wDkH3HAyI8g46HNFFHVlyKM4xA5BP8ArAOv+zmrOnKFCkDnnrzRRTihyNGIfL9AcflS208hJjLEpsZse+OtFFD3HbQzookk1S1jdQyYL4PqBkGtW2VWtFVlBDozNx1Izg0UUPYUtz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent nonfollicular pustules superimposed on&nbsp;edematous erythema in a 46-year-old woman&nbsp;with AGEP. A skin biopsy showed intracorneal pustules with numerous neutrophils and neutrophilc infiltration of the epidermis and upper dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Vincent C.B. Lin, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40618=[""].join("\n");
var outline_f39_42_40618=null;
var title_f39_42_40619="Nausea vomiting terms";
var content_f39_42_40619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions of terminology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Vomiting",
"       </td>",
"       <td>",
"        Forceful oral expulsion of gastric contents associated with contraction of the abdominal and chest wall musculature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Nausea",
"       </td>",
"       <td>",
"        The unpleasant sensation of the imminent need to vomit, usually referred to the throat or epigastrium; a sensation that may or may not ultimately lead to the act of vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Regurgitation",
"       </td>",
"       <td>",
"        The act by which food is brought back into the mouth without the abdominal and diaphragmatic muscular activity that characterizes vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Anorexia",
"       </td>",
"       <td>",
"        Loss of desire to eat, that is, a true loss of appetite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Sitophobia",
"       </td>",
"       <td>",
"        Fear of eating because of subsequent or associated discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Early satiety",
"       </td>",
"       <td>",
"        The feeling of being full after eating an unusually small quantity of food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Retching",
"       </td>",
"       <td>",
"        Spasmodic respiratory movements against a closed glottis with contractions of the abdominal musculature without expulsion of any gastric contents, referred to as \"dry heaves\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Rumination",
"       </td>",
"       <td>",
"        Chewing and swallowing of regurgitated food that has come back into the mouth through a voluntary increase in abdominal pressure within minutes of eating or during eating",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Gastroenterology 2001; 120:263.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40619=[""].join("\n");
var outline_f39_42_40619=null;
var title_f39_42_40620="GIST progn criteria";
var content_f39_42_40620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed modification of NIH consensus criteria for risk stratification of GISTs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1\" colspan=\"3\">",
"           Original NIH",
"           <sup>",
"            [1]",
"           </sup>",
"           criteria",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_left\">",
"           Risk group",
"          </td>",
"          <td class=\"subtitle2_left\">",
"           Size, cm",
"          </td>",
"          <td class=\"subtitle2_left\">",
"           Mitotic rate, per 50 HPF",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Very low risk",
"          </td>",
"          <td>",
"           &lt;2",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Low risk",
"          </td>",
"          <td>",
"           2-5",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\" rowspan=\"2\">",
"           Intermediate risk",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"          <td>",
"           6-10",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           5-10",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\" rowspan=\"3\">",
"           High risk",
"          </td>",
"          <td>",
"           &gt;5",
"          </td>",
"          <td>",
"           &gt;5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           &gt;10",
"          </td>",
"          <td>",
"           Any",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Any",
"          </td>",
"          <td>",
"           &gt;10",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1\" colspan=\"3\">",
"           Proposed",
"           <sup>",
"            [2]",
"           </sup>",
"           criteria",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_left\">",
"           Risk group",
"          </td>",
"          <td class=\"subtitle2_left\">",
"           Size, cm",
"          </td>",
"          <td class=\"subtitle2_left\">",
"           Mitotic rate, per 50 HPF",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Level I",
"          </td>",
"          <td>",
"           &le;5",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\" rowspan=\"2\">",
"           Level II",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"          <td>",
"           6-10",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           5-10",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\" rowspan=\"3\">",
"           Level III",
"          </td>",
"          <td>",
"           &le;5",
"          </td>",
"          <td>",
"           &gt;10",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           5-10",
"          </td>",
"          <td>",
"           6-10",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           &gt;10",
"          </td>",
"          <td>",
"           &lt;5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Level IV",
"          </td>",
"          <td>",
"           &gt;5",
"          </td>",
"          <td>",
"           &gt;10",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GIST: gastrointestinal stromal tumor.",
"    </div>",
"    <div class=\"reference\">",
"     1. Fletcher, C, et al. Int J Surg Path 2002; 10:81.",
"     <br>",
"      2. Huang, HY, et al. Surgery 2007; 141:748.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40620=[""].join("\n");
var outline_f39_42_40620=null;
var title_f39_42_40621="Outcome fulminant myocarditis";
var content_f39_42_40621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patients presenting with fulminant myocarditis have a better outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After an 11 year follow-up, the survival free of transplantation is better in patients who present with fulminant myocarditis (93 versus 45 percent for nonfulminant myocarditis, p = 0.05). However, long-term survival did not differ significantly according to the degree of inflammation on biopsy, ie, active versus borderline myocarditis (p = 0.38).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from McCarthy, RE, Boehmer, JP, Hruban, RH, et al, N Engl J Med 2000; 342:690.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40621=[""].join("\n");
var outline_f39_42_40621=null;
var title_f39_42_40622="Mercury levels in seafood";
var content_f39_42_40622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mercury levels in commercial fish and shellfish",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mercury concentration (PPM) (mean)",
"       </td>",
"       <td class=\"subtitle1\">",
"        No. of samples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Fish and shellfish with highest levels of mercury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mackerel King",
"       </td>",
"       <td>",
"        0.730",
"       </td>",
"       <td>",
"        213",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shark",
"       </td>",
"       <td>",
"        0.988",
"       </td>",
"       <td>",
"        351",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Swordfish",
"       </td>",
"       <td>",
"        0.976",
"       </td>",
"       <td>",
"        618",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilefish (Gulf of Mexico)",
"       </td>",
"       <td>",
"        1.450",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Fish and shellfish with lower levels of mercury&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anchovies",
"       </td>",
"       <td>",
"        0.043",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Butterfish",
"       </td>",
"       <td>",
"        0.058",
"       </td>",
"       <td>",
"        89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Catfish",
"       </td>",
"       <td>",
"        0.049",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clam*",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cod",
"       </td>",
"       <td>",
"        0.095",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crab&Delta;",
"       </td>",
"       <td>",
"        0.060",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crawfish",
"       </td>",
"       <td>",
"        0.033",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Croaker Atlantic (Atlantic)",
"       </td>",
"       <td>",
"        0.072",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flatfish*&loz;",
"       </td>",
"       <td>",
"        0.045",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haddock (Atlantic)",
"       </td>",
"       <td>",
"        0.031",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hake",
"       </td>",
"       <td>",
"        0.014",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herring",
"       </td>",
"       <td>",
"        0.044",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jacksmelt",
"       </td>",
"       <td>",
"        0.108",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lobster (spiny)",
"       </td>",
"       <td>",
"        0.09",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mackerel Atlantic (N. Atlantic)",
"       </td>",
"       <td>",
"        0.050",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mackerel Chub (Pacific)",
"       </td>",
"       <td>",
"        0.088",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mullet",
"       </td>",
"       <td>",
"        0.046",
"       </td>",
"       <td>",
"        191",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oyster",
"       </td>",
"       <td>",
"        0.013",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perch Ocean*",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pollock",
"       </td>",
"       <td>",
"        0.041",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salmon (canned)*",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salmon (fresh/frozen)*",
"       </td>",
"       <td>",
"        0.014",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sardine",
"       </td>",
"       <td>",
"        0.016",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scallop",
"       </td>",
"       <td>",
"        0.050",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shad American",
"       </td>",
"       <td>",
"        0.065",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shrimp*",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Squid",
"       </td>",
"       <td>",
"        0.070",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilapia*",
"       </td>",
"       <td>",
"        0.010",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trout (freshwater)",
"       </td>",
"       <td>",
"        0.072",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (canned, light)",
"       </td>",
"       <td>",
"        0.118",
"       </td>",
"       <td>",
"        347",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whitefish",
"       </td>",
"       <td>",
"        0.069",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whiting",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Mercury levels of other fish and shellfish&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bass (saltwater, black, striped)&sect;",
"       </td>",
"       <td>",
"        0.219",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bass Chilean",
"       </td>",
"       <td>",
"        0.386",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bluefish",
"       </td>",
"       <td>",
"        0.337",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Buffalofish",
"       </td>",
"       <td>",
"        0.19",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carp",
"       </td>",
"       <td>",
"        0.14",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Croaker White (Pacific)",
"       </td>",
"       <td>",
"        0.287",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grouper (all species)",
"       </td>",
"       <td>",
"        0.465",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Halibut",
"       </td>",
"       <td>",
"        0.252",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lobster (Northern/American)",
"       </td>",
"       <td>",
"        0.310",
"       </td>",
"       <td>",
"        88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lobster (species unknown)",
"       </td>",
"       <td>",
"        0.169",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mackerel Spanish (Gulf of Mexico)",
"       </td>",
"       <td>",
"        0.454",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mackerel Spanish (S. Atlantic)",
"       </td>",
"       <td>",
"        0.182",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Marlin*",
"       </td>",
"       <td>",
"        0.485",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monkfish",
"       </td>",
"       <td>",
"        0.180",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Orange Roughy",
"       </td>",
"       <td>",
"        0.554",
"       </td>",
"       <td>",
"        49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perch (freshwater)",
"       </td>",
"       <td>",
"        0.14",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sablefish",
"       </td>",
"       <td>",
"        0.220",
"       </td>",
"       <td>",
"        102",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scorpionfish",
"       </td>",
"       <td>",
"        0.286",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sheepshead",
"       </td>",
"       <td>",
"        0.128",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skate",
"       </td>",
"       <td>",
"        0.137",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Snapper",
"       </td>",
"       <td>",
"        0.189",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilefish (Atlantic)",
"       </td>",
"       <td>",
"        0.144",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (canned, Albacore)",
"       </td>",
"       <td>",
"        0.353",
"       </td>",
"       <td>",
"        399",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (fresh/frozen, all)",
"       </td>",
"       <td>",
"        0.383",
"       </td>",
"       <td>",
"        228",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (fresh/frozen, Albacore)",
"       </td>",
"       <td>",
"        0.357",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (fresh/frozen, Bigeye)",
"       </td>",
"       <td>",
"        0.639",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (fresh/frozen, Skipjack)",
"       </td>",
"       <td>",
"        0.205",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (fresh/frozen, Yellowfin)",
"       </td>",
"       <td>",
"        0.325",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuna (fresh/frozen, species unknown)",
"       </td>",
"       <td>",
"        0.414",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weakfish (Sea Trout)",
"       </td>",
"       <td>",
"        0.256",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Source of data: FDA 1990-2004, \"National Marine Fisheries Service Survey of Trace Elements in the Fishery Resource\" Report 1978, \"The Occurrence of Mercury in the Fishery Resources of the Gulf of Mexico\" Report 2000. Mercury was measured as Total Mercury except for species (*) when only Methylmercury was analyzed.",
"    <div class=\"footnotes\">",
"     ND: mercury concentration below detection level (Level of Detection (LOD) = 0.01 ppm).",
"     <br>",
"      &bull; The following species have been removed from the tables: Bass (freshwater) - not commercial; Pickerel - not commercial.",
"      <br>",
"       &Delta; Includes: Blue, King, Snow.",
"       <br>",
"        &loz; Includes: Flounder, Plaice, Sole.",
"        <br>",
"         &sect; Includes: Sea bass/Striped Bass/Rockfish.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mercury levels in commercial fish and Shellfish. US Food and Drug Administration. Available at file://www.fda.gov/Food/FoodSafety/Product-SpecificInformation/Seafood/FoodbornePathogensContaminants/Methylmercury/ucm115644.htm. Accessed 1/26/2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40622=[""].join("\n");
var outline_f39_42_40622=null;
var title_f39_42_40623="Approach to postmenarcheal bleeding";
var content_f39_42_40623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Approach to vaginal bleeding in the postmenarcheal adolescent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 619px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Paradise JE. Vaginal bleeding. In: The Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds). Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_42_40623=[""].join("\n");
var outline_f39_42_40623=null;
